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Abstract
Pannexins (PANX1, 2, 3) are a family of channel-forming glycoproteins that mediate
intracellular and paracrine signaling. In contrast to PANX2, PANX1 has been extensively
investigated in the skin, modulating cell differentiation, wound healing, and melanoma
development. PANX1 and PANX2 can co-exist in the same cell and form mixed channels
where their glycosylation seems to regulate their intermixing. N-glycosylation and caspase
cleavage have been proposed as modulators of the function of PANX1, but their effects on
PANX2 are unknown. We explored the PANX2 expression in mouse skin and showed that
a Panx2 splice variant (PANX2-202) is continuously expressed throughout aging skin.
Furthermore, PANX2 was detected in keratinocytes and is upregulated during their in vitro
differentiation. We showed that in UVB-induced apoptotic keratinocytes, caspase-3/7
cleaves the PANX2 C-terminus at residue D416. Notably, CRISPR-Cas9-mediated
deletion of PANX2 delays but does not impair keratinocyte apoptosis, and its caspasemediated cleavage is not required for this process. Thus, we propose that PANX2 promotes
keratinocyte death after UVB, which may contribute to skin homeostasis. Moreover, we
showed that N-glycosylation occurs at the N86 residue of PANX2, regulating folding and
cell surface trafficking but not its interaction with PANX1. As PANX1 is known to
modulate in vitro and ex vivo tumorigenicity of melanoma cells, we examined the effect of
a germline deletion on in vivo melanoma progression by crossing Panx1 knockout (Panx1/-

) mice with the melanoma model: BrafCA, PtenloxP, Tyr::CreERT2 (BPC). We found that

Panx1-deletion did not reduce melanoma formation or improve BPC-mice survival.
However, tumors in BPC-Panx1-/- mice exhibited increased infiltration of CD4+, CD8+ Tlymphocytes, and Granzyme B+ cells but not immunosuppressive FoxP3+ T-cells.
Remarkably, splenomegaly was also found in female BPC-Panx1-/- mice compared to
males. Overall, this study revealed the location of two post-translational modifications in
the PANX2 amino acid sequence modulating its localization and possibly its biological
function. We provided further evidence that regulation of pannexins in the skin may
influence cell death and the activity of the immune system during skin cancer conditions,
which may have translational application in improving checkpoint inhibitor
immunotherapy for melanoma.
ii
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Summary for Lay Audience
Pannexins 1 and 2 (PANX1, PANX2) are channel-forming proteins that participate in cell
growth, death, and cell-to-cell communication processes. Both proteins are present in the
skin, but only PANX1 has been thoroughly investigated and shown as essential for proper
skin formation and wound healing. Here, we discovered that a PANX2 variant is present in
the upper layers of the mouse skin regardless of age, and its levels increase during the
maturation of specific skin cells called keratinocytes. Notably, we proved that PANX2 also
speeds up death in keratinocytes exposed to ultraviolet light (UV), which could be a natural
mechanism for eliminating cancerous cells in the outermost layers of skin after sunburn.
We also showed that specialized enzymes cut PANX2 during this cell death process, but
the consequences of this cut are still unknown. Furthermore, as PANX1 and PANX2 can
exist simultaneously in the same cell, they have been shown to form mixed channels
depending on the presence of sugars in the PANX1 molecular structure. However, we
discovered that sugars in the PANX2 molecular structure are not required to interact with
PANX1 but define PANX2 location within the cell. Furthermore, abnormal levels of
PANX1 have been previously shown to assist the development of melanoma, a deadly type
of skin cancer. We showed that in mice genetically engineered to develop melanomas, the
absence of PANX1 does not diminish tumor formation or improve survival. Nevertheless,
melanoma tumors without PANX1 had increased infiltration of cells responsible for the
body's natural defenses against cancer. This study contributes to understanding the effect
of chemical modifications on PANX2 distribution and function within the cell. Besides, we
uncovered a new role for PANX2 in promoting skin cell death that may be essential to
preserve skin health after harmful insults like UV exposure. Moreover, our work lays the
foundation of the translational use of targeting PANX1 to enhance current therapies that
fight melanoma tumors involving specific cells used by the body's natural defense system.
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Chapter 1
1 Introduction
1.1 Overview of the Pannexin Family of Proteins
Pannexins are a family of three integral membrane glycoproteins designated Pannexin1
(PANX1), Pannexin2 (PANX2), and Pannexin3 (PANX3) discovered in the earlier 2000s
[1, 2]. Pannexins share homology with innexins but not connexins, two families of proteins
that physically join the cytoplasm of adjacent cells, forming gap junctions and
hemichannels in invertebrates and mammals. Initially, due to their topological similarities
to connexins, and limited sequence homology to innexins, it was thought that pannexins
could form gap junctions. However, that theory has already been revised since their
primary function is to make non-docking membrane channels [3-5]. Additionally, despite
differences in sequence homology, these three protein families exhibit similar topology
consisting in four α-helical transmembrane domains (TM), two extracellular loops (EL),
one intracellular loop (IL), and their amino (NT) and carboxyl (CT) termini exposed to the
cytoplasm [6] (Fig. 1-1). In particular, instead of six extracellular cysteines as in connexins,
pannexins have four conserved extracellular cysteine residues that form disulfide bonds
and are required for functional channel formation [7, 8]. Nevertheless, pannexins can form
large-pore channels permeable to the diffusion of ions and macromolecules up to one
kilodalton (kDa) in size and are involved in intracellular, paracrine, and autocrine signaling
[9, 10]. In the following sections, a more in-depth description of the structure, function,
and regulation will be focused on PANX1 and PANX2 and their contribution to health and
pathological states, as these are the most relevant for my thesis.

2

Figure 1-1

3

Figure 1-1 Representation of the mouse pannexin members and locations of residues
with reported post-translational modifications.
The pannexin family is represented by three tetra-spanning proteins that can oligomerize
to form membrane channels capable of dye uptake and conducts for nucleotides, ions, and
other metabolites. All pannexins share a similar topology with two extracellular loops, one
intracellular loop, and the amino and carboxyl terminus located in the cytosol.
Transmembrane domains are indicated with roman numerals, and numbers indicate the last
residue in the polypeptide sequence. Several post-translational modifications (colored
residues) have been identified mainly for PANX1 and PANX2. Figure created with Protter
[11].
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1.2 Alternative splicing of Pannexin 1 and 2 genes
The Pannexin1 gene (designated PANX1 in humans and Panx1 in mouse and rat) comprises
four introns and five exons encoding a 426 amino acids (aa) long glycosylated protein with
an expected molecular weight (MW) ranging from ~41-48 kDa and exhibits broad
expression in mammalian tissues and organs [6, 12]. The Pannexin 2 gene (designated
PANX2 in humans and Panx2 in mice) comprises four exons encoding the longest pannexin
protein (677 aa) with an expected molecular mass ~74.4 kDa [13]. Genes encoding PANX1
and PANX3 are located on the same chromosome (Chr) (Chr 11, in humans; Chr 9, in
mouse), and their proteins share a higher homology (~41% identity) in amino acid sequence
than with PANX2 (~30% identity), whose gene is located on a different Chr (human Chr22
and mouse Chr15) [2, 14]. Noticeably, the PANX2 C-terminus is longer than in the other
pannexins and shares only ~8% of sequence identity with PANX1 [15, 16]. The initial gene
expression profiling studies showed that Panx2 mRNA expression seemed restricted to the
central nervous system (CNS), where it was found most abundantly in the cortex,
hippocampus, cerebellum, and olfactory bulb olfactory epithelium [17-19]. However, more
recent reports indicated that Panx2 is more ubiquitously expressed and is present in
different cell types and other tissues such as skin, liver, retina, intestine, and kidney [2026]. Panx1 and Panx2 gene expression have been found to overlap in the adult rodent brain
but intriguingly are inversely regulated throughout development, with Panx1 more
abundant in neonatal and young tissues, whereas Panx2 is increased in the adult [14, 27,
28]. Furthermore, other studies showed that Panx2 is differentially expressed by
multipotential neural progenitor cells and mature neurons, with protein expression and
post-translational modifications (e.g., palmitoylation) modulating neuronal differentiation
[29].
Current annotations in genomic databases predict the presence of several alternative splice
variants for both pannexin genes, which some authors have confirmed in different tissues
and cell types. Therefore, various pannexins protein variants (also known as isoforms) may
contribute to different functions depending on their tissue of origin. To date, a more
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comprehensive understanding of the potential pannexin transcripts is still lacking, but a
few examples are given below.
Initially, Baranova et al. (2004) described that the exon 5 could be alternatively spliced in
human PANX1 (hPanx1a, 426 aa), generating the hPanx1b (422 aa) variant that differs in
a four-amino acid insertion within the C-terminus [2]. Notably, this hPANX1b variant
seems more prevalent in human tissues [30]. Ma et al. (2009) [30] uncovered another
variant (hPanx1bv, 425 aa) resulting from a codon duplication for the human PANX1 gene.
Overexpression of these three human variants showed more similar localization patterns
and functional properties than mouse PANX1, but the functional outcomes were speciesdependent [30]. It has also been reported that alternative splicing in exons 2 and 4
generates two Panx1 variants (Panx1b and Panx1d, 356 and 309 aa, respectively) in rat
pituitary cells. However, both variants were found more intracellular than the canonical
form and exerted a dominant-negative effect on the ATP-release activity when coexpressed with full-length PANX1 [31]. Another shorter PANX1 isoform (Panx1c, 356 aa)
was detected in the rat male reproductive tract, likely from splicing of exon 3 of canonical
rat Panx1 (Panx1a). Remarkably, in that study, all rat Panx1 variants were repressed by
testosterone in the epididymis [32].
Regarding PANX2, despite several predicted annotations in genomic databases of NCBI
and Ensembl, it appears that only one single splice variant has been discovered in the
human brain. Baranova et al. (2004) reported a shorter PANX2 splice variant (termed
PANX2alt2, 509 aa), in addition to the canonical human isoform (PANX2alt1 encoding a
protein of 633 aa), that is a product of the initiation in an alternative start codon and implied
to have a regulatory role [2]. In zebrafish, three Panx2 isoforms were found with
differential expression among tissues: Isoform drPanx2-A exclusive of the brain, drPanx2C, found in brain and retina, and drPanx2-B, more widely expressed in the zebrafish tissues
[33]. Since PANX2 isoform expression has not been extensively examined, it is unclear
whether other splice variants are differentially expressed in mammal tissues and exhibit
different functional characteristics compared to the canonical.
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1.3 Pannexin 1
The research interest in PANX1 has increased significantly due to its implication on several
physiological and pathophysiological processes such as keratinocyte differentiation [34,
35], glucose uptake [36], myogenesis [37], apoptotic cell clearance[38], inflammation [39,
40], tumorigenesis [41-44] and metastasis [43, 45-49], hypertension [50, 51], immune
response [52-56], HIV infection [57, 58] and ischemia [59-63]. Most cellular processes
involving the PANX1 channel are modulated by releasing ions, nucleotides, and
metabolites that vary by cell type [10, 38, 64-66]. The subcellular cycle of PANX1 starts
with its synthesis in the endoplasmic reticulum (ER), from where it is trafficked towards
the cell membrane regulated by COPII (coat protein II)-dependent ER-to-Golgi forward
trafficking with the later channel internalization independent of clathrin/caveolin/dynamin
II mechanisms [67, 68]. Interestingly, plasma membrane-localized PANX1 has a long halflife (>21-32h) [6, 69].
Some of the identified stimuli triggering PANX1 channel activation include mechanical
stress, voltage, increased intracellular calcium levels, ionotropic and metabotropic receptor
signaling, and C-terminus proteolytic cleavage [56, 64, 70-73]. PANX1 is mainly known
for mediating adenosine triphosphate (ATP) release at the plasma membrane, but it also
serves as a calcium leak channel when located at the ER [74]. Interestingly, as a negative
feedback mechanism of channel regulation, it has been shown that the binding of ATP to
extracellular binding sites not only blocks PANX1 currents and ATP release but can induce
channel internalization [68, 75, 76]. It has also been demonstrated that PANX1 channels
favor anionic over cationic permeants [10]. However, its caspase-mediated proteolytic
cleavage elicits efflux of a wide variety of metabolites from apoptotic cells (e.g.,
spermidine) that mediate intercellular signaling processes, including inflammation and
immune cell recruitment [38, 66].

1.3.1 Pannexin 1 channel three-dimensional structure
Published studies aiming at the 3D structure determination of pannexins have been limited
to PANX1. At least three independent groups have determined the molecular structure of
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PANX1 at near-atomic-resolution for humans (Homo sapiens) and frog (Xenopus
tropicalis) by cryo-electron microscopy, revealing a unique heptameric channel
architecture [77-79]. From the PANX1 structure, it was revealed that the extracellular
domain of each monomer comprises one helix, three β-sheets, and two conserved disulfide
bonds. Besides, the extracellular channel entrance forms a cap structure with a network of
electrostatic interactions securing a neutral potential in that region. Moreover, some
essential residues are placed strategically, forming the channel. For example, seven
tryptophan (W74) residues line the outer region wall, restricting the maximum size of
permeable molecules. An arginine (R75) residue from a neighboring helix forms a cationπ interaction with W74 and a salt bridge with an aspartic acid residue (D) at position 81,
stabilizing the tryptophan ring configuration. Michalski and collaborators (2020) [79]
showed that R75 residue is a significant determinant of anion selectivity of PANX1
channels in the open state that is critical for the channel inhibition by high concentrations
of ATP and its analogs [79, 80]. Mou et al. reported a narrow ring structure formed by
other residues (T21/E22/P23) in the N-terminus that controls channel opening [78].
The first transmembrane domain (TM) 1 appears tilted by ~30° in the membrane and places
the residue isoleucine (I) 58 at the narrowest point of the pore-lining region, with a hydrated
diameter of ~13Å. Consequently, the pore is substantially widened toward the intracellular
side, where TM2 makes the expanded pore with TM3 and TM4 arranged in the channel
periphery. Interestingly, the 3D structure exhibits a voluminous intracellular vestibule with
abundantly charged amino acids facing the pore lumen with an overall positive electrostatic
potential that facilitates the recruitment of anions or negatively charged molecules [77].
Due to the dynamic nature of the intracellular segments, the C-termini regions of the
oligomeric channel have not been resolved in the cryo-EM density maps. However,
accumulating evidence indicates that the C-terminus blocks the channel pore permeability
via a "ball-and-chain" mechanism [38, 81], a notion that is still to be proven for other family
members. A previous study used a genetically engineered PANX1 containing a Tobacco
Etch Virus (TEV) protease recognition sequence at the caspase cleavage site of the Cterminus [81]. These authors demonstrated that the proteolytic cleavage of PANX1 occurs
at the plasma membrane and induces the channel opening. However, even the detached
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PANX1 C-terminus fragment can inhibit cleavage-activated channels, implying a negative
feedback mechanism to control channel activation [81]. Interestingly, a progressive α1adrenoceptor-mediated PANX1 channel activation or cleavage of the C-terminal
autoinhibitory regions in each subunit produces a gradual increase in channel permeability
and has been proposed as a fine-tuning activation mechanism for this multimeric channel
[82].

1.4 Pannexin 2
Most studies have shown that PANX2 exhibits intracellular localization, yet in
overexpression systems, it has also been found at the cell membrane and colocalizing with
PANX1, forming heteromeric channels [5, 7]. However, previous colocalization studies
have also indicated that overexpressed PANX2 is mostly cytoplasmic and can be found
with markers of early endosomal sorting [83]. Additionally, PANX2 has been shown to
colocalize with an endosomal enriched mannose-6-phosphate receptor in a neuroblastoma
cell line [84]. More recently, Le Vasseur et al. (2019) have shown that ectopic and
endogenously expressed PANX2 localize at ER-mitochondria contact sites in C6 glioma
cells and mouse brain sections [85]. These many conflicting pieces of evidence suggest
that PANX2 channel localization could be cell-type dependent or due to regulatory and
sorting mechanisms such as post-translational modifications including palmitoylation and
glycosylation [86, 87], as I will discuss later in this chapter.
To date, the 3D structure of PANX2 channels remains to be solved, and there has been
some disagreement about whether PANX2 forms functional homomeric channels [14, 70].
Nevertheless, early studies determined that rat PANX2 forms active octameric channels in
Xenopus oocytes and in vitro vesicle assays. In such studies, a voltage-dependent opening
of PANX2 channels was detected at high positive membrane potentials, and unlike
PANX1, PANX2 channels did not respond to extracellular K+ and were unaffected by the
PANX1 blockers, Carbenoxolone and Probenecid [7]. Furthermore, it has been suggested
that PANX2 channels can be mechanically stimulated and are capable of dye uptake under
physiological Ca2+ and Mg2+ conditions [5]. Remarkably, the PANX2 channel function
appears to be compromised when combined with PANX1 [5, 7], suggesting that co-
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expression of both pannexins in the same cells may exert mutual inhibition, which has been
proposed as a mechanism of regulation. Despite this, the functional significance of PANX2
is not clear yet. Using a Panx2-knockout (KO) mouse model, it was proposed that PANX2
channel activation promotes neurodegeneration after ischemic brain damage [59]. In that
stroke model, only when both Panx1 and Panx2 genes were knocked out (Panx1-/- and
Panx2-/-), a reduction in infarct size and neurological damage was achieved after ischemia,
indicating potential compensatory roles between these two proteins in the CNS [59, 88].
These authors also showed that even in the absence of PANX1, Panx2 deletion reduced
dye leakage of primary cortical neurons loaded with calcein green dye after cytotoxichypoxia induced with sodium cyanide (NaCN), indicating that PANX2 is also capable of
forming dye-release channels in neurons.

1.5 PANX1/PANX2 heteromeric channels
Previous studies have investigated the potential interaction among pannexin family
members and intermixed channel formation due to co-expression patterns in tissues and
the significant sequence homology shared between pannexin family members. In Xenopus
oocytes, coinjection of rat Panx1 and Panx2 RNAs resulted in channel formation with
different functional properties from those formed by PANX1 alone [14]. Despite that
difference, further research by the same authors found that the pharmacological sensitivity
of heteromeric PANX1/PANX2 was similar to that of homomeric PANX1 channels [70].
Penuela et al. (2009) demonstrated that when HEK293T ectopically co-expressed both
Panx1 and Panx2 murine constructs, their proteins physically interact, and there is a
significant reduction in dye uptake incidence compared to cells expressing a single
pannexin paralog [5]. It has been proposed that this "intermixing" attenuates the
heteromeric channel function [5, 70]. Later, Ambrosi et al. (2010) focused on
characterizing purified oligomeric structures of pannexins channels and confirmed these
findings. However, PANX1/PANX2 heteromeric channels were unstable over time,
attributed to differences in monomer size and divergences in the homomeric and
heteromeric symmetry [89]. Interestingly, pannexins intermixing appears to be regulated
by the glycosylation status of each monomer, as is discussed later in this chapter.
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1.6 Post-translational modifications and regulation of pannexins
Various post-translational modifications (PTMs) have been reported on the pannexin
family to regulate their localization, interaction, and channel activity [13, 38, 86, 90].
Although proteomic discovery by mass spectrometry has identified several PTMs in
pannexins, currently PANX1 is the most characterized member, harboring at least six
different types of modifications that have been experimentally validated (Fig.1-1 and Table
1-1). In contrast, most PANX2 PTMs have been predicted or identified by biochemical and
high throughput studies using mass spectrometry but have not yet been studied thoroughly.
Until the writing of this thesis, the four main types of PTMs identified or predicted for
PANX2 were: N-glycosylation, caspase cleavage, phosphorylation, and S-palmitoylation
[86, 91].
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Table 1-1 List post-translational modifications reported for PANX1 and PANX2
Posttranslational
modification

N-glycosylation

Site

N254
Y10
Y150

Phosphorylation

Y192
Y198 (Y199 in
human)
Y308

Effect on the protein or
function
PANX1
Regulates trafficking and
intermixing with PANX2
Influences localization and
channel function
Regulates glycosylation and
trafficking
Unknown

Ubiquitination

Oxidation
Acetylation

[93, 94]†
[95] †
[96] †
[96-98] †

Activates channel

[99]

Inhibits channel

[100]

S182, S189 (S188
in human), S425

Unknown

[101-103],
[104] †

S328 † (S329 in
human), T302

Possible channel inhibition

[105]

C40, C346

Inhibits channel

[8, 90, 106]

Unknown

[38]

Irreversible channel opening

[38, 81, 86,
107]

Unknown/Putative Degradation

[96] †, [103,
108, 109] †

Inhibits channel

[110]

Inhibits channel; Unknown

[96, 111] †

S394* †

Caspase
cleavage

[3-5, 92] †

Possible channel activation

S206

S-nitrosylation

References

D167* only in
human
D378 (D379 in
human)
K201, K307,
K343, K355, K381
(K380 in human)
†, K409*
C426
K140; K203,
K204, K212

PANX2
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N-glycosylation

N86

Palmitoylation

C246 (predicted)

Regulates subcellular
localization (see Chapter 3)
Retain intracellular localization
and possibly prevents Nglycosylation

S514, S204, T275*
(A274 in human),
S279 (S278 in
Phosphorylation
Unknown
human), S495*
(P491 in human),
S593, S604
Ubiquitination
K183
Unknown/Putative Degradation
Predicted D373,
Caspase
D407, D416, and
Unknown
cleavage
D479

[5, 92, 112]
†
[87]

[113, 114] ¸
[96]†

[86]

Table Notes: *- amino acid residue not conserved among human, mouse, and rat paralogs.
† verified/discovered by high throughput mass spectrometry reported in PhosphositePlus®
database as of May-07-2021.
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One of the early characterized PTM for PANX2 was S-palmitoylation and was identified
by biochemical tests used to understand the reduced electrophoretic migration of neural
progenitor cell (NPC)-specific PANX2 protein species. However, the specific Spalmitoylation site in the PANX2 amino acid sequence was not confirmed [87]. In that
respect, Swayne et al. (2010) showed that endogenous PANX2 appeared palmitoylated
with an apparent molecular weight of ~85 kDa besides the non-palmitoylated ~60 kDa
immunoreactive species also found in NPC cultures. Notably, the higher MW species were
absent in adult brain tissue (e.g., hippocampus) and not observed in cultured neuronal cells
after differentiation. Furthermore, S-palmitoylation was implied to regulate PANX2
subcellular localization, where palmitoylated PANX2 in undifferentiated NPCs and
primary neurons exhibited intracellular staining of PANX2 along with ER and Golgi
markers but not in the plasma membrane. However, in mature neurons, differentiated
NPCs, and N2a cells (a mouse neuroblastoma cell line), non-palmitoylated PANX2 was
found at the cell membrane, indicating that this PTM may restrict the PANX2 sorting [87].
Interestingly, in that study, de-glycosylation did not markedly alter the electrophoretic band
migration of endogenous PANX2, and only the higher species were sensitive to depalmitoylation procedures.
Investigating PTMs offers a better understanding of pannexin regulation, which could
differ or have implications in health and disease states. Therefore, the following
subsections will focus on two mainly studied PTMs in PANX1 and PANX2: glycosylation
and caspase cleavage but will not include phosphorylation as it is not within the scope of
this thesis. A summary of the current model of regulation of PANX1 and PANX2 by Nglycosylation and caspase cleavage is shown in Fig. 1-2.
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Figure 1-2.
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Figure 1-2. Representation of regulation of PANX1 and PANX2 by N-glycosylation
and caspase cleavage
(A) Hypothesized snapshot of subcellular localization of PANX1 and PANX2. After
protein synthesis, PANX1 and PANX2 are N-glycosylated and may oligomerize in the
endoplasmic reticulum (ER) to function as intracellular channels, although this has not
been demonstrated for PANX2. PANX1 follows anterograde trafficking through the Golgi
apparatus, and high-mannose glycosylated species can be further modified to complex
glycosylation and localize to the cell membrane where it works as an ATP/ion channel or
can intermix with PANX2 monomers. PANX2 is N-glycosylated to high-mannose species
and is predominantly intracellularly located within the ER-mitochondria contact sites and
intracellular vesicles: endosomes and lysosomes. Although the details about PANX2
anterograde trafficking are yet to be elucidated, under some circumstances (overexpression
or co-expression with PANX1), PANX2 can reach the cell membrane and form channels.
(B) PANX1 and PANX2 species can intermix at the ER membrane or the plasma
membrane. Only PANX1 high-mannose or un-glycosylated species can intermix with
PANX2 (C). In physiological conditions, the opening of PANX1 channels is a reversible
process and regulated by intracellular and extracellular cues and post-translational
modifications; however, during apoptosis, the C-terminus of PANX1 can be cleaved by
active apoptotic caspases-3/7 causing the irreversible PANX1 channel opening and
releasing ATP, ions, and other metabolites to the extracellular milieu. PANX2 can also be
cleaved by caspase in vitro, but it is unknown if this also happens in apoptotic cells and
what the consequences of the cleavage are. Figure created with BioRender.com.
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1.6.1 N-glycosylation and localization of pannexins
N-linked-glycosylation (a.k.a. N-glycosylation) is a type of PTM known to modulate
protein folding and trafficking of membrane-bound proteins. N-glycosylation starts in the
ER lumen with the addition of high-mannose sugars to the synthesized proteins and is
carried out by glycosyltransferase enzymes. Further modifications occur to the attached
glycan moiety and are processed into complex-form glycans once the protein has trafficked
to the Golgi apparatus [115, 116]. The sequence motif Asn-X-Ser/Thr (where X is any
amino acid except Pro) constitutes a prerequisite for N-glycosylation, and prediction
servers use this feature for de novo identification of putative N-linked glycosylation sites.
Initial studies showed that PANX1 and PANX3 have consensus sites for N-linked
glycosylation on asparagine (Asn, N) 254 and 71, respectively [3-5]. In such cases,
enzymatic de-glycosylation and site-directed mutagenesis were used to verify the sites
[14]. Later, after cloning mouse PANX2, a similar approach was used, and a bioinformatic
prediction indicated its glycosylation site at N86, but the experimental confirmation of such
site was still lacking [13, 117].
Depending on the degree of N-glycosylation, pannexins glycosylated species are resolved
as different electrophoretic bands with increasing molecular weight.

For example,

unglycosylated PANX1 species (termed Gly0) are typically detected at 41 kDa, high
mannose species (termed Gly1) which are produced in the ER are shown at 44 kDa, and
more complex glycosylated species (termed Gly2), further modified in the Golgi
compartments, confer PANX1 with an estimated molecular weight of 48 kDa [5].
However, unlike others pannexins, PANX2 is only modified to a Gly1 species and presents
a primarily intracellular localization that has been previously associated with the lower
level of N-glycosylation [13]. Therefore, some authors [118] have speculated that the
absence of Gly2 species could indicate a differential trafficking pathway not involving the
transient layover at the Golgi apparatus and subsequent trafficking to the cell membrane,
as seen with PANX1 and PANX3 [67].
Previous evidence indicates that Gly2 species are evident in PANX1 and PANX3 and are
readily trafficked to the cell surface [13]. In such cases, their translocation toward the cell
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membrane is disrupted by glycosylation inhibitors or mutation of the respective asparagine
residues [13, 69, 117, 119]. However, it remains unclear if similar outcomes take place
regarding PANX2. As mentioned earlier, most of the evidence shown so far has led the
scientific community to consider that PANX2 has an intracellular localization [120-123].
However, our group and others have found that, under certain circumstances, it can
translocate to the plasma membrane, especially when PANX1 is co-expressed [29, 89]. In
this regard, it is still unclear whether the level of glycosylation in PANX2 plays any role
in such trafficking. Notably, PANX1 and PANX2 were shown to co-immunoprecipitate,
but only when PANX1 remains as lower glycosylated forms (Gly0 and Gly1), which likely
indicates that the glycosylation may regulate pannexins intermixing or that heteromeric
interaction may occur when these proteins are glycosylated in the ER [13].
Furthermore, as the PANX1/PANX2 heteromeric channels have different properties from
homomeric ones, they may be influenced by different glycosylated species between
monomers. Thus, glycosylation likely plays a role in regulating the heteromeric channel
function when the two pannexins are expressed in the same spatial-temporal circumstances.
Herein, the confirmation of the N-glycosylation site and its role in PANX2 subcellular
localization and intermixing with PANX1 will be the subject of Chapter 3.

1.6.2 Caspase cleavage of Pannexin 1 and 2 and their role in cell death
Caspases are a conserved family of cysteine-dependent aspartic-specific proteases
implicated in crucial cellular processes such as programmed cell death and inflammation
[124]. Caspase-3 and caspase-7 are known as executioner caspases and carry out the
proteolysis of several target proteins to coordinate the terminal events of apoptosis [125].
One of the most studied gating mechanisms for PANX1 is caspase-3/7-mediated cleavage
of the carboxyl-terminus inducing irreversible PANX1 channel activation [38, 81, 86, 126].
The first evidence of this caspase-mediated cleavage was demonstrated by Chekeni et al.
(2010), where the cleavage of human PANX1 was found to mediate the release of find-me
signals (i.e., nucleotides) from apoptotic Jurkat T-cells and consequently the recruitment
of monocytes and Cluster of differentiation (CD) 45+ leukocytes towards regions infused
with the supernatants of the apoptotic cells [38]. These authors showed that both caspases
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cleave in the IL and CT regions using in vitro cleavage assays with purified active caspases
3 and 7 and immunoprecipitated PANX1 protein (See sites in Table 1.1). Notably, only the
cleavage of the PANX1-CT was found responsible for the irreversible channel activation.
Furthermore, it was later shown that the cleaved PANX1 C-terminal peptide could inhibit
PANX1 channel function [81], but its interaction with the cytoplasmic vestibule of the
PANX1 channel seems to be delocalized and with a low affinity [127].
Remarkably, work by Yang et al. (2015) also implicated the non-canonical inflammasome
murine caspase-11 targeting the exact cleavage site of caspase-3/7 in PANX1-CT and
promoting pyroptosis (a pro-inflammatory form of cell death) through purinergic receptor
(P2X7)-dependent cytotoxicity [107]. The consequence of the caspase-mediated opening
of PANX1 channels at the plasma membrane has been investigated. PANX1 cleavage is
mainly recognized for inducing ATP release, impairing the cellular metabolic activity
during apoptotic conditions [10, 128]. However, recent work by Medina et al. (2020)
showed that this caspase-cleavage also facilitates the release of a broader subset of
metabolites from apoptotic cells that modulates processes like inflammation, wound
healing, and cell proliferation [66].
On the other hand, Penuela et al. (2014) confirmed caspase-cleavage in the murine paralogs
PANX1 and PANX2, but not PANX3 [86]. However, although these authors demonstrated
the C-terminus of PANX2 to be a target of caspase cleavage, the amino acid residue of the
cleavage site was not identified, nor whether PANX2 channels can be opened by caspase
cleavage in vivo. Interestingly, in ectopic overexpression systems, PANX2 is known to
sensitize cells to apoptotic signals [85, 129] and contribute to diverse forms of cell death
[25, 85, 88, 129]. Furthermore, as mentioned earlier, Bargiotas et al. (2011) showed that
PANX2 (along with PANX1) is linked to neuronal cell death, as demonstrated by in vitro
and in vivo models of acute neuronal damage [59]. These authors proposed that caspase
cleavage of pannexins could be a mechanism for channel activation during apoptosis in
ischemic stroke, a theory supported by Penuela et al. (2014) [86].
Accumulating evidence has shown conflicting roles of PANX2 at promoting or preventing
different types of cell death. Le Vasseur et al. (2019) proposed that due to the localization
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of PANX2 in the ER-mitochondria contact sites, it could promote the intrinsic apoptotic
pathway, which was supported by an increased sensitivity of PANX2-overexpressing C6glioma cells to staurosporine (STS)-induced apoptosis [85]. In contrast, Bertchold et al.
(2017) indicated an anti-apoptotic role of PANX2 when expressed in the pancreatic islets
where PANX2-deficiency sensitized pancreatic β-cells to cytokine-induced apoptosis and
disrupted glucose tolerance in vivo [22]. Lastly, a study performed by Lio et al. (2020)
showed a link between up-regulated PANX2 and the antioxidant response of prostate
cancer cells where silencing PANX2 expression increased intracellular ferrous iron (Fe2+)
and the lipid peroxidation end-product malondialdehyde [25]. That study suggested that
PANX2 may play a protective role against ferroptosis, a type of programmed cell death
distinct from apoptosis [130]. Considering that PANX2 can be targeted by apoptotic
caspases-3/7, it is unknown whether this caspase cleavage has a role in regulating cell
death.

1.7 Pannexins in the skin
1.7.1 Overview of the structure and components of the skin
The skin is the outermost and most extensive organ, constituting a barrier against hazardous
substances, ultraviolet radiation, and pathogens entering the body [131]. Among many
protective functions, the skin provides temperature regulation, mechanical and temperature
sensation through nociceptors [132] and other appendages (e.g., hair follicles, sweat
glands, and pilosebaceous units) [133]. Overall, the skin comprises three main layers:
epidermis, dermis, and hypodermis (Fig.1-3A).
The epidermis is the outermost layer that acts as a barrier to the external environment and
insults, prevents water loss, and maintains body homeostasis. This layer is avascular and
is subdivided by an inner proliferative basal keratinocyte layer, the spinous, granular, and
stratum corneum upper layers. All the upper epidermal layers are mainly formed by
keratinocytes that, upon a detachment from the basement membrane, undergo terminal
differentiation (keratinization), forming a layer of flattened dead cells (called corneocytes)
that are later shed from the skin (desquamation), where calcium plays a critical role in
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regulating keratinocyte proliferation and differentiation [134]. In addition, other minor cell
types can be found in the epidermis like the pigment-producing melanocytes, antigenpresenting Langerhans cells, and mechanoreceptive Merkel cells, each with a particular
function in this vital layer [131] (Fig. 1-3B). For example, melanocytes are a smaller cell
population in the epidermis that synthesize the UV-absorbing pigment melanin in response
to the α-melanocyte-stimulating hormone that is secreted by UV-exposed keratinocytes.
This pigment is stored in intracellular granules called melanosomes that are eventually
transferred to keratinocytes to shield their nuclei from mutagenic effects of UV radiation
[135].
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Figure 1-3.

Figure 1-3. Schematic representation of the skin structure and layers of the epidermis.
(A) Representation of the three main layers of the adult mammalian skin. The vasculature,
dermal nerves, and an array of skin appendages between the epidermis and the dermis are
shown. (B) In the epidermis, an inner layer (basal layer) of proliferative basal cells, known
as keratinocytes, detach from the basement membrane (region delimiting dermis and
epidermis) and start differentiating, forming the spinous, granular, and stratum corneum
layers. Ultimately, the last layer (outer cornified envelope) constitutes a barrier made of
dead cellular ghosts packing lipids and crosslinked bundles of keratin filaments. Some cell
types are shown within the epidermis: the pigment-producing melanocytes (located along
the basement membrane in humans and hair bulbs in mice), sensory Merkel cells, and
antigen-presenting Langerhans cells. Other skin resident non-epithelial cells (e.g., dermal
fibroblasts, immune, and stem cells) are not shown for simplicity. (Figure drawn in Adobe
Illustrator based on descriptions from [131]).
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The dermis is thicker than the epidermis and located between the basement membrane
(beneath the basal layer) and the hypodermal layer. The dermis comprises two layers: the
papillary layer, mainly made up of loose connective tissue, and the reticular layer
containing dense elastic fibers and collagen and housing some of the skin appendages. Part
of the skin vasculature (capillaries) can be found in the dermis, facilitating nutrient
transport. Fibroblasts are the primary dermal cell type, and myofibroblasts (differentiated
fibroblasts), mast cells, and other immune cells can also be found in this layer [136].
Underneath the dermis is the hypodermis formed by the subcutaneous fat and abundant
extracellular matrix (ECM) components like proteoglycans and glycosaminoglycans. This
layer comprises adipocytes, fibrocytes, and multiple immune cells and participates in
numerous functions such as insulation, cushion, energy storage, and the production of
growth factors, adipokines, and cytokines (reviewed at [136]).

1.7.2 Pannexin1 and 2 in the skin
Early work done by Penuela et al. (2007) showed endogenous PANX1 protein expression
(and PANX3) in murine skin, which was detected in the suprabasal epidermal layers
(stratum granulosum and spinosum) [3] and present in keratinocytes, fibroblasts, and hair
follicles [34, 35]. Furthermore, Cowan et al. (2012) later verified that PANX1 is present
in almost all layers of human skin with a profile punctate or diffused in cells of the
epidermis and adnexal structures, respectively [41]. Finally, work by Celetti et al. (2010)
and Penuela et al. (2014) explored the temporal regulation of PANX1 through skin aging,
demonstrating that PANX1 levels are detected in newborn skin but are later downregulated
in aged murine skin [34, 35]. Nevertheless, less is known about PANX2 in the skin, even
though its expression was already confirmed by two independent studies [21, 118].
Notably, Abitbol et al. (2019) showed that endogenous PANX2 is expressed at similar
levels in the skin of wildtype and double Panx1/Panx3-KO mice with a lower MW than
the canonical variant, apparently due to a splice variant (called Panx2-202) not previously
investigated [21]. In this case, the simultaneous germline deletion of Panx1 and Panx3 in
mice, among other effects (e.g., litter size, body weight, and bone morphology), impacts
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the dorsal skin thickness by reducing the epidermal, dermal, and hypodermal areas in
neonatal mice but not at older ages [21]. Interestingly, there was no apparent compensation
by the PANX2 splice variant in this double knockout mouse model as suggested with
PANX3 in a Panx1-KO model [35]. Although there are likely unknown functional
compensatory mechanisms to cope with the deficiency of these pannexins, Panx1 and
Panx3 have been found necessary for the early development of skin and wound healing
[35, 137, 138]. As PANX2 has been shown to regulate the timing of differentiation in
neurons [87], it is unknown whether this functional characteristic is unique to neuronal
lineage alone or present in skin cells. To the extent of our knowledge, no overt skin
phenotypes have been reported for the Panx2-KO mice published to date [59, 88], but a
closer look may reveal unnoticed significant differences.

1.7.3 Pannexin1 roles in skin cell differentiation and wound healing
The confirmation of PANX1 (and PANX3) in the epidermis increased the interest in
investigating their roles in keratinocyte differentiation. Specifically, PANX1 is expressed
at the cell surface in basal (undifferentiated) keratinocytes, but this localization changes to
a more intracellular once keratinocytes differentiate, along with a decrease in Panx1
expression while the levels of involucrin -a marker of keratinocyte differentiationincreases [3]. Notably, ectopic overexpression of murine PANX1 in immortalized rat
epidermal keratinocytes (REK) recapitulates trafficking to the cell surface and formation
of channels capable of dye-uptake [34]. However, it seems that the expression of these
pannexins needs to be regulated since their overexpression reduces the in vitro cell
proliferation of REK cells.
Moreover, in a model of REK organotypic epidermis, ectopic murine PANX1-expression
causes

dysregulation

of

REK

differentiation,

increasing

keratin

14

(a

basal/undifferentiation marker) and reducing the vital layer thickness. These results
implied that PANX1 was essential for proper skin architecture, especially at the early
stages of skin development. Remarkably, Penuela et al. (2014) showed that Panx1-KO
mice had decreased dorsal skin thickness, whereas the hypothermal layer was thicker
compared with that of WT mice [35]. That study also showed that PANX1 regulates the
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proliferation and migration of keratinocytes and dermal fibroblasts and is needed for rapid
wound healing upon injury. Significantly, Panx1-deletion delayed in vivo wound healing
in mice, increased the proliferation of primary dermal fibroblasts, and made them
irresponsive to differentiation upon transforming growth factor-beta 1 (TGF-β1)
stimulation compromising theirs in vitro contractile properties.
Interestingly, in vitro targeting PANX1-dependent ATP release in human dermal
fibroblasts with PANX1 blockers (carbenoxolone (CBX), probenecid (PBN), and 10Panx1
mimetic peptide) was recently shown to accelerate their migration, increase single-cell
motility, and promote F-actin redistribution [139]. In this regard, an apparent discrepancy
exists between Penuela et al. (2014) and Flores-Muñoz et al. (2021) [139] studies. In the
first study, the in vitro proliferation but not migration of murine neonatal dermal fibroblasts
was enhanced by the Panx1-KO that showed increased fibrosis but delayed wound healing
in vivo [35]. On the contrary, the latter study showed that PANX1-inhibition or knockdown in human dermal fibroblasts increased in vitro migration, as seen in their
Panx1-KO-derived primary dermal murine fibroblasts compared to WT-derived ones
[139].

1.8 Pannexins 1 and 2 in cancer
In the previous sections, most of the research evidence was based on the characterization
and regulation of pannexins during physiological conditions. However, growing research
indicates their dysregulation also contributes to pathophysiological processes like cancer
and inflammation [52, 97, 140]. A recent analysis by Xu et al. (2021) [141] using the
Oncomine database indicated the upregulation of PANX1 mRNA transcript levels in at least
14 different cancers and more significantly in malignancies such as sarcomas, lymphomas,
breast, esophageal, and head and neck cancers. The same study showed that although
PANX2 was upregulated in breast and lung cancer, it is downregulated in other six different
tumor types, including brain and CNS cancer, esophageal, lymphoma, and pancreatic
cancer [141]. Notably, these data also implied that there is likely an apparent inverse
relationship in the mRNA expression between both pannexins, although no significant
inverse correlation has been found.
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Indeed, PANX1 has been previously reported to play a tumor-promoter role and is
increased in a variety of cancer cell lines and tumors (e.g., breast, melanoma, glioma,
hepatocellular carcinoma, and myeloma) when compared to normal tissues (reviewed in
[140]). Recently, a study examining PANX1 in hepatocellular carcinoma indicated that its
upregulation is associated with poor patient prognosis and promotes invasion and
metastasis [48]. Moreover, PANX1 was highly expressed in different breast cancer
subtypes and linked to favoring an epidermal-to-mesenchymal transition (EMT) phenotype
and poorer outcomes in breast cancer patients [47]. Another report showed that PANX1
upregulation in testicular cancer confers sensitivity to cisplatin, a chemotherapeutic agent,
but downregulation of its expression in a related cancer cell line (I-10) increases resistance
to this drug [142]. However, genetic and pharmacological inhibition of PANX1 channels
also reduces in vitro migration and invasion of the same parental cell line of testicular
cancer by decreasing of ERK1/2 kinase activity, suggesting that these cancer cells may
exploit PANX1 function in a selective manner to alter their tumorigenic properties [143].
Notably, our group has demonstrated that PANX1 levels are elevated in cutaneous
melanoma, a melanocytic skin cancer [42-44], in contrast PANX2 has not been thoroughly
investigated in this regard. Therefore, the following subsections will be limited to the
current knowledge about PANX1 in cutaneous melanoma.
Conversely, PANX1 anti-tumorigenic roles have also been reported, where PANX1
expression is downregulated (e.g., gallbladder adenocarcinoma [144]) or absent (e.g.,
rhabdomyosarcoma [145, 146]), and its restitution can revert the cancer progression.
Notably, early studies looking at the expression of pannexins in human keratinocytic tumor
biopsies showed that PANX1 was downregulated in basal and squamous cell carcinomas
compared to normal skin, suggesting that its expression might offer a protective role
against keratinocyte malignant transformation [41]. However, considering that PANX1 is
a regulator of keratinocyte proliferation and differentiation, further work with a larger
sample size and related cell lines is warranted to clarify its role in promoting or suppressing
keratinocytic neoplasias.
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On the other hand, less is known about PANX2 in cancer. However, some relevant
information about PANX2 has been brought to light in a few studies. In that respect,
PANX2 has been proposed as a potential tumor suppressor in glioma with a positive
correlation between its gene expression and post-diagnosis survival time for glioma
patients [147]. A recent bioinformatic analysis done by Xu et al. (2021) showed that high
expression of PANX2 is significantly associated with better overall survival but negatively
correlated with tumor immune infiltration in low-grade gliomas [141], which can impact
negatively the efficacy of therapies that rely on the presence and activation of anti-tumor
immune cells as we will describe later for melanoma.

1.8.1 Skin cancer: Melanoma
In the pathological states of the skin, several external (i.e., sunlight, UV radiation, chemical
insults) and genetic factors could give rise to cancerous lesions. Cutaneous melanoma is
the most aggressive type of skin cancer that arises from uncontrolled proliferating
melanocytes, the neural crest-derived and pigment-producing cells in the skin. According
to the Global Cancer Observatory (https://gco.iarc.fr/), melanoma was responsible for
~47,2 % of skin cancer-related deaths worldwide in 2020 and is still increasing in incidence
and mortality [148]. Since the development of targeted and immune checkpoint therapies,
a significant reduction in mortality has been observed [149], but they are still far from
perfect, and current therapies do not benefit a large number of patients.

1.8.1.1 Cutaneous Melanoma overview
According to the growth and localization pattern of the melanoma tumor, there are four
major types of melanoma: Superficial spreading, nodular, lentigo malignant, and acral
lentiginous melanoma, with the first one being the most common [150]. Melanoma lesions
have two growth phases: radial, when malignant cells grow radially within the epidermis,
and vertical when the tumor cells invade deeper in the dermis acquiring metastatic
capabilities. It is suggested that these invasive malignant melanoma cells transit to a lymph
node and gain physical access to both lymphatics and blood vessels to further the metastatic
process. If it is not detected early, melanoma results in a highly metastatic cancer with a

27

fast progression and high lethality, diminishing the efficacy of therapies. Depending on the
tumor location, regional melanoma metastasis occurs in the skin, near (satellite lesions), or
relatively distant (in-transit) from the primary tumor site, as well as to subcutaneous tissue
and lymph nodes. However, distant metastases are commonly in the skin, lung, brain, liver,
and at later stages to the bone, and intestine but subclinical manifestations can appear in
almost any part of the body [151, 152].
One of the significant risk factors for melanoma development and other non-melanoma
skin cancers (e.g., keratinocyte-derived squamous and basal cell carcinomas) is exposure
to UV radiation, which causes pyrimidine dimers and oxidation of the genomic DNA [153].
Therefore, most tumors of melanoma patients exhibit a high rate of genetic alterations
(a.k.a. tumor mutational burden) due to UV exposure. However, both germline (e.g.,
mutations in CDKN2A and CDK4) and somatic mutations have been found to drive
malignant melanocyte transformation [154, 155]. Since several driver mutations have been
identified and implicated in melanoma onset and progression (reviewed at [156, 157]), the
following paragraphs will succinctly describe the alterations more relevant for the context
of this thesis.
The oncogenic pathway most frequently dysregulated in melanoma is the mitogen‐
activated protein kinase (MAPK) signaling pathway, which is crucial for the proliferation,
differentiation, and survival of melanocytes and melanoma cells. Among other mutations,
those in the BRAF gene, encoding a B‐raf proto‐oncogene serine/threonine-protein kinase
(BRAF) critical for the MAPK pathway, are the most common (~50%), where the valine‐
to‐glutamic acid substitution at codon 600 (V600E) and other gain-of-function somatic
mutations lead to constitutive activation of downstream MAPK signaling [158]. However,
rather than one, multiple mutations in other genes are usually present in melanoma cells,
while alterations of BRAF alone are insufficient for driving a malignant phenotype [159].
Other relevant mutations that drive MAPK signaling are located in the neuroblastoma rat
sarcoma viral oncogene homolog gene (NRAS), which is mutated in 20% of the cases and
is associated with increased tumor aggressiveness, therapy resistance, and reduced patient
survival [160]. Furthermore, the amplification of transcription factors like microphthalmia‐
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associated transcription factor (MITF) (especially the M‐MITF isoform), which regulates
differentiation and pigment production in melanocytes, has been correlated with poor
patient outcomes [161].
On the other hand, melanoma also harbors mutations that inactivate important players
regulating other pathways like the phosphoinositide 3‐kinase/protein kinase B (PI3K/AKT)
pathway regulating cell proliferation and survival of melanoma cells. As an example, the
tumor‐suppressor phosphatase and tensin homolog (PTEN) gene encoding a
phosphatidylinositol‐3,4,5‐triphosphate 3‐phosphatase (PTEN) exhibits loss-of-function
mutations and focal deletion in ~20% of melanoma patients cohorts of The Cancer Genome
Atlas Network (TCGA) (reviewed at [156]). PTEN constitutes a negative regulator of the
PI3K/Akt signaling pathway, important for melanoma onset and therapeutic resistance
[162]. Interestingly, BRAF and PTEN alterations have been found overlapping and
cooperating with melanoma development [163, 164]. Moreover, the loss of PTEN has also
been associated with resistance to targeted and immune checkpoint inhibition (reviewed at
[156]), highlighting the significance of this genomic alteration for melanoma progression.

1.8.1.2 Overview of melanoma treatments
Overall, current treatments include the surgical removal of the localized primary tumor and
surrounding healthy tissue with a sentinel lymph node biopsy depending on the thickness
and ulceration of the lesion [165]. If necessary, to avoid the cancer spread, the remaining
lymph nodes affected by the tumor are removed. The two main options for metastatic
melanoma are targeted therapy and immunotherapy (Fig. 1-4). The former is based on
inhibiting the druggable mutant proteins (BRAFV600E and Mitogen-activated protein kinase
kinases (MEK)) that support a dysregulated MAPK/ERK pathway (Fig. 1-4A). However,
this is only pertinent for patients with BRAF-mutant metastatic melanomas. Nevertheless,
the combination of BRAF and MEK inhibitors has been required to curve the continuous
resistance mechanisms to single-agent therapy (like reactivation of MAPK/ERK and
alternative signaling pathways [166]) and is usually accompanied by adverse side effects
[167]. Although this type of therapy has improved survival for a subset of patients, there
are still cases that develop resistance to treatment [165].
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Figure 1-4.
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Figure 1-4. Schematic of the two main therapy options for metastatic melanoma:
targeted therapy and checkpoint inhibitors.
(A) Representation of the most dysregulated pathways in melanoma. Mutations in the
BRAF gene are present in ~50% of all melanoma skin cancers, causing constitutive
activation of the MAPK signaling. These mutations activate BRAF kinase resulting in the
gene expression that promotes cellular proliferation and survival. A combination of
inhibitors targeting mutant BRAF and MEK (a downstream effector in this pathway) is
currently used and has improved the patient response rate compared to single-agent
treatment. The phosphatidylinositol-3-kinase/protein kinase B/mammalian target of
rapamycin (PI3K/Akt/mTOR) signaling is another dysregulated pathway in melanomas
where inactivating mutations or downregulation of negative PTEN tumor suppressor has
been linked to alternative ways of resistance to targeted therapy. (B) Illustration recreated
from [168] showing the mode of action of checkpoint inhibitors in immunotherapy.
Monoclonal antibodies block PD-1, PD-L1, and CTLA-4. CTLA-4 is a negative regulator
of the “activation/priming” phase in T cells by binding with high affinity to B7 ligands,
needed for co-stimulation/interaction with CD28 molecules in the surface of T-cells after
antigen presentation through the T cell receptor (TCR) and the MHC-antigen peptide
complex (shown in red) of the antigen-presenting cells. PD-1 is on the surface of activated
T cells and interacts with PD-L1 (overexpressed by tumor cells), negatively modulating
the “effector” phase of the antitumoral response by inhibiting proliferation, survival, and
effector functions, as well as inducing apoptosis of tumor-specific T lymphocytes. Figure
created with BioRender.com.
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Conversely, immunotherapies take advantage of the intrinsic immunogenicity of the
melanoma tumor itself, where the high mutation burden produces recognizable tumor
antigens targeted by the immune system. Within the tumor microenvironment (TME),
several immune cell types can be found, for instance: tumor-infiltrating lymphocytes
(TILs),

Natural

killer

(NK)

cells,

macrophages,

dendritic

cells

(DC),

and

polymorphonuclear neutrophils [169]. In this sense, TILs are the workhorse and the
therapeutic targets of the well-known “checkpoint inhibitor therapy” to enhance tumor
elimination and prolong the anti-tumoral immune response [170]. Indeed, the presence of
TILs in tumors has been considered not only a predictor of melanoma prognosis but a
potential biomarker of response to cancer immunotherapy [171]. Specifically, checkpoint
inhibitor therapy aims to target negative immunoregulatory molecules present in the tumor
cells, FoxP3+ T regulatory (Treg), cluster of differentiation (CD)4+ T helper (Th), and the
effector CD8+ cytotoxic T lymphocytes (CTL) through an antibody-mediated blockade
(Fig. 1-4B). These checkpoint molecules play a role in inhibiting the immune response and
preventing autoimmunity while promoting self-tolerance and can be hijacked by the tumor
to avoid immune destruction (reviewed at [172]). Some examples are the cytotoxic Tlymphocyte-associated antigen-4 (CTLA-4), present in T cells upon activation but
constitutively expressed in Treg; the programmed cell-death protein 1 (PD-1) present in all
T cells, NK and B cells; and PD-1 ligands (PD-L1/2) present in somatic cells but
overexpressed in tumor cells. Combined MAPK inhibition and anti–PD-L1 therapy is also
a newer treatment option explored to improve tumor immune infiltration and long-lasting
response for patients with advanced melanoma [173]. Other immunotherapies modalities
are being tested and in use for melanoma treatment but are out of the scope of this thesis
and will not be addressed; however, they can be reviewed in [172, 174].

1.8.1.3 Tumor immune evasion during inflammation, implications for
melanoma immunotherapy
As mentioned above, cutaneous melanoma is amenable for immunotherapy due to the high
mutational load and the tumor immune cell infiltration. This crosstalk between tumor and
immune cells is heavily studied and offers various intervention strategies. However, the
immune component and its interaction in the TME exhibit a high degree of complexity and
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involve a series of pro-tumorigenic and immune-evasive mechanisms that need to be
overpowered for successful immunotherapy (Fig. 1-5). Some of these processes are briefly
described in the following paragraphs, but the underlying molecular mechanisms are
omitted as they are outside the scope of this thesis.
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Figure 1-5.

Figure 1-5. Summary of factors causing immune evasion phenotypes and
immunotherapy resistance in metastatic melanoma.
Melanoma tumor cells can escape the anti-tumoral immune-mediated response by
influencing the antigen presentation machinery and affecting the effector functions of antitumor-specific effector cells (CD8+ T lymphocytes, NK cells, and M1 macrophages).
Besides, dysregulation in metabolism and associated cellular pathways can exert selective
immune pressure in the TME, leading to immune exclusion and exhaustion phenotypes.
Finally, the recruitment of immune-modulator cells that yield pro-tumorigenic effects
(Treg, MDSC, M2 macrophages) is accompanied by the secretion of immune-suppressive
factors that allow the tumors to progress despite ongoing immune response infiltration and
inflammation. Figure created with BioRender.com.
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Melanoma cells can suppress anti-tumor immune cells by acquiring a less immunogenic
phenotype and immune escape mechanisms (reviewed in [169]). In this sense, due to
genetic or epigenetic alterations, tumor cells can downregulate the expression of tumorassociated antigens, disrupting or decreasing the expression of the major histocompatibility
complex (MHC) molecules. The latter reduces antigen presentation important for the first
steps of activation of tumor-specific naïve T cells. This mechanism hampers the treatment
with the therapies mentioned above using anti-CTL-4 and the PD-1/PD-L1 blockade that
requires peptide presentation for T cell (re)activation and clonal-proliferation of already
antigen-primed T cells present in the TME [175]. In addition, other evasive mechanisms
are mediated through the activation of PI3K or the WNT/β-catenin pathways in melanoma
cells [176-178]. A study in preclinical models of melanoma has shown that PTEN loss in
the tumor cells inhibits T cell-mediated tumor killing and is associated with decreased Tcell infiltration into tumors, an observation confirmed in patients [177]. The consequence
of this mechanism is then reducing the migration (“homing”) of T lymphocytes to tumor
sites or preventing their activation due to defects in chemokine production and recruitment
of DC cells to lymph nodes [178, 179].
Another mechanism involves the cargo from melanoma-derived extracellular vesicles,
which affects the maturation of DC, essential for T cell activation [180]. In addition,
accumulating evidence implicates the contribution of several tumor-derived soluble factors
(e.g., vascular endothelial growth factor (VEGF), tumor necrosis factors (TNFs),
transforming growth factor (TGF-β), interleukins (IL)-1,-6, -10, and prostaglandin E2
(PGE2)) in mediating immune cell suppression via the recruitment of tumor-associated
macrophages (TAMs), Tregs, and myeloid-derived suppressor cells (MDSCs) (reviewed
in [181]). Finally, even after tumoral T cell and NK cell infiltration occur, more hurdles
are thrown upon those effector cell types. In this regard, apart from the melanoma-derived
soluble factors and the role of immunosuppressive cells, as mentioned earlier, melanoma
cells can interfere with the effector/cytolytic function of anti-tumoral T-cells by
upregulating the expression of CTL4 in T cells and expressing high levels of PD-L1,
thereby causing T-cell anergy and hampering T cell activation [182]. Likewise, continuous
or chronic T-cell exposure to their cognate antigens (in the TME) may give rise to
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exhausted phenotypes impeding the execution of their effector function and permitting
melanoma tumor progression [183].
In summary, since host immune cells are essential as the first line of defense against tumor
cells, immunotherapies are desirable at the forefront of melanoma treatments. Decreased T
cell infiltration and the presence of immunosuppressive cells in the TME are two factors
downplaying the positive effect of immunotherapy. Even if melanoma has been branded
as a “hot” tumor due to the proinflammatory TME and diverse immune cell population
residing in the tumors, any increase of anti-tumoral effector immune cells would
undoubtedly increase the chances of success with immunotherapy [184].

1.8.2 Pannexin1 in cutaneous melanoma
Penuela et al. (2012) showed that Panx1 expression is low in normal mouse melanocytes
and highly expressed in isogenic mouse melanoma cell lines (B16-F0, -F10, -BL6).
However, no detectable protein expression was found for PANX2 or PANX3 [43]. That
study demonstrated that Panx1 knockdown in melanoma cells induces a more melanocytic
phenotype with reduced in vitro proliferation and migration and less metastatic capacity in
an ex vivo model [43]. In keeping with those findings, Freeman et al. (2019) demonstrated
that human melanoma cell lines also exhibited a high expression of PANX1 that was
confirmed in patient tumor biopsies at all stages of melanoma. Furthermore, our group
showed that decreasing PANX1 levels or inhibition of its function with CBX or PBN
channel blockers significantly reduced cell growth and migration of human melanoma cell
lines in vitro and ex vivo. These findings confirmed that PANX1 regulates the growth and
migration of melanoma cells, likely contributing to melanoma progression [42].
Some of the mechanisms involved in regulating PANX1 function in melanoma cells were
recently uncovered by Sayedyahossein et al. (2021), demonstrating a reciprocal regulation
of protein expression and cell membrane localization of PANX1 and β-catenin, an
important Wnt signaling transcription factor. In this case, it was found that the N-terminal
region of β-catenin physically interacts with the PANX1 C-terminus, which was proposed
to have a significant influence on the regulation of the stability and transcriptional activity
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of β-catenin. Moreover, endogenous PANX1 also seems to interact with calmodulin,
another regulator of Ca2+ signaling, hinting at the possibility of PANX1-modulation of both
canonical and non-canonical Wnt signaling pathways and aiding melanoma malignancy.
Importantly, in that study, a direct link between PANX1 and metabolic activity of
melanoma cells was identified, where PANX1 knockdown suppressed mitochondrial
metabolism and may also explain the PANX1-dependency of melanoma cells to sustain
proliferation and migration [42-44]. Given the notorious role of the Wnt/β-catenin pathway
supporting melanoma formation, metabolism, and metastasis [185, 186] and the newly
discovered links with the tumor promoter PANX1, further studies are needed to assess the
effectiveness of targeting PANX1 in the preclinical setting. Nevertheless, this newly
uncovered evidence establishes a dual role of PANX1 functioning as an ATP (and likely
Ca2+) channel and an interactome/signalome regulator within melanoma cells [187].

1.8.3 Considerations on pannexin regulation of the immune infiltration:
possible implications for melanoma
Although the role of PANX1 in melanoma cells is becoming clear, exactly how it favors
tumor progression in the TME is still a topic for future investigation. In this respect, it
needs to be considered the widespread expression of PANX1 in most cell types (tumor and
immune cells) constituting the TME [38, 42, 43, 97, 188]. PANX1 channels have been
implicated in regulating inflammation, apoptotic cell clearance, and immune cell
recruitment, which could severely influence melanoma progression [189].
Indeed, the release of ATP and other metabolites through PANX1 channels stimulates the
recruitment of immune cells and modulates inflammation in the surrounding tissue [38,
66]. Given the relationship between ATP‐regulated P2X7 channel/receptor (P2X7R) and
PANX1 channels [39, 40, 52] and their implication in melanoma tumor growth, Schneider
et al. (2014) originally proposed a model in which the increased ATP in the cellular
microenvironment would influence P2X7R/PANX1 channel formation and Nod-like
receptor family pyrin-domain containing-3 (NLRP3) inflammasome activation in
malignant melanocytes [190]. The NLRP3-mediated activation has been previously linked
to the PANX1 channel function [39, 40, 52, 191], although there is evidence that PANX1
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is not essential for this to happen in macrophages [192]. On the other hand, the P2X7R is
a non-selective cation channel that permits the efflux of K+ and influx of Na+ and Ca2+,
inducing plasma membrane depolarization and promotes the NLRP3 activation [193]. This
subsequent activation of NLRP3 inflammasome leads to the release of pro-inflammatory
cytokines interleukin- (IL-)1β and IL‐18, and increased cyclooxygenase‐2 and
prostaglandin‐E2 by melanoma cells [194]. Notably, although it was demonstrated only in
endothelial cells, a PANX1-dependent Ca2+ influx also supports the synthesis and release
of IL-1β independently of purinergic signaling [191].
IL-1β has been reported to be constitutively secreted in metastases [195, 196], tumorassociated macrophages, and fibroblasts, contributing to resistance to MAPK-inhibition in
melanoma [197]. Thus, it is plausible that PANX1-mediated IL-1β release could lead to
immunosuppression (reviewed in [198-200]). Interestingly, genetic or pharmacological
targeting of the NLRP3 inflammasome combined with anti–PD-1 therapy has increased the
treatment efficacy compared to anti-PD-1 monotherapy in a syngeneic melanoma mouse
model [196]. Thus, deletion or inhibition of PANX1 channels could indirectly reduce IL1β-derived immunosuppression, although further research is needed to demonstrate this.
On the other hand, if PANX1 is overexpressed in melanoma cells [42, 43], an excessive
ATP release would also have deleterious effects on CD4+ T lymphocytes and enhance the
proliferation of immunosuppressive Treg cells infiltrated in the melanoma tumor [201,
202]. Finally, another consideration is that due to the PANX1 involvement in melanoma
metabolism [44], a link to the direct activation of P2X7R in cancer cells could increase the
plasma membrane glucose transporter 1 (GLUT1) [203] and promote the Warburg effect,
leading to lactate release and acidification of TME. This has been reported to impede both
DCs differentiation and cytokine release in the TME, promoting M2 macrophage
differentiation (immunosuppressive type) and MDSCs activation (reviewed at [204]),
which could be advantageous for the tumor immune escape. PANX1 may influence the
intratumoral

immune

infiltration

to

favor

tumor

progression

and

immunosuppression/evasion (Fig 1-6), but more research in this regard still lacks in the
context of cancer.
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Figure 1-6.

Figure 1-6. The complexity of PANX1 expression in the tumor microenvironment.
PANX1 is highly expressed in melanoma cells, and its channel function modulates their
proliferation, migration, and metabolism. PANX1 function also contributes to the
clearance of apoptotic cells, immune cell chemotaxis and mediates the activation of
dendritic cells and T cells through purinergic signaling. In other contexts than cancer,
PANX1 was detected in leukocytes in the endothelium [97], dendritic cells [205], CD4+
[54], and CD8+ T cells [206], and macrophage and other myeloid cells present in the injury
sites during neuroinflammation [207]. It remains to be determined the influence of PANX1
expression in other immune cell types (marked with a red question mark) and tumorassociated cells that affect the inflammatory response within the tumor site.
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1.9 Rationale
Pannexins play a critical role in maintaining the skin architecture, homeostasis, and cellular
properties of different skin cells. PANX2 expression was found not restricted to the CNS
and has been previously reported in the skin. However, it remains elusive which skin cell
type expresses PANX2 and whether it is regulated during skin aging, as shown with the
other pannexin family members. Therefore, we sought to explore the PANX2 expression
in the two major skin cell types (keratinocyte and dermal fibroblast) and the skin of
newborn and adult wild-type C57BL/6 mice. Notably, apoptotic mechanisms balance the
proliferation of the cells in the skin (e.g., keratinocytes) to maintain epidermal thickness
and circumvent malignant transformation upon injury or insults like UV radiation. In the
pannexin protein family, only PANX1 and PANX2 can be targeted by apoptotic effector
caspases by cleaving their intracellular carboxyl-terminal domains. In this sense, the sites
for caspase cleavage of PANX2 remain uncovered, and it is unclear whether this PTM
occurs in cells as only in vitro enzymatic assays have shown its susceptibility to caspases.
Given that PANX2 has been found in the ER-mitochondria contact sites, it has been
suggested that it may play a role in contributing to the apoptosis process. Thus, using a
combination of bioinformatic predictions and mutagenesis, we seek to uncover the role of
PANX2 caspase cleavage and its consequences under UV-induced apoptosis in skin cells.
Furthermore, previous evidence pointed out that all the pannexin paralogs can be Nglycosylated, and although it is not a requirement, this influences PANX1 and PANX3
trafficking to the cell surface. However, until this thesis project, the specific glycosylation
site and its role on PANX2 subcellular translocation were unknown. On the other hand,
only lower glycosylated Gly0 and Gly1 PANX1 species have been shown to interact with
PANX2 when co-expressed together and tentatively forming a heteromeric channel, but it
was unclear whether PANX2 glycosylation status would also impact this intermixing.
Hence, we sought to study the N-glycosylation role on PANX2 localization and interaction
with PANX1 by generating a PANX2 glycosylation-deficient mutant at the putative site
for this PTM.
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Finally, during pathological states, like skin cancer, upregulation of PANX1 seems to foster
the malignant cellular properties of tumor cells. In melanoma, increased PANX1 promotes
proliferation and migration of malignant melanocytes. Nevertheless, the effect of high
PANX1 levels in the context of melanoma has not been studied in vivo. Due to the
ubiquitous expression of PANX1 in most cell types constituting the tumor tissues (e.g.,
cancer, stromal and immune cells) and its role in modulating immune cell recruitment and
inflammation, there is a potential function of this channel-protein within the TME favoring
pro-tumorigenic and immunosuppressive states of melanoma. To date, the PANX1 role in
melanoma in vivo or its impact on tumor immune infiltration has not been addressed, which
could have significant implications for the improvement of melanoma treatments, like
immunotherapy. Therefore, we explored the effect of the global deletion of PANX1 on in
vivo tumor progression and immune cell infiltration using a validated melanoma mouse
model.

1.10 Hypothesis
The overall hypothesis of this thesis is that: the regulation of PANX1 and PANX2 levels is
necessary to maintain skin homeostasis, modulate cell death and avoid malignant
transformation and cancer progression in the skin, while glycosylation and caspase
cleavage control their localization and biological function.
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1.11 Objectives
The research objectives of this thesis are the following:
Objective 1 – Manuscript 1: Chapter 2
Characterize PANX2 expression in normal mouse skin and evaluate its cleavage by
caspases and consequences for cell death during UV-induced apoptosis.
Objective 2 – Manuscript 2: Chapter 3
Define the site of N-glycosylation in PANX2 and its role in subcellular localization and
interaction with PANX1.
Objective 3 – Manuscript 3: Chapter 4
Study the effect of the global deletion of PANX1 on tumor progression and immune
infiltration in an inducible mouse model of metastatic melanoma.
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Chapter 2
A mouse Panx2 splice variant (Panx2-202) has been reported in the skin, but its expression
has not been thoroughly investigated. Furthermore, canonical PANX2 was shown to be a
substrate in vitro for apoptotic caspases, but it is unclear whether this PTM occurs in cells
during apoptosis. In this chapter, we assessed the PANX2 splice variant expression in
normal murine skin of different ages and identified the primary cell type where it is
expressed. Moreover, we evaluated the consequences of caspase cleavage of canonical
PANX2 in apoptotic keratinocytes using UVB irradiation as an apoptotic stimulus.
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2 Pannexin 2 is expressed in the murine skin and promotes UVBinduced apoptosis of keratinocytes
2.1 Introduction
Pannexins (PANX1, PANX2, PANX3) are channel-forming glycoproteins that participate
in paracrine signaling and are expressed in several tissues [1, 2]. Initial studies showed
abundant PANX2 levels in the central nervous system leading the scientific community to
consider that PANX2 expression is restricted. Recent evidence indicates a broader
expression and potential functions in other tissues like the skin [3]. Only PANX1 and
PANX3 orthologs have been characterized in the context of the skin, which can be found
in the different skin layers and appendages with various localization profiles [4, 5]. PANX3
remains steadily expressed after skin development [4], while PANX1 has the highest
expression levels at early postnatal stages but becomes downregulated in aged skin [6].
PANX2 expression has also been detected in the skin [3], but its exact distribution profile
and regulation have been largely unexplored in this tissue.
Moreover, PANX1 and PANX3 channels are regulated during keratinocyte differentiation
and are implicated in regulating proliferation, differentiation, and wound healing [4, 6-8].
Much less is known regarding PANX2, for which it has been established that it is expressed
in brain tissue and participates in regulating neurogenesis [9] and ischemia-induced
neurodegeneration [10]. Besides, PANX2 is downregulated in lower-grade glioma and was
recently shown to influence multiple molecular pathways and immune infiltration in these
cancer tumors [11].
Interestingly, PANX2 has been identified at the endoplasmic reticulum (ER)-mitochondria
interface [12], and it has been suggested to promote cell death. However, the roles of
PANX2 seem to be different depending on the type of cell death and the cell insult. For
example, although PANX2 has been found downregulated in gliomas, its overexpression
in rat C6 glioma cells reduces their oncogenicity and accelerates staurosporine-induced
apoptosis [12, 13]. Furthermore, genetic deletion of Panx2 (along with Panx1) reduces
neuronal cell death through necrosis and protects mice from ischemic stroke [10]. In
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contrast, it was reported that pro-inflammatory cytokines reduce PANX2 expression in
pancreatic β-cells and increase cytokine-mediated apoptosis causing severe diabetes in
mice [14]. More recently, PANX2 expression was shown to be enriched in prostate cancer
cells, negatively regulating a form of cell death known as ferroptosis, where it was
implicated in regulating lipid peroxidation and the cell uptake of ferrous iron [15]. Despite
these findings, little is known about the roles that PANX2 might play in the skin and
whether this pannexin influences cell death.
The skin is frequently subjected to damage by ultraviolet light (UV), where apoptosis has
an important physiological function to maintain homeostasis [16]. Notably, PANX2 has
been shown to undergo in vitro cleavage by apoptotic caspases-3/7 (Penuela et al., 2013).
However, the sites for this post-translational modification have not been confirmed nor its
occurrence in the cellular context. Considering PANX2 is present in the skin, it is possible
that, in this context, it could undergo cleavage by apoptotic caspases and modulate the
UVB-induced apoptosis of these cells.
In the current study, we sought to explore the temporal regulation of PANX2 expression in
the developing and mature skin at the protein and transcript levels. Furthermore, we studied
PANX2 localization, determined what cell type is primarily expressing PANX2 in the skin,
and investigated whether the caspase-mediated cleavage of this pannexin can result from
UVB radiation-induced apoptosis as a relevant biological model of cell death in the skin.
We hypothesized that PANX2 is cleaved by executioner caspases and promotes the
apoptosis of skin cells after UVB insult.

2.2 Materials and Methods
2.2.1

Cell lines, transfection, and culture conditions

Human embryonic kidney (HEK293T CRL-3216™) cells were obtained from ATCC®
(Manassas, VA, USA). Rat epidermal keratinocytes (REK) immortalized cell line was a
kind gift from Dr. Dale Laird and was previously characterized in [6, 17, 18]. Media and
most supplements were obtained from GIBCO® (Grand Island, NY, USA) and
Invitrogen™ (Carlsbad, CA, USA). Unless otherwise stated, cells were grown in DMEM
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(1X) (GIBCO, REF#12430-054, Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (FBS) (WISENT INC Cat# 080-150, QC, Canada), 1% penicillinstreptomycin (Pen Strep) (GIBCO, REF#15140-122, Grand Island, NY, USA) and
maintained at 37°C under humidified 5% CO2–95% air. For in vitro differentiation studies
with REK cells, the culture medium was supplemented with calcium chloride at 2.0 mM
final concentration for 72 h, or stratified piles of overgrown monolayer cultures were kept
for the same length of time. For transient transfections, the cells were transfected using 5
µg of plasmid DNA with Lipofectamine 3000 (Invitrogen™ REF# L3000-015, Carlsbad,
CA, USA) as per manufacturer instructions. For apoptosis assays, 24 h post-transfection,
cells were split in half for immunofluorescence staining, and the rest used for Incucyte®
Live-cell imaging of UVB-induced apoptosis experiments.

2.2.2

Isolation and culture of mouse epidermal keratinocytes and dermal
fibroblasts

The Animal Care Subcommittee of The University of Western Ontario approved all
procedures with mice (Protocols 2019-069 and 2019-070). Isolation of primary
keratinocytes and dermal fibroblast from neonatal dorsal skin (P4) was performed
following the protocols described in [6]. Primary keratinocytes were cultured in KBM™
Gold™ Basal Medium (Lonza Cat#: 00192151, Walkersville, MD, USA) supplemented
KGM-Gold™ Keratinocyte SingleQuots® (Lonza Cat#: 00192152 Walkersville, MD,
USA) at 37⁰C, 5% CO2. The culture medium was replaced first at 16 h post-harvesting and
later every 48h. Keratinocytes were kept for up to 3 weeks until they reached 60-70%
confluency without any passaging before the experiments. For primary keratinocyte in
vitro differentiation, non-confluent cell monolayers were exposed for 72 h to culture
medium supplemented with a final concentration of 1.8 mM of CaCl2. Fibroblasts were
cultured in DMEM media supplemented with 10% FBS and 1% Pen Strep and growth in
plates coated with type I rat tail collagen (Corning REF#354236, Bedford, MA, USA) until
cells reached 70-80% confluency. Cultures of primary dermal fibroblasts were only
passaged for a maximum of three times, and visual inspection of a spindle-shaped
morphology was continuously assessed before the experiments. Fibroblast stimulation with
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TGF-β was performed as previously indicated in [6] with 200 pM TGF-β (PeproTech)
dissolved in culture media for four days.

2.2.3

CRISPR-Cas9-mediated PANX2 deletion in REK cells

CRISPR/Cas9 technology was used to generate PANX2 knockout REK cells (REKPANX2KO) according to Synthego's nucleofection CRISPR protocol. CRISPRevolution
single‐guide RNA (sgRNA) EZ kit targeting beginning of exon 2 of rat Panx2 gene
(sequence: GCACAACUUCACCCGUGACC) and Cas 9 2NLS nuclease were obtained
from Synthego (Synthego Corporation, Menlo Park, California). 106 cells/reaction were
used for nucleofection with complexed ribonucleoprotein (9:1, sgRNA to Cas9 ratio) and
NucleofectorTM solution L + supplement in a Nucleofector™ II (Amaxa biosystems,
Germany) according to the manufacturer's instructions. Expansion and clonal selection
were then performed post-nucleofection and genomic DNA isolated for genome
sequencing and analysis by Inference of CRISPR Edits (Synthego). Platinum Taq DNA
High Fidelity polymerase (Invitrogen REF#11304-011, Carlsbad, CA, USA) was used for
PCR to genotype the target region as per manufacturer instructions using the following
primers

Px2-F

(5’-GGGGGTTCATTTGGGGAACA-3')

and

Px2-R

(5’-

CAGGAAGTTGAGCTCGGAGG-3'). The genomic deletion was confirmed by Sanger
sequencing provided by the London Regional Genomics Centre (Robarts Research
Institute, London, ON, Canada).

2.2.4

Mutagenesis of Flag-tagged PANX2 constructs

Mouse Panx2 (canonical) construct from [5] was used to fuse a single FLAG epitope
(DYKDDDDK) to the N-terminal region of the PANX2 using the In-Fusion HD Cloning
Kit protocol (Clontech®, Mountain View, USA) as per the manufacturer's directions using
the

following

primers:

NFLAG

sense

(5'

-

ACCATGGATTACAAGGACGACGATGACAAGGGTTCTTCCCACCACCTCCTGG
AGC-3') and antisense (5'-GTCGTCCTTGTAATCCATGGTGAATTCCACCACACTG3'). Procleave web server [19] was used to predict the caspase cleavage consensus sites,
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and site-directed mutagenesis was performed by NorClone Biotech Labs (London, ON,
Canada).

2.2.5

Protein extractions and western blots

Cell lysates and co-immunoprecipitation assays were performed as described in [5, 20].
Total protein concentrations were quantified with Pierce™ BCA Protein assay kit (Thermo
Scientific REF#23225, Rockford, IL, USA). 40 µg of total protein were resolved by 10%
SDS-PAGE or TGX Stain-Free FastCast 10% Acrylamide stain-free gels (Cat#161-0183,
Bio-Rad, USA) and transferred onto nitrocellulose membranes using an iBlot™ Blotting
System (Invitrogen, USA). Membranes were blocked with 3% bovine fraction V heat
shock serum albumin (BSA)(BioShop REF# ALB001.100, Burlington, ON, Canada) in
0.05% Tween 20-Phosphate Buffer Saline (T-PBS) for 45 min and probed overnight at 4ºC
with the primary antibodies. Primary antibodies used for Western blots were: anti-PANX2CT-523 [20] (1:500 dilution); Anti-FLAG® M2 monoclonal antibody (REF#F3165,
SIGMA-ALDRICH, St. Louis, MO, USA), anti-Panx2-NT (Cat#ARP42778_T100; Aviva
Systems Biology, San Diego, CA) [9], mouse monoclonal anti-PANX2 (clone N121A/31
75-213) antibody (UC Davis/NIH NeuroMab Facility, CA, USA) [3], and cleaved caspase3 (D175) (REF#9661S, Cell Signaling Technology, USA) were used at 1:1000 dilution;
anti-GAPDH (Cat# MAB374, RRID: AB_2107445, Millipore, USA) was used at 1:5000
as the gel loading control. For detection, secondary antibodies IRDye® -800CW and 680RD (LI-COR Biosciences, Lincoln, NE, USA) were used at 1:25000 dilution. Western
blots were visualized with Odyssey® infrared imaging system (LI-COR, NE, USA) except
for the skin lysates. For skin protein lysate immunoblots on nitrocellulose membranes,
stain-free total protein was used for total protein determination imaged with a ChemiDoc™
MP System (Bio-RAD, USA). As an internal control to assess blot-to-blot variations, a
brain lysate control was resolved on each gel and used for normalization. Normalization
and densitometry measurements of bands of interest were done using Image Lab™
Software (Ver 6.0.1., Bio-Rad Laboratories, Inc). Other densitometry and lane profile
analyses for molecular weight estimations of caspase-cleaved PANX2-fragments were
performed using the ODYSSEY application software (ver 3.0.16, LI-COR, NE, USA).
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2.2.6

Immunofluorescence and imaging

Dorsal skin tissue samples were fixed in 10% neutral buffered formalin overnight at 4ºC,
processed in the Molecular Pathology Core Facility at Robarts Research Institute (London,
ON, Canada) and subsequently embedded in paraffin. Five μm-thick sections were
deparaffinized in xylene, rehydrated in graded alcohols, and washed in PBS. Antigen
retrieval was performed using 1.5% of Vector Labs Tris-based Antigen Unmasking
Solution (Cat# H-3301, Vector Labs, Burlingame, CA) heating for 5 min in a 750W
microwave (at 80% power) and then let cool down at room temperature (RT) for 10 min.
Next, sections were rinsed once in distilled water, followed by PBS for 5 min. The sections
were incubated with blocking solution (3% BSA, 0.1% Triton X-100 in 1X PBS) for 1h at
room temperature in a humidity chamber. Immunofluorescence labeling of sections was
performed overnight at 4ºC with the primary antibodies diluted in blocking solution. Rabbit
anti-PANX2 -CT, -IL, -NT polyclonal antibodies were used at ~100 µg/mL final
concentration. Alexa Fluor 488 goat anti-rabbit IgG (Cat#A-11008, Thermo Fisher
Scientific, USA) (2.9 µg/mL) was used as a secondary antibody. Slides were mounted
using VECTASHIELD® mounting medium (Vector Laboratories). For coverslips
immunostaining, cell monolayers were washed with D-PBS (Gibco) and fixed with icecold methanol: acetone (5:1, v/v) for 15 minutes at 4ºC. Coverslips were blocked for 1h at
RT with 10% Normal Goat Serum (Life Technologies REF#50062Z, Frederick, MD,
USA). Primary anti-PANX2-CT or anti-FLAG antibodies were used in 1:100 and 1:500
dilutions in 1% Normal Goat Serum-2% BSA-PBS. Coverslips were incubated with
primary antibodies for 1 h at RT, then washed with PBS and re-incubated with donkey antimouse antibody Alexa FluorTM 488 (1:400, Cat# A-21202, Invitrogen) and Texas RedTMX goat anti-rabbit (diluted 1:500, REF#T6391, Life Technologies, Eugene, OR, USA) to
label FLAG-tagged PANX2. Aqua-Mount medium (LERNER LAB, REF#13800, MI,
USA) was used as mounting media. In all cases, Hoechst 33342 (REF#H3570, Life
Technologies, Eugene, OR, USA) (diluted 1:1000 in double-distilled water) was incubated
with the samples for 7 min at RT to stain cell nuclei. Images were obtained on a Zeiss LSM
800 AiryScan confocal microscope from the Schulich Faculty Imaging Core Facility using
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the following objectives: LCI Plan-Neofluar 25x/0.8 1 mm Korr DIC for skin sections and
Plan-Apochromat 63x/1.40 Oil DIC M27 for coverslips.

2.2.7

Detection of caspase cleaved PANX2 fragments

In vitro caspase-3 cleavage and IP of cleaved fragments were performed as described in
[21]. For UVB-induced apoptosis assays, Protein lysates from apoptotic cells were
obtained after eight hours of post-UVB-irradiation, and a similar IP (using 250 µg of total
protein) was performed to capture the PANX2 cleaved fragments. 25 µg of the input protein
lysates were used for assessing protein expression by Western blot. In both cases (after
caspase-3 treatment or in-cell UVB-induced apoptosis), the beads used for IP were dried
by aspiration and resuspended in 2X Laemmli buffer (with β-mercaptoethanol), boiled for
5 min, and ran in 10% SDS-PAGE gel for immunoblots with the anti-FLAG monoclonal
antibody.

2.2.8

RNA isolation and real-time qPCR.

Total RNA was extracted from flash-frozen mouse dorsal skin samples at different ages
using Ambion TRIzol™ Reagent (Life Technologies, REF#15596018, Carlsbad, CA,
USA) and purified using the RNAeasy® Plus Mini kit (REF#74134, QIAGEN GmbH,
Hilden, Germany). For cell cultures, RNA was extracted with the RLT lysis buffer
(Qiagen), and QIAshredder spin columns (REF# 79654, QIAGEN GmbH, Hilden,
Germany) were used instead of the TRIzol. All protocols were used following the
manufacturer's instructions. RNA concentration was determined using an Epoch
Microplate Spectrophotometer (BioTek®, Winooski, VT, USA). Reverse transcription
(RT)-PCR was performed using the High Capacity cDNA Reverse Transcription Kit with
RNase inhibitor (Applied biosystems REF#4374966, Thermo Fisher Scientific, Vilnius,
Lithuania). A CFX96 Touch TM Real-Time PCR Detection System (Bio-Rad, Hercules,
CA, USA) and Sensifast SYBR Green PCR Master Mix (Cat#1725274, Bio-RAD, USA)
was used to determine the mean quantitation cycle (Cq) for each sample by triplicate and
the relative transcript expression was calculated using the ΔΔCt method in Bio-rad CFX
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Maestro Software, ver 1.1 (Bio-rad, USA). Primer sequences used for real-time-qPCR are
listed in Table 2-1.
Table 2-1 Primers used for real-time qPCR
GENES

FORWARD (5' ->3')

REVERSE (5' ->3')

AMPLICON

(bp)

Panx2
Panx2-202
Krt5
Krt10
Krt14
Ivl
Lor
Gapdh
Rn18s (18s)
Acta2
Panx2
Krt10
Krt14
Ivl
Lor
Gapdh

2.2.9

Mouse
ACTGTGGAGTTTTGAGGGGC
GCAGTACCGGGTGAACAGAG
CAGCCCGTGTCTCCTCTCTAC
GTAGCCGCGGGCGTACA
TGAGGAGCTGCAACAGACAG
AGGTTGGCACACTGCTTCTT
CAGCTGGCCCTGAAACAATC
AGTTGTTGGTACTCGGCGTT
AGTGAGAAAGTGACCATGCAGA CTGCCAGGATCTTGCTCTTCAG
CTCCTGTGAGTTTGTTTGGTCT CACACAGTCTTGAGAGGTCCC
TCCCTGGTGCTTCAGGGTAAC
TCTTTCCACAACCCACAGGA
TGTGTCCGTCGTGGATCTGA
TTGCTGTTGAAGTCGCAGGAG
GTAACCCGTTGAACCCCATT
CCATCCAATCGGTAGTAGCG
GCTGGACTCTGGAGATGG
GCAGTAGTCACGAAGGAATAG
Rat
ACCAAAGATGCTCCGCTCC
GGGTGAGCACACATGGAATG
AGCTGGCCCTGAAACAATC
ATTTGCAGGTTTCCAACATACCC
CGTCAGTTCACCTCCTCCAGC
GAAACGAGACATGCCCCCGTA
AGTGCCAGTGACTGTTCCAG
ATCTTTCACGGGGTTTGCCT
CCCAGTGTCTCTCACATCACC
TAAGGAGAAGGGGAACCCCGA
GGCATTGCTCTCAATGACAA
TGTGAGGGAGATGCTCAGTG

118
95
135
161
196
105
93
150
151
156
90
250
129
184
77
223

UVB irradiation for induction of apoptosis

48 h post-transfection REK-PANX2KO cells cultured in 60-mm plates were washed once
with sterile D-PBS (without Ca2+ or Mg2+) (Gibco REF#14190-250). Cell monolayers kept
in pre-warmed D-PBS were placed 16 cm below a UVM-26 EL series, 8-watts lamp (UVP,
Upland, CA) and immediately subjected to lethal UVB treatment (302 nm, 1500 J/m2) or
mock-irradiated. A UVB-dosimeter was used to control the irradiance intensity. Then,
culture media was immediately replaced, and cells were kept in the incubator until being
harvested for protein lysates or cultured in the Incucyte® Live-cell Imaging System for
continuous cell death monitoring.

2.2.10

Live-cell imaging of UVB-induced caspase-3 activation and
cytotoxicity

Five thousand cells/well were seeded in a flat-bottom 96-well culture plate (SARSTEDT
REF#83.3924, Nümbrecht, Germany) with MEM (Gibco Cat# 11095-080, Grand Island,
NY, USA) culture media supplemented with 10% FBS and 1% P/S antibiotics. Cells were
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allowed to attach to the bottom of the plate for 30 min in the incubator before being
monitored. After UVB treatment, pre-warmed MEM culture media was added
supplemented with IncuCyte® Caspase-3/7 Green Apoptosis Reagent (Sartorius, Cat#
4440, USA) at 1/1000 dilution and Cytotox Red Reagent (Sartorius, Cat# 4632, USA) at
250 nM final concentration. Live-cell images were acquired with a 10x objective every two
hours for 50h, with phase, green, and red channels using an IncuCyte® S3 Live-Cell
Analysis System (Essen BioScience, Ann Arbor, MI, USA). Acquired data was analyzed
using the Cell-by-cell Analysis Module in the IncuCyte® 2020A Software package (Essen
BioScience Inc., USA).

2.2.11

IncuCyte data analysis and time to apoptosis calculation

The fold change (from phase or fluorescence data) over time was calculated by dividing
the object counts (determined by Cell-by-cell Analysis) of any given time point by the
counts acquired at the beginning of the experiment (i.e., 0 h). To account for transfection
efficiency, the fold change was divided by a normalization factor (Nf) calculated as per
equation 1:
𝑁𝑓 = 1 + 𝑇𝐸 (1),
Where TE corresponds to the transfection efficiency and non-transfected cells were
arbitrarily set as TE=0 (e.g., Nf=1 if cells are untransfected). TE was estimated by the
percentage of cells positive for PANX2(FLAG) immunofluorescence (IF) grown in
coverslips and fixed at the start of apoptosis experiments. Counts were done by automatic
quantification using Cell Profiler Software (ver 4.0.7, Broad Institute, USA ) [22]
(Lamprecht et al., 2007) using at least fifty non-overlapping IF images per field. In this
case, IF images were acquired with a Ni-E Fluorescence Microscope (Nikon, Japan) using
an S Plan Fluor ELWD 20x Ph1 ADM 0.45 N/A objective. Normalized data are shown in
time-course graphs after adjusting the range of values from 0 % (first measurement) to
100% (last acquired value) using GraphPad Prism software (version 8.0). For the
estimation of the time to apoptosis, normalized data were fitted to an allosteric sigmoidal
function (equation 2):
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%Cact =

Cmax × 𝑡 𝑎
𝑡50%𝑎 +𝑡 𝑎

(2),

where %Cact corresponds with the percent of caspase activation (Cact) at any given time
(t); Cmax is the caspase activation when ~100% of the cells are apoptotic and Caspase-3/7
signal is saturated, t50% is the time to reach half-maximal caspase activation (~50% of cells
are apoptotic), and a is the slope factor in the curve. Only accurate curve fitting was used
for the estimations considered when the goodness of fit (R2) ≥ 0.95.

2.2.12

Statistical analysis

Unless otherwise indicated, all data are presented as the mean ± standard error mean (s.e.m)
and represent at least three independent biological replicates or experiments (N=3)
conducted with at least two technical replicates (n=2). Statistical analyses are indicated in
the figure captions and were performed using GraphPad Prism software (version 8.0) (La
Jolla, CA, USA).

2.3 Results
2.3.1

Two PANX2 splice variants are expressed in the mouse dorsal skin

Due to the previous role of PANX1 and PANX3 in regulating cellular processes in the skin
(e.g., keratinocyte differentiation and wound healing) and the earlier detection of PANX2
in the skin [3], we sought to characterize PANX2 expression in mouse skin. Earlier, we
reported [23] another splice variant (termed as Panx2-202, as mRNA transcript, PANX2202, as protein variant) that is predicted for the mouse Panx2 gene (Fig. 2-1A, Table 2-2)
and appears in the mouse genome annotation by Ensembl (release 103). PANX2-202
differs in length from the canonical PANX2, encoding a 26 amino acid (aa) shorter protein
of an estimated molecular weight (MW) of ~71.7 kDa.
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Figure 2-1.
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Figure 2-1 Transcript and protein levels of PANX2 variants are differentially
regulated in mouse dorsal skin.
(A) Diagram representing the Panx2 gene coding exons in green as per Ensembl (release
103) annotation. Straight lines with grey arrowheads represent the intronic regions of the
sequence. Underneath, blue and grey rectangles depict the coding sequence (CDS) of splice
variants vertically aligned with the gene representation at the top. Regions amplified by
qPCR primers are shown as dashed lines. Differences in protein length and molecular
weight (MW) are shown on the right (B) mRNA expression of each Panx2 splice variant
in male and female dorsal skin. Gapdh was used as the reference gene for normalization.
Bars are the geometric mean expression (geomean) ± s.d. (C) Western blots showing the
canonical PANX2 (~75 kDa, blue arrowhead) was lower in the skin than the PANX2-202
splice variant (~70 kDa, black arrowhead). Migration of skin PANX2 protein bands
differed from an intense band found in mouse whole brain (4-week-old) (apparent MW of
~89 kDa). Mouse canonical PANX2 was overexpressed in HEK293T cells as control
(PANX2-HEK293T lane). (D) Densitometric analysis of WB showed a more abundant
PANX2-202 transiently increased in four-week-old mice skin but restored at previous
levels at 12 weeks. Two-way ANOVAs and Tukey posthoc tests were used for multiple
comparisons. Same letter indicates no statistical difference among groups. Significance
was considered when p<0.05.
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Table 2-2 Pannexin 2 orthologs information in genomic and protein databases as of
April 2021.

Species
Homo
sapiens

Rattus
norvegicus
Mus
musculus

Ensembl
Transcript ID

NCBI
RefSeq
Protein ID

Uniprot
ID

Isoform

Length
(aa)

MW
(kDa
)

ENST000003958
42.3
ENST000001596
47.9

NP_443071.2

Q96RD6-3

Canonical

677

74.45

NP_00115377
2.1

Q96RD6-1

Isoform-1

643

70.64

-

NP_955441.2

P60571-1

674

74.43

ENSRNOT0000
0089707.1

-

R9PXY9

Canonical
Predicted
Isoform

634

70.25

NP_00100200
5.2

Q6IMP4-1

Canonical

677

74.61

-

Q6IMP4-2

PANX2-202

651

71.69

ENSMUST0000
0162424.2
ENSMUST0000
0161372.2
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According to computational annotations, the mouse PANX2-202 (Uniprot identifier:
Q6IMP4-2) differs from the canonical PANX2 protein sequence in the insertion of eight
amino acids after position 75 (insertion sequence: "ARVSSLPS") located in the first
extracellular loop domain and the replacement of the distal end of the C-terminal region
(from 632-677) with the "SSSPPSRSREQL" amino acid sequence (Fig. S2-1, S2-2B).
Based on these differences, we designed specific qPCR primers (Fig. 2-1A) to accurately
detect the expression of both isoforms in mouse dorsal skin. We used real-time qPCR to
detect transcripts of both Panx2 splice variants in the skin at all ages investigated (postnatal
day (P) 0, 4 and 4-, 12-weeks-old skin). We found no significant differences in mRNA
expression levels among Panx2 transcripts at each age investigated when comparing male
and female mice (Fig. 2-1B). Interestingly, Panx2-202 mRNA was significantly increased
only at P0 compared to the canonical variant in male mice, and a similar trend (p>0.05)
was observed in female skin, but this difference was not sustained in later ages (P4-12
weeks).
At the protein level (Fig. 2-1C), using our rabbit anti-PANX2-CT polyclonal antibody [20,
24], we detected multiple immunoreactive bands with one distinctively at the expected
molecular size of the smaller PANX2-202 (~70 kDa) variant. This isoform trended more
abundant than the canonical PANX2 (expected at ~75 kDa, appearing as a faint band) and
was continuously detected at all ages investigated. Notably, in 4-week-old skin, PANX2202 was transiently increased (p<0.05) compared to other ages (Fig 2-1C, D). In addition,
immunoblot band profile analysis in 4-week-old whole brain lysates showed that the
endogenous PANX2 exhibits an immunoreactive band with a higher apparent molecular
weight (~85.7 ± 2.3 kDa) and other multiple bands of lower intensity detected at ~75.1 ±
2.1 kDa (Fig. 2-1C, whole-brain lane)

2.3.2

PANX2 expression is abundant in the epidermis and is likely
regulated during the early stages of keratinocyte differentiation

Previously, it has been shown that PANX1 and PANX3 are expressed in the murine
epidermis and other skin adnexal structures of the skin [25]. Therefore, we sought to
localize PANX2 in the skin of C57BL/6N mice using immunofluorescence staining of skin
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sections collected at P0, P4, and four weeks of age. We used three different rabbit
polyclonal anti-PANX2 antibodies raised against the intracellular loop (IL-), carboxyl (CT) or amino (NT) terminal domains (Fig. 2-2, Fig. S2-2) of PANX2 [20, 21]. All the
antibodies exhibited abundant intracellular and diffused staining in cells from the
suprabasal layers of the skin (stratum spinosum, granulosum, and the cornified layer),
suggesting that PANX2 is primarily present in differentiating epidermal keratinocytes (Fig.
2-2) in the skin at P0, P4, and up to 4 weeks of age. In addition, we found staining in the
cornified layer that may represent nonspecific immunostaining or remnants of PANX2 in
that epidermal layer. Besides, a diffused PANX2 staining was also detected in the outer
root sheaths of hair follicles and other regions of the dermis (Fig. S2-2A).
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Figure 2-2.

Figure 2-2 . Pannexin 2 is abundant in the suprabasal layers of the epidermis of mouse
dorsal skin.
(A) Representative immunofluorescence micrographs of endogenous PANX2 protein
immunostaining (green) in formalin-fixed sections (N=3) of dorsal skin at postnatal days
(P) 0, 4, and 4 weeks old. Intense intracellular PANX2 staining with anti-PANX2-CT
polyclonal antibody is visualized in cells of the suprabasal layers of the skin. As a control
for antibody specificity, sections were stained with the secondary antibody without the
primary antibody (Secondary only Ctrl). Nuclei stained with Hoechst 33342 are shown in
blue), and dashed lines denote the basal membrane dividing the epidermal and dermal
layers. Scale bar = 100 µm.
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To further confirm and characterize PANX2 expression in the skin cells, we isolated
primary keratinocytes and dermal mouse fibroblasts from skin at P4. Western blots with
the PANX2-CT rabbit antibody confirmed the presence of the PANX2-202 protein band
in both cell types corresponding with the estimated MW (~70 kDa) (Fig. 2-3A, B). This
was consistent with the staining observed in the dermis and epidermis and suggested that
PANX2 may not be limited to a single layer of the skin. Since we detected PANX2-202
protein in primary dermal fibroblasts, in vitro experiments were performed to test for
changes in Panx2 mRNA expression upon TGF-β induction of fibroblast activation into
myofibroblasts. We found that mRNA levels of the canonical variant remained unchanged,
but Panx2-202 mRNA was significantly downregulated after TGF-β treatment (Fig. S2-3).
On the other hand, as the PANX2 staining was more prevalent in the suprabasal layers of
the epidermis, we sought to verify whether PANX2 levels were regulated by early
differentiation in keratinocytes. In the epidermis, keratinocytes detach from the basement
membrane and occupy the suprabasal layers to undergo terminal differentiation ending in
cornification, a specialized cell death process different from apoptosis [26]. Thus, we tested
a commonly used model of in vitro differentiation based on the culturing of primary
keratinocytes with increased levels of CaCl2 [27]. However, the increased Ca2+
concentration in the culture medium did not markedly alter the protein levels of PANX2202 (Fig. 2-3C, D) nor the expression of both Panx2 mRNA splice variants. Nevertheless,
there was a significant increase in expression of suprabasal/differentiation markers keratin
10 (Krt10) and loricrin (Lor), indicating early stages of keratinocyte differentiation (Fig.
2-3E).
As in vitro differentiation of primary mouse keratinocytes is limited by the finite life span
of these primary cells, we also employed an immortalized rat epidermal keratinocyte
(REK) cell line [17] to examine changes in the mRNA expression of the rat Panx2
canonical ortholog during in vitro differentiation. These cells can be grown in traditional
media and maintained in culture for long periods while spontaneously initiating
differentiation upon reaching confluence when overgrown as cell monolayers [18].
Therefore, we assayed three conditions: (i) non-confluent, to resemble a basal-like state,
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and 72h-cultured confluent monolayers in the presence (ii) or absence (iii) of CaCl2 as
differentiated stages. We observed that the endogenous rat Panx2 transcript was 3.4-fold
significantly upregulated (p<0.01) after confluency and with a similar effect (1.6-fold,
p<0.05) after CaCl2 supplementation compared to the non-confluent cells (Fig. 3F). While
we observed drastic morphologic changes (i.e., cuboidal shape) of the cells under
differentiation conditions (not shown), no changes were detected in the transcript
expression of the basal marker keratin 14 (Krt14). Remarkably, in both confluent and
+CaCl2 conditions, we found a significant (p<0.05) increase (189.6- and 194.4-fold,
respectively) in transcripts of the rat keratin 10 (Krt10), an early differentiation/suprabasal
marker. In addition, the late differentiation marker, loricrin (Lor), exhibited a 5.3-fold
significant (p<0.05) upregulation whereas, unexpectedly, involucrin (Ivl) was 3.9-fold
downregulated (p<0.05) in confluent versus non-confluent REK cells. Overall, confluency
and calcium supplementation stimulated REK differentiation and increased canonical
Panx2 mRNA expression in these cells.
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Figure 2-3.
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Figure 2-3 PANX2 levels are regulated in keratinocytes during in vitro CaCl2-induced
differentiation.
(A, B) Immunoblot used for MW estimation of PANX2 variants detected in primary mouse
keratinocytes and dermal fibroblasts. Numbers indicate different mice. (C-E) Analysis of
endogenous PANX2 protein and mRNA expression of in vitro CaCl2- differentiation
experiments with primary mouse keratinocytes. Four independent primary cell isolations
(N=4) were used for the assays. Relative mRNA expression is shown as geometric mean ±
s.d. Gapdh was used as the reference gene. Unpaired t-test was used for statistical analysis
of densitometric results in (D). ANOVA followed by a Sidak's test were used for multiple
comparisons of the log2 (mRNA expression). (F) mRNA expression analysis of Panx2 rat
paralog in rat epidermal keratinocytes (REK) cell line in different conditions. One-way
ANOVA followed by a Tukey's test were used for multiple comparisons. Keratinocyte
differentiation was assessed by mRNA expression of cytokeratins Krt5, Krt14 for
undifferentiated cells; Krt10, involucrin (Ivl), and loricrin (Lor) for late differentiation
markers in mouse and rat cells. Unpaired t-tests were used for comparisons between
treatments. Symbols represent different samples or independent experiments with at least
N=3. Statistical significance was considered when *p<0.05, **: p<0.01.
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2.3.3

In vitro caspase-3 cleavage of canonical PANX2 C-terminus
occurs at D400 and D416

Considering our previous report [21] on the canonical PANX2 in vitro cleavage by
executioner caspases-3/7, we sought to identify the specific sites for caspase-mediated
cleavage. Using the webserver Procleave [19], we obtained a list of putative cleavage sites
for caspase-3 (Figure 2-4A; Table 2-3). The most likely sites for cleavage were predicted
to be located in the canonical PANX2 C-terminal domain and based on the size of the
predicted fragment reported previously [21], we selected D400 and D416 for site-directed
mutagenesis to replace the aspartic residues for alanine (D→A) and generate putative
caspase-3/7 cleavage-resistant PANX2 mutants (PANX2D400A, PANX2D416A, and
PANX2D400A/D416A) for validation purposes.
Table 2-3 Predicted Caspase 3/7 cleavage sites in mouse PANX2 according to
Procleave.

AEPD†GSAE

Nterminal
fragment
size
(kDa)
47.1

Cterminal
fragment
size
(kDa)
27.5

266

ASPD†GPVG

30.1

44.5

0.925

650
400

DMGD†LLSI
TVRD†SGIQ

71.6
45.5

3.0
29.1

0.727
0.707

Rank

Amino
acid
position

P4-P4'
context

1

416

2
3
4

Prediction
score
0.965

Domain

C-terminus
Extracellular
loop
C-terminus
C-terminus

†, cleavage site.
Similar to the methodology used before in [21], we performed in vitro incubation of
immunoprecipitated PANX2 with purified active caspase-3 (see Fig. 2-4B, C) to detect the
remaining N-terminal PANX2 fragments after cleavage. In these experiments, caspase-3
cleavage of PANX2 resulted in the loss of immunoreactivity of the band corresponding to
the full-length protein (~75 kDa) (Fig. 2-4D, E). Three major N-terminal PANX2
fragments were identified by western blot with apparent MW of 48, 46, and 30 kDa,
respectively, as determined by analysis of the lane profiles (Fig. 2-4E, Fig. S2-4A). For all
the caspase-3 treated groups (canonical PANX2 wildtype and mutants), a common ~30
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kDa protein band was detected, corresponding with a putative cleavage product if PANX2
caspase-cleavage were to occur at D266 (Fig. 2-4A, C, E, and Fig. S2-4B-E). In contrast,
caspase-3 cleaved mutants PANX2D400A and PANX2D416A showed the absence of the bands
corresponding to each expected N-terminal cleavage product of ~46 and ~48 kDa,
respectively (Fig. 2-4E, Fig. S2-4 C-D, F-H). Notably, in the caspase-3 treated (+) lane,
the band corresponding to full-length protein is retained for PANX2D416A although at a
lower intensity, suggesting partial or reduced cleavage efficiency at the amino acid site
D400 compared to the D416, which was not evident in the PANX2D400A mutant. As an
experimental control, the specificity of the anti-PANX2-NT antibody was verified using
IgG as a control for the immunoprecipitation, which yielded no background bands in the
immunoblots (Fig. 2-4F).
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Figure 2-4.
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Figure 2-4 Canonical mouse PANX2 C-terminus is cleaved by caspase-3 in vitro at
D400 and D416.
(A) Diagram of the secondary structure of mouse PANX2 showing the putative caspases
cleavage sites (D266, 400, 416, and 650). D400 and D416 were selected for site-directed
mutagenesis based on their CT-terminal localization and detectable cleavage products by
WB. (B, C) Illustrations depicting expected N-terminal cleavage fragments and the
methodology used for immunoprecipitation (IP) and detection of the fragments after
incubation of PANX2 with purified caspase-3. (D) Immunoblot used as INPUT for IP of
protein lysates from overexpressed N-terminal FLAG-tagged PANX2 and caspaseresistant mutants in HEK293T cells. (E) Immunoblot showing IP of full-length PANX2
incubated (+) or not (-) with purified active caspase-3. Protease digestion products were
separated simultaneously in the same 10% SDS-PAGE gel and blotted with an anti-FLAG
antibody to reveal the N-terminal fragments. Dim bands in the non-caspase treated lanes
were considered unrelated degradation products. (F) Immunoblot of controls using IgG for
IP. As expected, no background bands confirmed the specificity of anti-PANX2-NT
antibody. Estimation of MW of fragments performed using densitometric analyses (see
Fig. S2-4). Results are representative of four independent experiments (N=4).
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2.3.4

PANX2 C-terminus undergoes cleavage at D416 in UVB-induced
apoptotic keratinocytes

We explored whether caspase cleavage of PANX2 occurs in keratinocytes undergoing
apoptosis after UVB exposure. For these studies, we overexpressed the mouse canonical
PANX2 construct in REK cells. However, to avoid confounding factors derived from the
endogenous rat Panx2 ortholog expression in these cells, we first generated a CRISPRCas9-mediated Panx2 knockout cell line (REK-PANX2KO). Genotyping and WB
confirmed the success of Panx2 knockout in one of the selected clones (clone 19),
indicating a 212 bp deletion that encompasses the 1st intron and the 2nd exon of the rat
Panx2 gene verified by sanger sequencing (not shown) (Fig. 2-5A, B). In wildtype REK
cells, endogenous PANX2 appeared as a faint band (~70 kDa) detected with two
commercially available anti-rat PANX2 antibodies that were previously validated in [3, 9,
28] (Fig. 2-5B).
We hypothesized that the activation of effector caspases-3/7 in UVB-irradiated REK cells
induces the cleavage of the PANX2 C-terminus and is likely to promote the programmed
cell death process in the cells. Forty-eight hours post-transfection, REK-PANX2KO cells
transiently expressing either mouse canonical PANX2 wildtype (wt), PANX2D400A,
PANX2D416A, or PANX2D400A/D416A were exposed to UVB radiation. Full-length PANX2
protein and N-terminal fragments were then IP using the anti-PANX2-NT antibody.
Western blot analysis showed cleaved fragments only in PANX2 wt and PANX2D400Atransfected REK-PANX2KO cells, indicating that cleavage of PANX2 in these apoptotic
cells occurs only at the C-terminal D416 residue (Fig. 2-5D, Fig. S2-5). Moreover, as
expected, ~30 kDa fragments were not observed with any of the constructs, indicating that
executioner caspases cannot target the residue D266 in the second extracellular loop of
PANX2. Moreover, cleaved-caspase-3 was detected only in the post-UVB input lysates,
indicating a successful caspase activation and apoptosis after UV irradiation (Fig. 2-5E).
Taken together, our results revealed that, in UVB-induced apoptotic keratinocytes, PANX2
C-terminus undergoes caspase-3/7 cleavage at residue D416.
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Figure 2-5.
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Figure 2-5 PANX2 C-terminus is cleaved at D416 during UVB-induced apoptosis of
REK cells.
(A) Genotyping of rat Panx2 CRISPR-Cas9 knockout REK cells (REK-PANX2KO). PCR
of CRISPR-Cas9-targeted region amplified a band with faster migration than WT (red
arrow). Sanger sequencing indicated a 212 bp deletion encompassing the 1st intron and the
2nd exon of the rat Panx2 gene. (B) Immunoblot showing the success of PANX2 knockout
in selected REK-CRISPR-Cas9-edited clones. Endogenous rat PANX2 appears as a ~70
kDa faint band (indicated by arrowhead) no longer visible in the CRISPR-edited REKPANX2KO cells. (C) Methodology to detect PANX2 cleaved fragments. (D) Immunoblot
after IP showing cleavage of canonical PANX2 wildtype (wt) and the mutant PANX2D400A
but no PANX2D416A or PANX2D400A/D416A mutant after UVB-irradiation. Non-transfected
control (Ctrl) lanes indicate nonspecific bands unrelated to PANX2 cleavage. (E)
Immunoblot of input lysates showing (cleaved) caspase3 activation and decreased
immunodetection of full-length PANX2 post-UVB irradiation. Results are representative
of three independent experiments (N=3).
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2.3.5

PANX2 contributes to UVB-induced apoptosis of REK cells
independently of its caspase cleavage

PANX2 has been implicated in different cell death processes [10, 12-15], from which it
seems that any functions during cell death may be dependent on the cell type in question.
Based on earlier studies with PANX1 in apoptotic cells [29], it has been proposed that the
irreversible caspase-cleavage of PANX1 channels may be detrimental for the cells due to
an increased plasma membrane permeability and the repercussion of C-terminal truncation
on channel properties and cell death [30, 31]. To assess whether the PANX2 cleavage
contributes to apoptosis in REK cells, we evaluated the effect of genetic deletion of
endogenous rat Panx2, the rescue with the transient expression of the mouse canonical
ortholog (PANX2 wt, 98.2 % amino acid sequence identity compared with rat PANX2)
and the caspase-cleavage resistant mouse PANX2D416A mutant after UVB exposure (Fig.
6). We used a green fluorescent DEVD-peptide substrate of caspase-3/7 dye multiplexed
with a cell-membrane impermeable cyanine dye (Cytotox Red) to monitor UVB-induced
caspase-3/7 activation and cytotoxicity concurrently in an IncuCyte live-cell imager.
Our results showed that from 20-48h post-UVB-irradiation, apoptotic caspases were
activated in 100% of the cells (Inset in Fig. 2-6A). As a quantitative measure for comparing
the timing for apoptotic activation between experimental groups, we estimated a parameter
(defined herein as t50%, dashed lines in Fig. 2-6A) for the length of time post-UVB required
to detect caspase-3/7 activation in ~50 % of the cell population. Thus, a delayed caspase
activation would correspond with increased values of t50%. Notably, our analysis showed
most groups had significant differences among t50% (F3, 32 = 38.68, p<0.0001), where REKPANX2KO cells had a significant delay (t50%=8.7 ± 0.8 h, p<0.0001) in caspase activation
compared to wildtype REK cells (t50%= 5.9 ± 0.6 h) (Fig. 2-6B). Compared to nontransfected REK-PANX2KO, overexpression of mouse PANX2 wt and PANX2D416A
caspase-resistant mutant elicited a partial rescue increasing the rate of caspase activation
(p<0.05) with decreased t50% of 7.9 ± 0.3h and 7.3 ± 0.3h, respectively (not significant, ns);
yet both cases had a t50% significantly greater (p<0.0001) than wildtype REK cells (Fig. 26B). These findings indicated that: (i) the genetic deletion of Panx2 (as in REK-PANX2KO
cells) delays caspase-3/7 activation and, consequently, the onset of apoptosis, and (ii)
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caspase-cleavage of PANX2 (expected in mouse canonical PANX2 wt) does not affect the
timing of executioner caspase activation and thus the apoptosis rate of UVB-irradiated
REK cells.
Further analysis showed that at eight hours post-UVB, the % change (compared to 0h) in
caspase-3/7 activation (F3, 31 = 40.98, p<0.0001) was significantly greater (p<0.0001) for
wildtype REK (89.25 ± 4.76%) compared to the rest of REK-PANX2KO groups and
regardless of their transfection or not with the mouse Panx2 orthologs (wt or D416A).
Interestingly, after eight hours post-UVB, REK-PANX2KO cells overexpressing the noncleavable PANX2D416A mutant (66.52 ± 4.94 %) had a significantly higher (p<0.05 and
p<0.0001) caspase-3/7 activation than the overexpressing PANX2 wt (54.99 ± 8.43%) and
non-transfected (nt) (42.08 ± 14.91%) cells, respectively (Fig. 2-6C). To assess the
outcome of the caspase-3/7 activation and apoptotic process across all the time points, we
compared the differences (F3, 32 = 12.42, p<0.0001) in the area under the curve (AUC) from
the kinetic caspase activation plots and noticed that regardless of PANX2 wt (or
PANX2D416A) transfection, REK WT remained significantly higher (p<0.05) compared to
REK-PANX2KO cells (Fig. 2-6D). However, no differences in the overall caspase-3/7
activation were found between PANX2D416A and PANX2KO wt–transfected cells, while,
remarkably, the non-transfected REK-PANX2KO group exhibited the lowest (p<0.05)
caspase activation. In agreement with the above, these results suggested that in UVBirradiated REK cells, PANX2 promotes the apoptosis rate (based on the caspase-3/7
activation) regardless of its proteolytic cleavage at D416.
As another measure of cell death, we also assessed changes in the membrane integrity that
occurred upon UVB exposure indicating cytotoxicity. After UVB-irradiation, a delay in
the time of detection in the loss of membrane integrity was found in non-transfected REKPANX2KO (at ~22-24h) that was approximately three-fold compared to the other groups
expressing any PANX2 (~6-8h) (Fig. 2-6E). Overall, the AUC (F3, 29 = 13.91, p<0.0001)
in the plots of % of change in cytotoxicity was markedly lower (p<0.05) in non-transfected
REK-PANX2KO compared to the other groups, while the ectopic expression of mouse
PANX2 wt (or PANX2D416A mutant) ultimately rescued the pattern observed in the REK
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wildtype cells (Fig. 2-6E, F). This finding indicates that PANX2 may play a role in
influencing membrane disruption or alteration at the later stages of apoptosis in the UVBirradiated REK cells. Finally, we conducted immunofluorescence staining and confocal
microscopy imaging analysis to rule out any possible effects of the D416A mutation on the
subcellular localization of PANX2. The PANX2 wt and PANX2D416A mutant showed a
similar intracellular distribution within REK-PANX2KO cells (Fig. 2-6G) along with the
occasional cell membrane and perinuclear localization described in our work presented in
Chapter 3 [24]. In summary, our results suggest that PANX2 promotes UVB-induced
apoptotic cell death of keratinocytes, independent of its caspase cleavage.
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Figure 2-6.
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Figure 2-6 PANX2 promotes UVB-induced apoptosis of REK cells independently of
its caspase-3/7 cleavage.
(A-C) Time-course, half-maximal caspase activity (t50%), and timepoint analysis of the
caspase-3/7 activation. A significant delay in caspase-3/7 activity (increased t50%) was
found in REK-PANX2KO compared to wildtype REK cells. Transient expression of
canonical PANX2 wt partially (~50%) rescues caspase activation in REK-PANX2KO cells
with a modest increase when PANX2D416A mutant is expressed. (D) Overall caspase-3
activation (area under the curve (AUC)) was no different between PANX2D416A and
PANX2 wt overexpressed in REK-PANX2KO cells (E). Cytotoxicity time-course revealed
a delayed and significantly decreased uptake of Cytotox Red Dye by the REK-PANX2KO
cells. Similar cytotoxicity onset was found between wildtype REK and PANX2 wt- and
PANX2D416A-expressing REK-PANX2KO cells. (F) Overall cytotoxicity (AUC) in
PANX2 wt and the PANX2D416A mutant was similar to that observed in REK wildtype. (G)
Representative immunofluorescence confocal micrographs of REK-PANX2KO cells 48h
post-transfected with PANX2 wt or PANX2D416A mutant. Similar PANX2 intracellular
localization was observed using either the polyclonal PANX2-CT or monoclonal anti-Flag
antibodies. Scale bar=20 µm. IncuCyte live-imaging caspase-3/7 activation and
cytotoxicity data result from ten technical replicates per group (n=10). One-way ANOVA
followed by Tukey's post hoc test was used to compare the means. Same letters denote
groups with no difference in statistical significance considered when p<0.05.
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Figure S2-1
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Supplemental Figure 2-1. Sequence alignments between mouse PANX2 (canonical)
and PANX2-202 variants.
CLUSTAL O (1.2.4) was used to compare the amino acid sequences of mouse Panx2
variants. An asterisk denotes amino acid conservation; a colon denotes strong conservative
substitution; a period denotes a weakly conservative substitution; a space denotes nonconservative substitution with a different amino acid; while a dash represents an insertion
or deletion. Sequence regions characteristic of the PANX2-202 are highlighted with red
font.
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Figure S2-2
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Supplemental Figure 2-2. Immunofluorescence labeling of mouse dorsal skin with
polyclonal anti-PANX2 antibodies and epitopes mapped in PANX2-202 sequence.
(A)

Representative

immunofluorescence

micrographs

of

endogenous

PANX2

immunostaining (green) in formalin-fixed sections (N=3) of dorsal skin at postnatal days
0, 4, and 4 weeks old. Immunofluorescence using polyclonal antibodies against N-terminal
domain (NT) and the intracellular loop (IL) of mouse PANX2. Nuclei were stained with
Hoechst 33342 (shown in blue), and dashed lines denote the basal membrane dividing the
epidermal and dermal layers. Scale bar = 100 µm. (B) Topological representation of the
PANX2-202 splice variant. In red, residues corresponding to the unique regions of this
Panx2 splice variant. In blue, light green and purple, epitopes recognized by the three rabbit
anti-mouse polyclonal antibodies used in this study.
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Figure S2-3

Supplemental Figure 2-3. Endogenous Panx2 mRNA levels in primary dermal mouse
fibroblasts decrease after in vitro myofibroblast activation with TGF-β.
TGF-β differentiation protocol was performed as reported in [99]. Alpha-smooth muscle
actin (α-SMA) (Acta2 mouse gene) was used as a myofibroblast activation marker. At least
N=3 biological replicates were assayed by duplicate. A paired t-test was used to compare
the means log2(relative expression) among treatments. Statistical significance is shown as
p<0.05(*).
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Figure S2-4
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Supplemental Figure 2-4. Lane profile analysis of immunoprecipitations after in vitro
PANX2 caspase cleavage experiments
(A-D) Molecular weight estimation of bands detected after IP of PANX2 in protein lysates
treated (+) or not (-) with active caspase-3. Protein lysates were obtained from HEK293T
cells overexpressing PANX2 and caspase-resistant mutants D400, D416, and D400/D416.
Graphs on the right show the lane profiles with the peaks' vertical position indicating the
relative migration of bands in WB as per MW markers (y-axis, in kDa). The high of the
peak (in the x-axis) corresponds with the band’s integrated intensity (densitometry)
normalized over the whole WB. (E-H) Superposition of peaks between different lanes
(indicated by colored text) to compare the appearance of cleavage fragments by evaluating
their migration and band intensity. (see Fig. 2-4 for other details and whole WB).
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Figure S2-5
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Supplemental Figure 2-5. Lane profile analysis of IP after in-cell PANX2 caspase
cleavage experiments in UVB-induced apoptotic REK-PANX2KO cells.
(A-E) Molecular weight estimation of bands detected after IP of PANX2 from protein
lysates of cells treated (UVB) or not (Mock) with UVB radiation. REK-PANX2KO cells
overexpressed PANX2 and caspase-resistant mutants D400, D416, and D400/D416.
Graphs on the right show the lane profiles with the peaks' vertical position indicating the
relative migration of bands in WB as per MW markers (y-axis, in kDa). The high of the
peak (in the x-axis) corresponds with the band integrated intensity (densitometry)
normalized over the whole WB. (F-H) Superposition of peaks between different lanes
(indicated by colored text) to compare the appearance of cleavage fragments by evaluating
their migration and band intensity. (see Fig. 2-5 for other details and whole WB).
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Figure S2-6
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Supplemental Figure 2-6. Caspase cleavage site D416 in mouse PANX2 is conserved
in the human but not in the rat ortholog.
Clustal-O tool in the Uniprot database was used for multiple sequence alignment of
canonical PANX2 isoforms of the mouse, rat, and human orthologs. An asterisk denotes
amino acid conservation; a colon denotes strong conservative substitution; a period denotes
a weakly conservative substitution; space denotes non-conservative substitution with a
different amino acid; while a dash represents an insertion or deletion.
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2.4 Discussion
Alternative splicing has been reported for pannexin genes, but in most cases, the biological
relevance of these splicing events remains unknown. Initial work by Baranova et al. (2004)
analyzed the human PANX2 sequence identifying two PANX2 human splice variants,
PANX2alt1 and PANX2alt2, with the latter encoding a shorter protein isoform that was
speculated to play an unknown regulatory role. In that study, a single mouse Panx2
ortholog was identified by BLAST search, and comparative analysis of the genomic
sequence and the transcript expression was validated by in situ hybridizations, but it was
limited to the adult murine brain. Here, we have characterized the expression of a novel
PANX2 isoform (Panx2-202) previously unveiled in [23] that bears a different molecular
weight and partial sequence than canonical PANX2 found initially in the brain [1, 32].
Furthermore, Abitbol et al. (2019) showed that in Panx1/Panx3 double knockout mice,
PANX2-202 was expressed in the skin at similar levels to wildtype mice. Although we
observed that canonical Panx2 mRNA transcripts were also present in the skin at all ages
investigated, our results confirmed such findings.
In the literature, discrepancies in the length and sequence of annotated PANX2 variants
exist and are attributed to differences in cloning/sequencing procedures and predictions
based on the available genomic sequences [33]. Interestingly, the mouse PANX2-202
isoform is reported exclusively in the Ensembl database (release 103 – as of February 2021)
(Table 2-2) and not in NCBI. It is important to note that the transcript annotation may vary
per Genomic database. Ensembl transcripts are automatically annotated based on
experimental evidence and are, in most cases, manually curated by the HAVANA group
[34]. However, the NCBI annotations may not match those in Ensembl and include
predictions done by a different automated computational analysis (Gnomon method),
combining homology searching with ab initio modeling supported by expressed sequence
tag (EST) evidence from the current genomic sequences. Most of the studies analyzing
mouse PANX2 have worked with the canonical sequence, but it should be noted that the
expression of different splice variants may be tissue-specific. Based on the length and
sequence, PANX2-202 may have different properties (e.g., subcellular localization,
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channel function, and interaction with binding partners) than canonical PANX2. However,
the functional implications of these differences and the consequences of their differential
expression remain to be evaluated.

2.4.1

PANX2 is always present in the skin and is regulated during
keratinocyte differentiation

We found that PANX2 is present in the suprabasal layers of the skin epidermis and, in
contrast to the other pannexins paralogs [4, 6, 25], its expression is not drastically affected
by age or the sex of the mice. Notably, the PANX2-202 variant trended to be more abundant
than the canonical isoform at all ages and sex assayed. However, transient differences at
P0 (at mRNA level in male mice) and four weeks old (at the protein level) could indicate
an age-specific temporal regulation of PANX2 levels in the skin, yet with unknown
biological significance. Nevertheless, the apparent disparity in mRNA and protein
expression levels agrees with previous findings that mouse Panx2 transcripts do not
correlate with their protein levels [3].
PANX2 seems to have a similar localization pattern as PANX1 and PANX3 in the stratum
granulosum and spinosum of thin murine skin [4, 5, 25]. In this work, three different antiPANX2 polyclonal antibodies were employed for immunofluorescence, showing an
intracellular localization, which correlates with previous observations made by us and
others in other cell types and ectopic overexpression systems [3, 12, 20, 24, 35]. However,
given that this endogenous labeling was not compared with a true negative control (e.g.,
Panx2 knockout tissue), the diffuse staining pattern may arise from other proteins due to
the polyclonal nature of the antibodies, and further confirmation is still warranted.
The level of PANX1 and PANX3 is regulated during keratinocyte differentiation [4, 6, 25];
therefore, we asked whether PANX2 could be influenced by differentiation in
keratinocytes. PANX2-202 was more abundant than the canonical isoform in primary
mouse keratinocytes, suggesting that this splice variant is more prominent than the
canonical variant in this cell type. Our in vitro differentiation experiments with primary
keratinocytes and REK cells showed similar trends with increased mRNA and protein
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expression of endogenous PANX2 orthologs in differentiated keratinocytes. Considering
the high staining intensity of PANX2 in the stratum spinosum and granulosum of the
mouse epidermis, the putative detection of both variants of our antibodies, and the trends
of increasing protein levels after Ca2+-induced keratinocyte in vitro differentiation, we
concluded that PANX2 is most likely to be upregulated during keratinocyte differentiation.
Nevertheless, further work should address whether PANX2 modulates keratinocyte
differentiation directly and forms functional channels in keratinocytes.

2.4.2

PANX2 promotes keratinocyte apoptosis independently of its
caspase cleavage

Accumulating evidence implicates PANX2 in different cell death processes such as
necrosis in neurons, apoptosis in glioma cells, cytokine-induced apoptosis in β-cells, and
ferroptosis in prostate cancer cells [10, 12-15]. The skin is often challenged by UV
radiation (particularly UVB), causing several skin pathological conditions [36]; therefore,
apoptosis constitutes a protective mechanism essential to remove UV-damaged skin cells
(e.g., keratinocytes) and avoid the risk of malignant transformation. Keeping in mind that
PANX2 could be implicated in cell death, we sought to study the contribution of PANX2
during UVB-induced cell death of keratinocytes. Here, we uncovered for the first time that
PANX2 undergoes caspase-mediated cleavage in apoptotic keratinocytes. In continuation
with our previous studies [21], we have identified two sites (D400 and D416) in the
PANX2 C-terminus that are targeted in vitro by executioner caspase-3 and demonstrated
that in REK cells, at least only one of the predicted sites (D416) undergoes cleavage upon
UV irradiation. Notably, genetic deletion of endogenous PANX2 delayed but did not
prevent REK UVB-induced apoptosis, indicating that PANX2 is not essential but
contributes to the apoptotic machinery in these cells. Furthermore, overexpression of
canonical mouse PANX2, especially the caspase-resistant mutant PANX2D416A,
accelerated the caspase-3 activation rate and membrane permeability in UVB-irradiated
REK-PANX2KO cells. Therefore, we concluded that caspase-mediated cleavage is not
needed for the role of PANX2 in the apoptosis of UVB-damaged cells. Nevertheless, these
results are in keeping with the pro-apoptotic function of PANX2 [12].

103

It is essential to note that despite the high conservation of PANX2 proteins between both
mouse and rat species (98.2 % identity), the amino acid sequence of endogenous rat
PANX2 has a natural conservative substitution of aspartic acid with glutamate at the
position 416 (D→E), that is not present in human PANX2 (Fig. S2-6). Based on this
difference, endogenous rat PANX2 (as in wildtype REK) is not expected to be cleaved by
caspases 3/7. In this respect, our results support our hypothesis that PANX2, but not its
caspase-mediated cleavage, functions as a promoter of UVB-induced apoptosis, as shown
with both PANX2 orthologs. Moreover, regarding the murine PANX2-202 isoform, both
cleavage sites at D400 and D416 are still conserved in the amino acid sequence; therefore,
we speculate a similar caspase cleavage is likely to occur. However, future work should
address whether the PANX2-202 function is affected by caspase cleavage under apoptotic
conditions. To our knowledge, there are no reports of abnormal skin phenotypes in the
Panx2 knockout (KO) mouse model [10, 14, 37, 38]. Nevertheless, considering that
PANX2 assists with the death of UV-damaged keratinocytes, skin homeostasis in Panx2KO mice might be compromised after UV exposure or other apoptotic insults. Thus, it will
be interesting to determine whether Panx2-KO mice have skin repair or renewal defects.

2.5 Conclusions
In conclusion, this work sheds light on PANX2 regulation in the skin and specifically
during two critical processes related to skin homeostasis: keratinocyte differentiation and
apoptosis. We demonstrated that the expression of splice variants is a factor to be
considered when studying PANX2 in the skin and perhaps in other tissues. This is the first
study to identify the caspase-3 cleavage sites in PANX2 and its pro-apoptotic role in
keratinocytes. These novel findings provide a better understanding of the tissue-specific
regulation and function of PANX2.
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Chapter 3
N-glycosylation is a post-translational modification that acts as a regulator of the
localization and intermixing of PANX1 and PANX3, but its effects on PANX2 are
currently unknown. Since PANX1 and PANX2 have been reported to interact, the
objectives in this chapter were to validate the predicted N-glycosylation site of PANX2
and study the effects of glycosylation on PANX2 localization and interaction with PANX1.

A version of this paper is published:
Sanchez-Pupo RE, Johnston D, Penuela S. N-Glycosylation Regulates Pannexin 2
Localization but Is Not Required for Interacting with Pannexin 1. Int J Mol Sci. 2018 Jun
22;19(7):1837. doi: 10.3390/ijms19071837. PMID: 29932112; PMCID: PMC6073767.
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3 N-glycosylation regulates Pannexin 2 localization but is not
required for interacting with Pannexin 1
3.1 Introduction
Pannexins (PANX1, PANX2, and PANX3) are membrane-spanning glycoproteins capable
of forming large-pore channels that allow the passage of ions and macromolecules involved
in paracrine and autocrine signaling [1, 2]. PANX1 is the most widely expressed pannexin
family member and the most studied, with evidence supporting that its channels act as ATP
and Ca2+ conduits [3-6] and are implicated in critical cellular processes such as cell death
after brain ischemia [7] and inflammation [8]. On the other hand, PANX2 is the largest
family member, and its expression was thought to be restricted to the central nervous
system (CNS). Recently, it has been reported that PANX2 can also be expressed in other
tissues such as skin, kidney, and liver [9, 10], while PANX3 is predominantly expressed in
skin, cartilage, and bone [4, 5, 11-13]. In contrast to the heptameric type of channels formed
by PANX1, it has been suggested that PANX2 can form octameric or heptameric channels
[14], and it is still unclear whether its channel function would be similar to the other family
members.
Interestingly, PANX1 and PANX2 expression have been found to overlap in adult rodent
brains, although they are inversely regulated throughout development, with PANX1 being
more abundant in neonatal and young tissues, whereas PANX2 is more abundant in the
adult [15-18]. Under ischemic conditions, both PANX1 and PANX2 are expressed in the
brain, and their overlapping channel functions contribute to neurodegeneration. The
deletion of PANX1 and PANX2 in a double knockout mouse model was necessary to
observe a reduction in cell death after ischemia, perhaps due to their redundant or
complementary functions [19].
N-glycosylation is a post-translational modification in the endoplasmic reticulum (ER) and
is recognized to profoundly affect protein folding and trafficking of membrane-bound
proteins [20]. The prediction of putative N-linked glycosylation sites for pannexins has
been made in the past, and it has been demonstrated that PANX1 and PANX3 can be N-
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glycosylated at Asn (N) 254 and N71, respectively. These studies comprised further
characterization using enzymatic digestion with endoglycosidases that confirmed that all
three members of the pannexin family are differentially N-glycosylated but not Oglycosylated [11, 21]. However, for PANX2, the predicted site of N-glycosylation at
residue N86 remains to be validated [22].
Unlike other pannexins, PANX2 is only modified to a high-mannose glycosylation species
(termed as Gly1) and presents a predominantly intracellular localization that has been
associated with this lower level of N-glycosylation [22-26]. Previous evidence supports the
concept that complex glycoprotein species (Gly2) (further processed at Golgi) present in
PANX1 and PANX3 traffic readily to the cell surface [22]. However, our group and others
have stated that PANX2 can also translocate to the plasma membrane [17, 22] [14], but it
is still unclear whether glycosylation plays a role in regulating PANX2 trafficking.
PANX2 has been shown to interact with PANX1, and when co-expressed together, they
can form heteromeric channels with reduced channel properties compared to homomeric
ones [22, 27]. Although this has only been tested in ectopic expression systems, it has been
suggested that it might function as a mode of regulation in cells that endogenously express
both proteins. Interestingly, the PANX1/PANX2 interaction only occurs with the Gly0 and
Gly1 species of PANX1 [22], and it is unknown whether PANX2 glycosylation has any
impact on the formation of these intermixed channels. Previous studies have shown that
PANX1 and PANX2 are often co-expressed in the same cells under normal conditions [15,
16, 27-30], which may later modulate pathological processes such as ischemia-induced
neurodegeneration and brain damage in vivo [31]. Understanding how these channels are
regulated by post-translational modifications (PTM)s, such as N-glycosylation, may
provide further insight into their role in homeostasis and disease and be used for therapeutic
purposes.
The present study aimed to validate the predicted N-linked-glycosylation site of PANX2
and determine its role in regulating the subcellular localization and intermixing of PANX2
with PANX1. Herein, we generated a PANX2 mutant protein completely devoid of Nglycosylation that, when overexpressed, exhibits a high level of intracellular aggregation
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with decreased traffic to the plasma membrane compared with wildtype PANX2. We found
that N-glycosylation of PANX2 is not required for PANX1/PANX2 intermixing but
facilitates PANX2 trafficking and localization at the plasma membrane when co-expressed
with PANX1. Nevertheless, the intracellular localization of un-glycosylated PANX2
reduces its interaction with PANX1 at the cell surface and may impact their channel
function in cells that co-express both glycoproteins, such as neurons. Collectively, we
propose that N-glycosylation may be necessary for the proper processing of PANX2 at the
endoplasmic reticulum, regulating its intracellular distribution, but it is not required for
interacting with PANX1.

3.2 Materials and Methods
3.2.1

Cell lines, constructs, and transient transfections

Media, supplements, and reagents were obtained from GIBCO® and Invitrogen™
(Carlsbad, CA, USA). Normal rat kidney (NRK) (ATCC® CRL-6509™), human
embryonic kidney cells (HEK293T) (ATCC® CRL-3216™) were obtained from ATCC
(Manassas, VA, USA). Adherent HEK293 cells (AD293, Cat# 240085) were obtained from
Agilent Technologies, Inc. (Santa Clara, CA, USA). Cell cultures were grown in highglucose DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin,
100 µg/ml streptomycin, and 2 mM L-Glutamine. At ~50% of confluency, cells were
transfected adding Lipofectamine 3000 (Invitrogen™) following manufacturer directions.
2 µg of pcDNA3.1 (Invitrogen™) plasmids encoding mouse PANX2 [22] or PANX2N86Q
or their respective FLAG-tagged versions were used for transfections in 35 mm culture
plates. After 48h for single transfections and 72h for co-transfections, proteins were
extracted, and expression levels were determined by Western blot. For co-transfections
experiments with mouse Panx1 construct [11], the DNA levels were reduced to 0.5 µg.

3.2.2

Mutagenesis and cloning of new FLAG-tagged PANX2 constructs

As described by [11], PANX2 has a predicted N-glycosylation consensus site located at
asparagine (N) 86 on the first extracellular loop. Site-directed mutagenesis service
(NorClone Biotech Labs, London, ON, Canada) was used to generate a new expression
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PANX2 construct encoding a replacement of asparagine by glutamine at position 86,
referred as PANX2 N86Q. FLAG-tagged PANX2 was obtained by inserting a single FLAG
sequence with In-Fusion HD Cloning Kit (Takara Bio, Inc.) at the end of the coding region
of the PANX2 C-termini. Primers used for FLAG insertion were Forward: 5’GTTTAAACTTAAGCTTCATGCACCACCTCCTGGAG-3'

and

Reverse:

5’-

GCCCTCTAGACTCGAGCTCACTTGTCATCGTCGTCCTTGTAATCAAACTCCAC
AGTACT-3'. All the constructs were verified by sequencing.

3.2.3

Protein extractions and Western blots

For co-immunoprecipitation (Co-IP) assays, cell lysates were obtained using Triton-based
extraction buffer (IP buffer) (1% Triton X-100, 150 mM NaCl, 10 mM Tris, 1 mM EDTA,
1 mM EGTA, 0.5% NP-40). The rest of the protein extractions were performed with SDSbased buffer (RIPA buffer) (0.1% SDS, 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP40 and 0.5% Sodium Deoxycholate). In each case, lysis buffers were complemented with
a final concentration of 1 mM NaF, 1 mM Na3VO4, and one tablet of cOmplete™-mini,
EDTA-free Protease Inhibitor Cocktail (Roche). Total protein concentrations were
quantitated by bicinchoninic acid (BCA) assay (Thermo Scientific Pierce). For Western
Blots, 50 µg of total protein were resolved in 8% SDS-PAGE and transferred onto
nitrocellulose membranes using an iBlot™ Blotting System (Invitrogen). Membranes were
blocked with 3% bovine serum albumin (BSA) and 0.05% Tween 20-Phosphate Buffer
Saline (T-PBS) for 45 min at room temperature and probed overnight with a 1:1000
dilution of the rabbit affinity-purified antibodies anti-PANX2 -CT-523 [22]. Mouse
monoclonal anti-FLAG® M2 (Sigma, Cat. # F3165), monoclonal mouse anti-GAPDH
(Millipore Cat# MAB374, RRID: AB_2107445), and anti-α-Tubulin (Millipore-Sigma
Cat# 05-829, clone DM1A) antibodies were used at 1:2000, 1:1000 and 1:5000 dilutions,
respectively. For detection IRDye -800 and -680RD (Life Technologies™) were used as
secondary antibodies at 1:10000 dilution, and the membranes were scanned on a Li-Cor
Odyssey infrared system (Li-Cor, USA). Unless otherwise indicated, GAPDH was used as
a loading control.
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3.2.4

Immunofluorescence, confocal imaging, Linescans and
colocalization analysis

Cells were grown on coverslips at ~70% of confluency and were transfected as described
previously in subsection 4.1. After 48h of transfection, coverslips were washed with DPBS (Gibco®) and fixed with ice-cold 80% methanol and 20% acetone for 15 minutes at
4⁰C. Coverslips were blocked with 2% BSA-PBS for 1h and primary antibodies were used
diluted in blocking buffer as follows: polyclonal anti-PANX2-CT (2 mg/mL, 1:100
dilution), polyclonal anti-PANX1-CT (1 mg/mL, 1:100 dilution), anti-PDI monoclonal
antibody (1 mg/mL, 1:400 dilution) (1D3, Enzo® Life Sciences, ADI-SPA-891-D), cisGolgi marker anti-GM130 (1 mg/mL, 1:300) (Abcam, Prod#: ab169276), anti-FLAG® M2
(1mg/mL, 1:500) (Sigma, F3165), mouse monoclonal anti-Lamp-2 (1 mg/mL, 1:300)
(DHSB, clone H4B4). Coverslips were incubated with primary antibodies 1 hour at room
temperature, then washed with PBS and incubated with the secondary antibodies: Alexa
Fluor 488 goat anti-rabbit IgG (2 mg/mL, 1:700) or goat anti-mouse antibody Alexa Fluor
647 (2 mg/mL, 1:400) (LifeTechnologies), that were selected to avoid bleed-through
between dyes. Mitochondrial labeling was performed using MitoTracker™ Red CMXRos
(M7512, Thermofisher) as per manufacturer directions, and cells were fixed with freshly
prepared paraformaldehyde (4%) and then permeabilized with 0.1% Triton X-100 before
blocking step. Coverslips were rinsed with PBS followed by water once and counterstained
with Hoechst 33342 (Life Technologies™, USA) (1:1000, in water) for 5 min to stain
nuclei and then mounted with the custom-made Airvol mounting medium. Imaging was
performed with an LSM 800 Confocal Microscope (Carl Zeiss) using a Plan-Apochromat
63x/1.40 Oil DIC objective (Zeiss). Image acquisition for colocalization was performed
sequential laser scanning and with the multitracking feature of the Zeiss software with
settings to avoid wrong excitation-crosstalk and bleed-through of the channels.
Colocalization was quantitated with the colocalization plug-in of the Zeiss software.
Regions of interest (ROI) were drawn in dual-labeled cells selecting individual cells
expressing PANX2 or the mutant and co-stained with organelle markers. Controls of
single-labeled cells were used to determine thresholds of intensities for every single
channel and manual thresholding was used to determine the region of pixels colocalized in
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the intensity scatterplots. Pearson correlation coefficient was determined for each cell as a
colocalization measure and was expressed as means ± S.E.M., representative of at least
three independent transfections. Linescans using the Zeiss software tool were used to detect
overlapping fluorescence peaks in cells co-transfected with PANX1.

3.2.5

Cell surface biotinylation assays

Cell surface biotinylation assays were performed as described in [22]. Briefly, cells were
grown in 60 mm plates and used for biotinylation 72h following transfection with PANX2
or N86Q constructs. After culture media was aspirated, the cell monolayer was rinsed twice
with ice-cold D-PBS supplemented with Ca2+ and Mg2+ (Gibco®). Then, cells were
incubated only with D-PBS (non-labeling as a negative control) or with a solution of 1,5
mg/mL EZ-Link™ Sulfo-NHS-SS-Biotin (Thermo Scientific) in D-PBS for 30 min on ice
and covered from light. Plates were washed once again with D-PBS and then incubated
with 100 mM glycine dissolved in D-PBS for 30 min to quench the remaining labeling
biotin washed once more with D-PBS. Lysates were prepared using RIPA buffer as
described before. For pull-down of cell surface biotinylated proteins, 250 µg of total
protein was incubated overnight with 50% slurry of 50 µL NeutrAvidin agarose beads
(Thermo Scientific). Samples from lysates and initial flow-through wash were collected,
the beads were spun down (at x 500 g, 4⁰C), and then washed three times with RIPA buffer.
The samples and the beads were mixed with 2x Laemmli buffer plus 10% βmercaptoethanol and placed at 95ºC in a heat block for 5 min. 50 µg of total protein from
lysates and the beads supernatant were resolved in parallel with 8% SDS-PAGE gel and
then transferred to nitrocellulose membranes as previously described. PDI or GAPDH were
used as controls of non-specific biotinylation of intracellular/cytoplasmic proteins, and Ecadherin was used as a positive control of cell surface protein.

3.2.6

Co-immunoprecipitation (Co-IP) assays

Co-immunoprecipitation (Co-IP) of protein complexes was performed at 4°C by incubating
overnight 1 mg of total protein from pre-cleared (with Protein A/G beads alone) lysates
with 5 µg/ml of rabbit polyclonal anti-PANX2-CT or anti-PANX1-CT affinity-purified
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antibody crosslinked to Pierce Protein A/G-Agarose beads (Thermo Scientific), and the
same amount of beads (~30 µL) was used for IP in each case. Control experiments to
evaluate unspecific binding to the beads were performed in parallel using beads with no
antibody. To remove unbound proteins, four washes with 500 µl of ice-cold IP buffer were
performed. Then, beads were dried by aspiration and resuspended in 2X Laemmli buffer
(10% (v:v) β-mercaptoethanol), boiled for 5 min, spun down, and the supernatants (IP
samples) were used for WB. For WB analysis, 50 µg of protein of each lysate was loaded
into the INPUT lanes and ran along with the IP samples. The intensities of the bands in
each lane were obtained by densitometry and were used for quantitation.

3.2.7

De-glycosylation assays

Lysates from HEK293T ectopically expressing mouse PANX2 and the N86Q were used to
validate the N-glycosylation site of the mouse PANX2 construct. Enzymatic deglycosylation with Peptide-N-glycosidase F (PNGase F) and Endoglycosidase H (EndoH)
were used to detect the presence of all complex forms of N-glycosylation and highmannose modification, respectively. PNGase F (Sigma-Aldrich) and EndoH (New England
Biolabs) digestions were performed according to their manufacturer's instructions. Briefly,
at least 35 µg of total protein was denatured at 100 °C for 5 minutes in denaturing buffer
(0.1% (v/v) SDS, 0.05 M 2-mercaptoethanol, 50 mM phosphate buffer, pH 7.5) and
subsequently incubated for 1h at 37°C with 10 units of the PNGase F, 0.7 % (v/v) of Triton
X-100 or 2500 U of Endo H in supplier's digestion buffer. In parallel, control samples were
assayed without endoglycosidases. Protein samples were separated on an 8% SDSpolyacrylamide gel electrophoresis gel (PAGE) and transferred to nitrocellulose
membranes for WB.

3.2.8

Densitometric analysis of Western blots

Densitometry analysis was performed in the Odyssey Application Software Version 3.0.16
(LI-COR Biosciences, USA). For cell surface biotinylation experiments, the fraction of
biotinylated protein detected at the cell surface was calculated using the integrated intensity
(I.I.) of protein bands detected in the Neutravidin lanes divided by the I.I. of protein bands
detected in their corresponding input-lysate lanes. For Co-IP experiments, quantitative
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analysis was performed by calculating the I.I. ratio (Co-IP protein / IP-target protein).
Quantitation results were expressed as means ± SEM representative of at least three
independent experiments.

3.2.9

Statistics

Statistical analysis was performed using the statistical package of GraphPad Prism® Ver.
5.03 (GraphPad Software, Inc.). Cell surface biotinylation data were analyzed with a nonparametric Mann-Whitney U test for unpaired data. Data derived from quantitation of CoIP assays and colocalization were analyzed with a two-tailed unpaired t-test with Welch's
correction. A probability of p<0.05 was considered statistically significant.

3.3 Results
3.3.1

Characterization of the PANX2 N-glycosylation site at asparagine
86

Previous research has shown that ectopic expression of full-length mouse PANX2
presented N-glycosylated species with high-mannose modification [22]. Based on the
analysis of the canonical sequence of PANX2 (UniProt ID: Q6IMP4-1), this modification
might occur at N86 that is located in the first extracellular loop of PANX2 [20] (Fig. 31A). To validate this prediction, we generated a full-length PANX2 mutant (PANX2N86Q,
referred to herein as N86Q) with the substitution of the N86 with glutamine (Gln, Q) that
prevents the attachment of N-linked glycans to this specific site. As shown in Fig. 3-1B,
Western blotting (WB) of overexpressed constructs of N86Q and wildtype PANX2 (as
glycosylated control) indicated that the electrophoretic band corresponding to N86Q
mutant migrated faster than its wildtype counterpart, characteristic of a reduction in
molecular weight.
To analyze whether N-glycosylation was prevented in the N86Q mutant, enzymatic deglycosylation with endoglycosidase H (Endo H) and Peptide -N-Glycosidase F (PNGase
F) were applied to the protein lysates and analyzed by WB (Fig. 3-1C). Both deglycosylation treatments did not cause any shift in migration of the N86Q band. However,
wildtype PANX2 exhibited a small shift after treatment which relocated the migration of
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this band to the same position as that of the faster migrating N86Q mutant. Thereby, the
differences in electrophoretic migration can be explained by differences in molecular
weight due to the elimination or absence of N-glycosylation. These findings validate N86
as the only N-glycosylation site in PANX2, as Penuela et al. and others predicted [22].
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Figure 3-1.

Figure 3-1 PANX2 is N-glycosylated at asparagine 86.
(A) Based on sequence analysis, PANX2 (Uniprot ID: Q6IMP4-1) is predicted to contain
four transmembrane domains, one intracellular (IL) and two extracellular loops (EL). The
predicted N-glycosylation site is located at Asn86 in the first extracellular loop (EL1) (red
residue) (B) Western blot (WB) comparing wildtype PANX2 and mutant N86Q, the latter
shows a faster-migrating band than the wildtype counterpart indicative of decreased
molecular weight. (C) Cell lysates of HEK293T transiently expressing PANX2 and N86Q
mutant were subjected to enzymatic digestions with PNGase F and EndoH N-glycosidases.
WB analysis confirmed that N86 is the only glycosylation site for PANX2 since only the
wildtype protein exhibited a band shift after treatment with both glycosidases and the deglycosylated PANX2 band ran to the same position as the N86Q mutant. GAPDH was used
as the loading control. Molecular weights are noted in kDa.
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3.3.2

N86Q forms intracellular aggregates

To determine whether glycosylation influences PANX2 subcellular localization, we
ectopically expressed PANX2 WT and N86Q in different reference cell lines and evaluated
whether the subcellular distribution changes due to the cell type as reported for PANX1
and PANX3 [32]. Because our group had demonstrated before [33] that PANX1 influences
PANX2 trafficking, we selected Normal Rat Kidney cells (NRK), that in our experience
have a minimal expression of endogenous PANX1 (Fig. 3-2D), and "adherent" human
embryonic kidney cells (AD293) that endogenously express the human ortholog PANX1
(Fig. 3-3D). Likewise, these cell lines were selected as they are suitable transfection hosts
with a relatively large cytoplasm which facilitates the visualization of the subcellular
localization of proteins.
Confocal immunofluorescence imaging revealed an intracellular localization of ectopic
PANX2 (Figures 3-2A and 3-3A, top panel), with perinuclear distribution and spread in
intracellular compartments. Interestingly, in both cell types assayed, the mutant N86Q
localized intracellularly with a large subpopulation forming punctate aggregates (Figures
3-2A and 3-3A, bottom panel).
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Figure 3-2
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Figure 3-2 PANX2 N-glycosylation-deficient mutant (N86Q) forms intracellular
aggregates in NRK cells.
(A) Confocal micrographs of PANX2 and N86Q ectopically expressed in NRK cells,
immunolabeled with anti-PANX2 antibody (green), revealed that PANX2 is predominantly
localized intracellularly. The mutant N86Q is also localized intracellularly but appeared
mostly as punctate aggregates. Nuclei (blue) were counterstained with Hoechst 33342.
Scale bars = 20 μm. (B) Representative images of a small subpopulation of NRK cells
expressing PANX2 or N86Q showed minimal apparent localization at the cell surface
(indicated with white arrows). Scale bars = 5 μm. (C) Western blot analysis of cell-surfacebiotinylated proteins with EZ-Link™ Sulfo-NHS-SS-Biotin pulled down with
NeutrAvidin® beads showed very low detection of PANX2 but not the N86Q mutant at
the cell surface of NRK cells. E-cadherin was used as a positive control of cell surface
protein labeling and GAPDH was used as a negative control of intracellular proteins (no
biotin internalization). Non-transfected NRKs (nt) were used as a negative control (D)
Western blot of protein lysate from NRK cells indicated that endogenous PANX1 protein
is barely detectable in these cells. Overexpressed PANX1 was used as a positive control
(Ctrl +), and endogenous α-tubulin was used as the protein loading control. Molecular
weights noted in kDa.
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3.3.3

PANX2 localization at the cell surface is reliant on Nglycosylation status and the level of PANX1

Despite the predominant intracellular localization, in a subpopulation of cells, PANX2 and
the N86Q mutant (to a lesser extent) were apparent in limited regions of the cell surface
(Figures 3-2B and 3-3B, arrows). To corroborate these results, cell surface biotinylation
assays followed by immunoblotting were conducted using a cell-impermeable
biotinylation reagent (Sulfo-NHS-SS-Biotin). NRKs (low endogenous PANX1, Fig. 3-2D)
showed a faint band of PANX2 and no detection of N86Q at the cell surface in the
neutravidin pull-downs (Fig. 3-2C). Also, AD293 cells (with a higher level of endogenous
PANX1, Fig. 3-3D) exhibited low PANX2 and no detectable N86Q mutant protein at the
cell surface (Fig. 3-3C). However, in subsequent experiments, we also used human
embryonic kidney (HEK293T) cells (Fig. 3-3D) that have been used in previous studies
[11, 22] because of their increased transfection efficiency and enhanced protein expression
due to the SV40 T-antigen [34]. After ectopic expression in HEK293T cells, we performed
the same cell-surface biotinylation assays and noticed that PANX2 WT protein was
detected (~4% of the total PANX2 expression) at the cell surface (Fig. 3-3E). Under these
overexpression conditions, the N86Q mutant was also detected in the biotinylated-protein
fractions (Fig. 3E), with a significant (p=0.0286, N=4) reduction (to ~1% of its total
amount) in the cell surface protein pool compared to PANX2 WT (Fig. 3-3F). Therefore,
although the PANX2 cell membrane trafficking is reduced when it is not N-glycosylated,
its cell surface localization is not entirely abrogated when overexpressed in HEK293T
cells.
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Figure 3-3.
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Figure 3-3 Localization of PANX2 and N86Q in AD293 and HEK293T cells
expressing endogenous PANX1.
(A) Immunolabeling of PANX2 and N86Q mutant (green) showed that both localize
mostly intracellularly, but the N86Q mutant aggregates intracellularly in AD293 cells.
Scale bars = 20 μm. (B) A subpopulation of AD293 cells displayed PANX2 localization at
the cell surface, less evident with the N86Q mutant (indicated with white arrows) Scale
bars = 5 μm. Nuclei (blue). (C) Cell Surface Biotinylation Assays on AD293 cells showed
a weak detection of the PANX2 wildtype but not N86Q mutant in surface-labeled fractions.
GAPDH was used as a control for biotin internalization. (D) Immunoblots of AD293 and
HEK293T cells confirmed that both cell lines express endogenous PANX1. Overexpressed
human PANX1 served as a positive control (Ctrl +), and endogenous α-tubulin was used
as the loading control. Line dividing upper panel of PANX1 WB indicates differences in
exposure of the same blot to better detect endogenous PANX1 compared to the
overexpressed positive control. (E) Cell surface biotinylation experiments performed on
HEK293T cells showed that overexpressed PANX2 and the mutant N86Q are detectable
at the cell surface. Protein disulfide-isomerase (PDI) was used as a control for biotin
internalization. (F) Densitometric analysis and quantification of cell surface biotinylation
experiments performed in HEK293T cells revealed a significant reduction of N86Q cell
surface detection compared to PANX2. Cell surface detection was calculated relative to
the total protein in input lanes. Statistical significance was considered when p<0.05 (*
p=0.0286, N=4 independent experiments), Mann Whitney U test. Error bars denote mean
± SEM Molecular weights are noted in kDa.
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3.3.4

PANX2 and N86Q aggregates localize to the endoplasmic
reticulum and Golgi apparatus

Because of the prominent intracellular localization of PANX2 and the mutant N86Q, we
were interested in determining the subcellular compartments to which these proteins could
be trafficking. We transiently overexpressed these proteins in AD293 cells and used
immunolabeling with different organelle markers to assess their intracellular location by
confocal microscopy (Figures 3-4 and 3-5).
As shown in Fig. 3-4A, PANX2 immunolabeling exhibits a broad cytoplasmic distribution
highly overlapping (Pearson's Colocalization Coefficient (PCC)PANX2-PDI=0.49 ± 0.02;
n=41, N=3) with the chaperone protein disulfide-isomerase (PDI), a known marker of the
endoplasmic reticulum (ER). The mutant N86Q had significantly (p<0.0001) less overlap
(PCCN86Q-PDI=0.34 ± 0.03, n=57, N=3) with PDI, although there was also a more punctate
distribution of PDI that colocalized with N86Q. These observations suggest that N86Q is
confined to some punctate regions enriched in PDI and other subcellular organelles. We
also observed an apparent alteration of the ER morphology when N86Q was expressed.
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Figure 3-4.
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Figure 3-4 PANX2 and N86Q colocalize with markers of the endoplasmic reticulum
and Golgi.
Representative confocal micrographs of PANX2 and N86Q ectopically expressed in
AD293 cells. Co-immunolabeling with anti-PANX2 antibody (green) and organelle
markers (magenta): (A) PDI, endoplasmic reticulum (ER); (B) GM-130, cis-Golgi matrix.
PANX2 has a perinuclear localization and is spread intracellularly in the cytoplasm,
partially colocalizing with endoplasmic reticulum and Golgi markers. N86Q aggregates
also overlap with ER and Golgi markers and disrupt their distribution. Yellow arrowheads
indicate representative regions of colocalization. Nuclei (blue) were counterstained with
Hoechst 33342. Scale bars = 20 μm. Pearson Correlation Coefficients (right) were
calculated for multiple regions of interest (ROI)s corresponding to double-labeled cells.
Statistical significance was considered when p<0.05 (*** p<0.0001, N=3 independent
experiments), Unpaired two-tailed t-test with Welch's correction. Error bars denote mean
± SEM.
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Figure 3-5.
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Figure 3-5 PANX2 and N86Q do not localize to late endosomes/lysosomes or
mitochondria.
Confocal micrographs of PANX2 and N86Q ectopically expressed in AD293 cells. Coimmunolabeling with anti-PANX2 antibody (green) and organelle markers (magenta): (A)
Lamp-2, lysosomes and late endosomes, and (B) Mitotracker® Red, mitochondria showed
that neither PANX2 nor N86Q mutant exhibited significant overlap with the markers.
Nuclei (blue) were counterstained with Hoechst 33342. Nuclei (blue) were counterstained
with Hoechst 33342. Scale bars = 20 μm. Pearson Correlation Coefficients (right) were
calculated for multiples ROIs corresponding to double-labeled cells. There was no
statistical significance (p>0.05, N=3, unpaired two-tailed t-test with Welch's correction) in
the degree of colocalization between PANX2 and N86Q with the markers. Error bars
denote mean ± SEM.
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Quantitation of colocalization with cis-Golgi marker, Golgi matrix protein 130 (GM130)
(Fig. 3-4B) showed a significantly (p=0.0001) higher colocalization with N86Q mutant
(PCCN86Q-GM130= 0.43± 0.04; n=41, N=3) than with PANX2 WT (PCCPANX2-GM130= 0.23 ±
0.03; n=30, N=3). In this case, cells that overexpressed PANX2 WT exhibited changes in
the distribution of GM130 compared to un-transfected ones (seen in the same field of view,
Fig. 3-4B). These changes were more pronounced in cells overexpressing the mutant
N86Q, in which not only the cis-Golgi morphology changed, but GM130 also appeared to
accumulate within N86Q aggregates.
On the other hand, lysosome-associated membrane protein 2 (LAMP-2) and the fixable
and cell-permeant Mitotracker™ Red CMXRos were assayed to label lysosomes/late
endosomes and active mitochondria, respectively (Fig. 3-5). We did not observe
colocalization with LAMP-2 (PCCPANX2-Lamp-2= -0.08 ± 0.01; n=59, N=3; PCCN86Q-Lamp-2=
-0.05 ± 0.02; n=49, N=3) or Mitotracker (PCCPANX2-Mitotracker= -0.08 ± 0.03; n=25, N=3;
PCCN86Q-Mitotracker= -0.13 ± 0.06; n=31, N=3), and there was no difference in the distribution
of both markers upon overexpression of PANX2 WT or N86Q.

3.3.5

PANX2 N-glycosylation is not required for the interaction with
PANX1

Since PANX2 interacts only with the core non-glycosylated Gly0 and Gly1 species of
PANX1 [22], we were interested in determining the outcome with the un-glycosylated
species of PANX2. For these experiments, PANX1 was ectopically co-expressed with
either PANX2 or non-glycosylated N86Q mutant in HEK293T cells. Using coimmunoprecipitation assays (co-IP, Fig. 3-6A), we observed that both PANX2 and N86Q
could co-IP in a complex with PANX1 and occasionally, although not statistically
significant (p>0.05, N=4) (Fig. 3-6B and C), N86Q pulled down more PANX1 than the
WT PANX2. In addition, consistent with what was reported before by Penuela et al. (2009)
[22], we noticed that only Gly0 and Gly1 PANX1 species interacted with both variants of
PANX2.
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Due to the lack of available antibodies from different species to perform double
immunolabeling of both pannexins, we used C-terminal FLAG-tagged PANX2 and N86Q
co-expressed with PANX1 in HEK293T cells. Confocal imaging of PANX2-FLAG or
N86Q-FLAG coexpressed with PANX1 (Fig. 3-7A) showed that PANX2-FLAG exhibits
intracellular and cell surface localization overlapping with PANX1 (see Linescan analysis
on the right upper panel, Fig. 3-7A). N86Q-FLAG formed predominantly intracellular
aggregates like its untagged counterpart (Fig. 3-3A); however, a small subpopulation of
N86Q-FLAG could still be detected at the cell surface colocalizing with PANX1 (see
Linescan analysis on the right bottom panel, Fig. 3-7B), but to a lesser degree than PANX2FLAG. Taken together, these findings suggest that the glycosylation of PANX2 is not
required for the interaction of PANX1/PANX2 but can determine the differential
subcellular localization of glycosylated and un-glycosylated species, especially in the
presence of PANX1.
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Figure 3-6.

Figure 3-6 PANX2 glycosylation is not required for the interaction and
immunoprecipitation with PANX1.
(A) Reciprocal co-immunoprecipitation (co-IP) experiments showed that PANX2 and
N86Q co-IP in a complex with overexpressed PANX1 in HEK293T cells. Colored
arrowheads denote bands of co-IP proteins detected in WB. (B and C). Quantitative
analysis (see Materials and Methods section 3.4.8) of co-IP shows that the interaction of
N86Q with PANX1 is not significantly different (p>0.05, N=4) than with PANX2, and in
both cases, the complexes only involved the non- and lower- glycosylated species of
PANX1 (Gly0 and Gly1). Beads Ctrl denote control IPs done in parallel without antibodies.
Protein sizes in kDa.
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Figure 3-7.

Figure 3-7 N-glycosylation enhances PANX2 trafficking to the plasma membrane and
colocalization with PANX1.
Confocal micrographs of PANX2-FLAG (A) and N86Q-FLAG (B) (both shown in
magenta) ectopically co-expressed with mouse PANX1 (shown in green) in HEK293T
cells. Seventy-two hours post-transfection, PANX2-FLAG partially colocalized with
PANX1 at the cell membrane (black arrows in Linescan, panel A) with a subpopulation
still in intracellular compartments. N86Q-FLAG formed intracellular aggregates and
showed limited colocalization with PANX1 at the plasma membrane (Linescan, panel B).
Yellow arrowheads denote regions of colocalization of PANX1 and FLAG labeling, also
depicted with black arrows in the corresponding linescans. Insets: Linescans profiles
showing regions of maximal colocalization of overlapping fluorescence peaks (black
arrows). Nuclei (blue, Hoechst 33342). Scale bars = 20 µm.
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3.4 Discussion
Pannexins are a family of channel proteins implicated in significant physiological and
pathological functions, and most of the current research has been conducted to analyze
their level of expression and distribution within mammalian tissues and their role in diverse
diseases [35]. However, there is still a need to understand the biophysical properties of
these channels and the different ways of regulation that prevent or promote detrimental
effects of their exacerbated channel activity. Pannexins are N-glycosylated, and as integral
membrane proteins, this modification seems essential in regulating their trafficking, as was
demonstrated formerly for PANX1 and PANX3 [11, 22]. Unlike the other pannexins,
PANX2 is modified only to Gly1 species, an early post-translational modification
occurring in the ER lumen. This step is generally followed by further oligosaccharide
editing in the Golgi apparatus to yield complex glycosylation. To date, there is no evidence
showing further processing of PANX2 in Golgi, and only studies in PANX1 and PANX3
showed that trafficking of these two pannexins to the plasma membrane is mediated by
Sar1-dependent COPII vesicles [36] with N-glycosylation affecting their final destination
[11, 37, 38]. Thus, it is not surprising that N-glycosylation would regulate the route of
PANX2 trafficking and localization and possibly its channel formation.
This study sought to determine the N-glycosylation site by generating a glycosylationdeficient mutant (N86Q) based on the predicted N-linked glycosylation site reported by
Penuela et al. [22]. Our results showed that N86Q substitution generated a PANX2 mutant
with a faster-migrating electrophoretic band than PANX2 WT, which does not shift after
N-glycosidase digestion, confirming that N86 is the only N-glycosylation site for PANX2.
In all the cell lines assayed (NRK, HEK293T, and AD293), we observed that
overexpression of the PANX2 WT and N86Q constructs exhibited the same electrophoretic
properties (Figures 3-2C and 3-3C).
Independently of the cell type used for ectopic expression, the N86Q mutant appeared to
form punctate aggregates localized to intracellular compartments along with the ERchaperone PDI and the cis-Golgi matrix marker GM130. Compared to the N-glycosylationdeficient mutants of PANX1 and PANX3 [11], un-glycosylated PANX2 exhibited an
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exacerbated abnormal intracellular aggregation. This raises the possibility that the lack of
N-glycosylation may have affected the proper protein folding of PANX2. We cannot rule
out that the intracellular accumulation of N86Q could be an artifact of overexpression,
which, concomitant with the lack of glycosylation, might have induced misfolding and ERstress [39].
As mentioned earlier, PANX2 has been reported to be mostly intracellularly localized, but
in some instances, it can also translocate to the plasma membrane [14, 17]. Interestingly, a
previous report by Swayne et al. (2010) showed endogenous PANX2 expressed in postnatal
murine hippocampal neural stem and progenitor cells (NPCs) and the mouse
neuroblastoma (N2a) cell line, with immunoreactive species likely N-glycosylated and
other of higher molecular weight, sensitive to de-palmitoylation. In that study, the authors
showed that S-palmitoylated PANX2 species are likely not N-glycosylated and are
predominantly distributed to the Golgi apparatus and ER in undifferentiated neurons [17].
However, hippocampal granule neurons and differentiated N2a cells expressed "unpalmitoylated" PANX2 species localized to the cell membrane with a shift to the expected
electrophoretic migration of N-glycosylated and un-glycosylated species [17]. Although
that study could not determine which glycosylated (or not) species were at the cell
membrane, our results showed that it is possible for un- and N-glycosylated species to
traffic to the cell membrane, especially when it is co-expressed with PANX1 (also known
to be present in neurons). Therefore, N-glycosylation may be dispensable for PANX2 cell
membrane trafficking but is certainly a regulator of the PANX2 intracellular sorting and
its cell membrane expression.
Moreover, Swayne et al. (2010) showed that treatment with glycosidases had no significant
effect on endogenous PANX2 electrophoretic mobility suggesting that they were unglycosylated [17]. That study relied on antibody detection of endogenous PANX2, and the
protein bands identified were of lower molecular weight than the predicted full-length
PANX2 used in this study (677 aa, [40]). Further studies are needed to determine if the
expression of certain un-glycosylated endogenous isoforms of PANX2 is cell-type specific
and whether glycosylation has measurable effects on the PANX2 cellular function. To date,
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there are no reports of mutations in the PANX2 gene site encoding N86, but our results
predict significant changes in PANX2 behavior if its glycosylation is affected. It is also
possible that the un-glycosylated form of PANX2 may be preferentially expressed in some
cells and tissues determining the primary function of the PANX2 channel and its
subcellular localization.
Our study showed significant intracellular subpopulations of PANX2 likely localized in
the ER and partially colocalized with the cis-Golgi marker. Interestingly, the
overexpression of the N86Q mutant changed the distribution of PDI and GM130 compared
to PANX2 WT, suggesting that the formation of aggregates may disrupt the morphology
of ER and cis-Golgi. GM-130 is a peripheral membrane protein in the cis-Golgi matrix that
is important for maintaining Golgi structure [41] and regulating ER-to-Golgi transport of
proteins and glycosylation [42]. Thus, the aggregation of N86Q may interfere with the
protein transport from the ER, causing the accumulation of GM130.
Boyce et al. (2014) indicated that pannexins contain putative recognition sequences for
endocytic and endo-lysosomal targeting, which could account for the control of pannexin
trafficking. Interestingly, recently published work by Boassa et al. described the
localization of a recombinant PANX2 fused to mini-SOG tag that was transiently expressed
in HeLa cells [26]. These authors used correlated light and electron microscopy imaging
to detect PANX2 localization at cytoplasmic protrusions. Also, immuno-colocalization in
HEK293T cells using assorted vesicular markers displayed PANX2 WT (untagged)
localized to early or recycling endosomes rather than ER. However, they mentioned that
when the ER marker calnexin was used, they detected colocalization with overexpressed
PANX2 in HEK293T cells. Our findings are consistent with these reports [24] since we
found PANX2 primarily in the ER (Fig. 3-4A). However, as others have reported, we did
not find conclusive evidence of PANX2 in endo-lysosome compartments (Fig. 3-5A) [25,
26]. Based on our results, PANX2 may have an intracellular channel function in the ER,
similar to the proposed calcium-leak channels formed by PANX1 and PANX3 [6].
In some instances, PANX2 distribution exhibited limited cell surface localization that was
more apparent when higher endogenous or ectopic PANX1 protein was expressed in the
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studied cell lines. This is consistent with our previous observation of increased PANX2 at
the cell surface when co-expressed with PANX1 under overexpression conditions [22].
Herein, we used three different cell lines with varying endogenous PANX1 levels and
different protein production capacities. We noticed that in cells with low endogenous
PANX1 (e.g., NRKs), there was barely any PANX2 at the cell surface based on
immunolabeling and cell surface biotinylation pull-downs. In AD293 and HEK293T cells,
it was possible to detect low levels of overexpressed PANX2 at the cell surface, while the
mutant PANX2 (N86Q) had a detectable but significantly decreased presence only at the
cell membrane of HEK293T cells. This result could be attributed to the increased protein
expression in HEK293T cells that contains the SV40 T-antigen and have high transfection
efficiency. This feature might have allowed the overexpressed PANX2 to bypass protein
quality control mechanisms resulting in more PANX2 trafficking to the plasma membrane
[43].
Further research is needed to evaluate N-glycosylation of endogenous PANX2 and
examine if PANX2 can form channels at the plasma membrane under physiological
conditions. To date, limited studies have attempted to evaluate PANX2 channel function
[14, 15], and several factors make it challenging to test PANX2 channel activity, such as
its intracellular localization, the lack of evidence of in vivo functional channel formation
[27], and the unknown mechanisms of activation [14].
Work done by Bruzzone et al. [15] showed that PANX1 and PANX2 were abundantly
expressed in the CNS, and co-injection of both pannexin RNAs in paired Xenopus oocytes
resulted in the formation of heteromeric channels with functional characteristics different
from those formed by PANX1 monomers but with similar pharmacological sensitivity [27].
Ambrosi et al. [14] suggested that PANX1/PANX2 heteromeric channels tend to be
unstable, and they attributed that to differences in monomer size and oligomeric symmetry
between these two pannexins. We have previously shown that PANX1 and PANX2 do
form a complex as determined by co-IP experiments. Interestingly, when both pannexins
are co-expressed, the level of interaction between PANX2 and glycosylated species of
PANX1 depends on the latter's glycosylation [22]. Here, we showed in vitro that the
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PANX2 glycosylation-deficient mutant could readily form complexes with PANX1; thus,
PANX2 glycosylation is not required to intermix the two pannexins. Although it was not
statistically significant, N86Q seemed to pull down PANX1 more efficiently than WT
PANX2. However, in confocal images, the N86Q aggregates did not show higher overlap
with PANX1-immunolabeling than PANX2 WT. Consistent with our previous report [22],
complex N-glycosylation of PANX1 hinders their interaction since PANX2 and N86Q
interacted only with the Gly0 and Gly1 forms of PANX1.

3.5 Conclusions
Finally, we conclude that PANX2 glycosylation is not required for PANX1/PANX2
intermixing but assists the cell surface localization of PANX2, which is also increased by
the presence of PANX1. In cells where both pannexins are co-expressed, glycosylation
may act as a mechanism of regulation defining whether these channels will serve as
intracellular or plasma membrane channels with different physiological and pathological
functions.
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Chapter 4
PANX1 regulates immune cell recruitment, is implicated in tissue inflammation and plays
pro-tumorigenic roles in melanoma cells. Although genetic or pharmacological inhibition
of PANX1 decreases tumorigenic properties of mouse and human melanoma cells in vitro
and ex vivo, studies assessing its function on in vivo melanoma tumor formation and
immune cell infiltration are lacking. In this chapter, we used an inducible mouse model of
melanoma with a Panx1 global deletion to evaluate tumor progression and immune cell
infiltration compared to the corresponding wildtype controls.
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4

Global Pannexin 1 deletion increases tumor-infiltrating
lymphocytes in the BRAF(V600E)/Pten(del) mouse melanoma
model

4.1 Introduction
Malignant melanoma is a type of skin cancer that develops from melanocytes and becomes
a life-threatening disease when it spreads to various organs [1]. Depending on the diagnosis
and the mutational landscape of the tumor biopsies (e.g., BRAF mutation status), targeted
therapy with mutant kinase inhibitors or immunotherapies with monoclonal antibodies
against immune checkpoint inhibitors are currently being used for melanoma treatment.
The use of immune checkpoint inhibitors enhances anti-tumoral T cell-mediated immune
responses, but unfortunately, about ~60% of melanoma patients do not respond to this type
of therapy [2-4]. Regardless of the treatment options, their effectiveness is usually
dampened due to the insufficient effector activity of tumor-infiltrating lymphocytes (TILs)
[5], recurrence, and development of multiple resistance mechanisms [6, 7]; therefore,
innovative therapy concepts are still warranted.
Pannexin1 (PANX1) is a channel-forming membrane glycoprotein that mediates the
passage of nucleotides, ions, and other metabolites involved in intercellular communication
[8]. We have previously demonstrated that PANX1 expression correlates with tumor cell
aggressiveness in isogenic mouse melanoma cell lines, and its knockdown reduces
melanoma tumor size and metastasis to the liver in chick chorioallantoic membrane (CAM)
xenografts [9]. More recently, we showed that PANX1 is highly expressed in human
melanomas, and genetic or pharmacological PANX1-targeting decreases the tumorigenic
properties of melanoma cells [10]. Mechanistically, we have recently demonstrated that
PANX1 regulates melanoma cell growth and metabolism through direct interaction with
β-catenin and modulation of the Wnt signaling pathway [11]. Considering all these
findings, PANX1 has become an attractive target for preclinical melanoma research, but it
is still unclear whether genetic silencing of the Panx1 mouse gene would impact melanoma
development in vivo.
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In addition, PANX1 influences the inflammatory response [12-17] and is expressed in
different subtypes of immune cells like macrophages and lymphocytes [12, 18, 19].
Previous evidence shows that PANX1-mediated adenosine-5’-triphosphate (ATP)
permeability enables activation and functional enhancement of T cells [16, 17]. On the
other hand, the release of ATP through caspase cleaved PANX1 channels in apoptotic
leukemic lymphocytes has been shown to induce the recruitment of inflammatory cells
(e.g., monocytes)[12]. Paradoxically, the caspase-dependent PANX1 channel opening in
dying macrophages and lymphocytes releases other metabolites that suppress, in vivo,
proinflammatory signals of myeloid cells in the surrounding tissue [8]. Considering the
broad PANX1 expression in different cell types present in the tumor microenvironment
(TME), no studies have specifically addressed yet whether PANX1 modulates tumoral
recruitment of immune cells that are critical players in the TME and targets of the current
immunotherapies [13].
Previous characterization of a constitutive global Panx1 knockout mouse (Panx1-/-,
Panx1KO)(developed by Genentech) [15] demonstrated that mice are viable, and no overt
phenotypes were detected on Panx1-/- mice by histological and pathological examinations.
However, due to Panx1 expression in the skin [9, 20], our group used the same Panx1-/mouse strain to characterize skin in normal and pathological conditions (e.g., wound
healing) and demonstrated differences in dorsal skin thickness and delayed wound healing
[9, 20]. These observations indicated an essential role of PANX1 in keratinocyte and
dermal fibroblast differentiation and wound repair in the skin. However, melanocytes are
also known to express low levels of PANX1 that become upregulated in mouse melanoma
cells [9]. The combination of this Panx1-/- mouse line with a cancer model had not been
tested yet, and in the case of cutaneous melanoma, this approach may offer new insights
into the roles of PANX1 in the context of this cancer and its immune infiltration, which
could be useful for testing future therapeutic interventions.
In this work, we crossed a global Panx1-/- mouse strain with the inducible melanoma model
BRafCA/+, PtenLoxP/Loxp, Tyr::CreERT2 (abbreviated as BPC) mice that harbors two
oncogenic driver mutations found in human melanomas [21-23]. Furthermore, due to the
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role of PANX1 in regulating tumor growth and in various aspects of the immune response
[12-17], we sought to evaluate the effects of the Panx1 germline deletion on in vivo
melanoma progression and the tumor immune infiltration of a hybrid mouse model.
Our results showed that Panx1 global deletion did not reduce in vivo BRAF/Pten-driven
melanoma progression but increased the tumor infiltration of effector immune T cell
populations and Granzyme B+ cells. Besides, the expression of early T cell activation
marker CD69, the LAG-3 checkpoint receptor or PD-L1 in the tumors was similar among
genotypes, indicating that Panx1 germline deletion may not influence the T cell immune
activation or immunosuppressive mechanisms through T cell exhaustion and immune
checkpoint regulators. This study also showed that female PANX1-deficient BPC mice
might have significant changes in their immune phenotype with increased spleen size
compared to their male counterparts. Future preclinical work targeting PANX1 in
melanoma may increase the incidence of effector T-lymphocytes in the tumors and
improve the response to immunotherapies using immune checkpoint inhibitors.

4.2 Materials and Methods
4.2.1

Mouse breeding and genotyping

C57BL/6, Tyr::CreERT2; BrafCA/+; PtenLoxP/LoxP (BPC) mice were obtained from Jackson
Laboratory, (Stock # 013590). Mice were kept on a 12:12 h light:dark cycle with normal
chow and water available ab libitum. For deletion of Panx1, BPC mice were crossed with
the previously characterized global Panx1–/– mice in a C57BL/6N background strain [15,
20] (Genentech Inc., San Francisco, CA). Genotyping was performed on genomic DNA
derived from the toes using PCR as described in [21].

4.2.2

Melanoma tumor induction, monitoring, and sample collection

All experiments performed on the mice were approved by the Animal Care Committee of
the University Council on Animal Care at the University of Western Ontario, London ON,
Canada (UWO AUP# 2019-070). 3–4-weeks-old BPC mice were used for tumor induction
experiments: Panx1+/+ (7 females and 8 males) and Panx1–/– (9 females and 4 males).
Cutaneous melanomas were induced with topical application of 4-hydroxytamoxifen (4-
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HT) (Sigma) on the skin of the lower back as per protocol in [21]. Mouse body weight and
tumor dimensions were monitored every 3–4 days as soon as the tumors were visible for
up to 4 months. Measurements were done with a digital caliper, and tumor volume was
calculated using the modified ellipsoid formula V = (W(×2) × L)/2, where V is tumor
volume, L and W are the longest (length) and shortest (width) tumor diameters,
respectively. The endpoint was considered when the tumor volume (or total combined
tumor volume, in case of multiple tumors per animal) reached 2.0 cm3, or tumors showed
signs of heavy ulceration, or the animals had poor body condition. Euthanasia was carried
out using carbon dioxide asphyxiation followed by cervical dislocation. The spleens were
weighed and measured using a ruler. Draining inguinal lymph nodes compromised with
pigmented lesions were classified as metastatic sites and counted per mouse. All the
collected tissue samples were fixed overnight with Periodate-Lysine-Paraformaldehyde
(PLP) fixative or flash-frozen in liquid nitrogen and stored at –80 ºC until processing for
RNA extraction.

4.2.3

Tissue Processing, RNA Extraction, real time-qPCR

Frozen tissues/tumor samples were ground in liquid nitrogen with a mortar and pestle and
then used for RNA extraction. Total RNA was extracted using TRIzol™ Reagent
(Invitrogen) according to the manufacturer’s protocol and purified using the RNAeasy®
Plus Mini kit (Qiagen). RNA concentration was determined using an Epoch Microplate
Spectrophotometer (BioTek®). cDNA was generated using the High Capacity cDNA
Synthesis Kit (Thermo Fisher Scientific; REF 4368814) in a T100TM Thermal Cycler (BioRad). SYBR®Green Real-Time PCR Master Mix (Bio-Rad) was used along with the
primers listed in Table 4-1, where mouse gapdh and 18S were the housekeeping gene
controls. Real-time qPCR was performed in a CFX96 Touch TM Real-Time PCR
Detection System (Bio-Rad). All the assays involved at least three technical replicates
(n=3), and the relative mRNA expression analysis was determined using the ΔΔCt method
calculated in the Bio-rad CFX Maestro Software, ver 1.1 (Bio-rad). Between assays, a nontamoxifen treated skin BPC-Panx1+/+ sample was used as the control for interplate
variation.
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Table 4-1. List of primers used for real-time qPCR analysis
Target gene
Panx1
S100a1
CD3ε
CD4
CD8β1
Ptprc(CD45)
FoxP3
ncr1
Adgre1(F4/80)
CD69*
LAG-3*
PD-L1*
IL-1β*
gapdh
18s

Forward primer (5’-3')

Reverse primer (5’-3')

ACAGGCTGCCTTTGTGGATTCA
CCATGGAGACCCTCATCAAT
ATGCGGTGGAACACTTTCTGG
GCGAGAGTTCCCAGAAGAAG
AAGAAGCAATGCCCGTTCC
ATGGTCCTCTGAATAAAGCCCA
TTGCCAAGCTGGAAGACTGC
TGTTGAGAACAGCAGCCTTG
CTTTGGCTATGGGCTTCCAGTC
GGGCTGTGTTAATAGTGGTCCTC
CTCCATCACGTACAACCTCAAGG
TGCGGACTACAAGCGAATCACG
TGGACCTTCCAGGATGAGGACA
TGTGTCCGTCGTGGATCTGA
CGGACAGGATTGACAGATTG

GGGCAGGTACAGGAGTATG
TTCTGGACATCCAGGAAGC
GCACGTCAACTCTACACTGGT
AAACGATCAAACTGCGAAGG
TGAGGGTGGTAAGGCTGCA
TCAGCACTATTGGTAGGCTCC
CAGACGGTGCCACCATGACT
AGGATTATGCATGCCAGACC
GCAAGGAGGACAGAGTTTATCGTG
CTTGCAGGTAGCAACATGGTGG
GGAGTCCACTTGGCAATGAGCA
CTCAGCTTCTGGATAACCCTCG
GTTCATCTCGGAGCCTGTAGTG
TTGCTGTTGAAGTCGCAGGAG
CAAATCGCTCCACCAACTAA

* qSTAR qPCR mouse primer pairs from OriGene Technologies Inc., Rockville, MD,
USA, CD69 (Cat.# MP201944); Lag-3 (Cat.# MP207670); PD-L1 (Cat.# MP201906);
IL-1b (Cat.# MP206724)
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4.2.4

Tissue preparation, cryo-sectioning, and immunofluorescence
staining

Tumor tissues samples that were fixed in PLP (1% PFA, 0.1 M L-Lysine, 0.01 M sodium
periodate) overnight at 4°C were washed three times for 5 mins in phosphate buffer (0.075
M sodium phosphate dibasic and 0.025 M sodium phosphate monobasic) and incubated
sequentially in 10%, 20% and 30% sucrose phosphate solutions, each overnight at 4°C.
Tumors were then embedded and frozen in Fisher Healthcare™ Tissue-Plus™ O.C.T.
Compound (Fisher Scientific Cat.# 23-730-571) and stored at -80 °C until sectioning.
Eight-micron-thick serial cryostat sections were immuno-stained with the fluorescentconjugated antibodies diluted in 1% BSA, 0.1% Tween-20 and 5% rat blocking buffer.
Counterstaining was done with 10 µg/mL of Hoechst 33342 (Life Technologies Ref.#
H3570) for 7 min, at room temperature. Sections were mounted with ProLong™ Gold
Antifade Mountant (ThermoFisher Cat. # P10144).

4.2.5

Antibodies used for immunofluorescence

Alexa Fluor® 647 anti-mouse CD4 (clone RM4-5) and Alexa Fluor® 647 anti-mouse
CD8a (clone 53-6.7) (BioLegend, USA, Cat.#: 100530 and 100727, respectively) were
used for immunofluorescence at a final concentration of 2.5 µg/mL, and eFluor 660 antimouse FOXP3 (clone FJK-16s) eBioscience™ (ThermoFisher Scientific, Cat.# 50-577380) was used at 1 µg/mL. As controls for staining specificity, the eFluor 660 rat IgG2a
kappa Isotype Control (eBR2a) (eBioscience™, ThermoFisher Sci., Cat. # 50-4321-80)
and Alexa Fluor® 647 Rat IgG2a, κ Isotype Ctrl (BioLegend, USA, Cat. #: 400526) were
used at the same dilution of their corresponding conjugated antibodies. Granzyme B (clone
D2H2F) rabbit mAb (Cell Signaling Cat. # 17215S), and rabbit Anti-Ki67 antibody
(ab833) were used at 1:200 dilution. Secondary antibodies goat anti-rabbit AF488 (Life
technologies) and Texas Red (ThermoFisher Cat. # T6391) were used at 1:500 dilution in
blocking buffer.

4.2.6

Image acquisition and analysis

Tile-scan imaging of whole tumor sections (20×) was acquired using an ORCA-flash4.0
LT plus (Model C11440) Hamamatsu digital camera with DAPI and Cy5 filters in an
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Eclipse Ni-E Fluorescence Microscope (Nikon) using an S Plan Fluor ELWD 20x Ph1
ADM objective N/A 0.45 and refractive index of 1. Granzyme B imaging was performed
in an LSM 800 Confocal Microscope (Carl Zeiss) using a Plan-Apochromat LCI PlanNeofluar 25x/0.8 Imm Korr Water DIC objective for tiles or 63x/1.40 Oil DIC objective
(Zeiss). For the images acquired with Nikon Fluorescence microscope, the noise
component was removed with Denoise. AI utility, and the fluorescence background was
subtracted in NIS-Elements Advanced Research Analysis software (ver. 5.21.02, Nikon).
Separated tile images per channel were converted to binary images, and automated image
analysis was performed using Cell Profiler Software (ver. 4.0.7, Broad Institute MIT)[24],
using a custom pipeline to determine the percent of nuclei (cells) with positive
immunostaining for the marker over the total number of cells normalized to the area of the
field of view. At least two serial cryosections per tumor were used for quantification.

4.2.7

Statistical analysis

All the statistical analyses were performed using GraphPad Prism® ver. 8 (San Diego, CA,
USA). Unless otherwise indicated, the results are expressed as the mean ± standard
deviation (SD), and the biological (N) and technical replicates (n) for a given experiment
are indicated in each figure. Animal numbers were estimated by a priori power analysis
(G*Power ver.3.1 [25])based on a pilot study using spontaneous tumor incidence data
comparing BPC-Panx1+/- (heterozygous) vs. BPC-Panx1-/-, with an effect size of 1.0 and a
power of 0.8. For multiple comparisons involving the genotype and sex of mice, two-way
ANOVA was performed, followed by a Tukey-Kramer post hoc test for unequal sample
sizes. For real-time qPCR data, log2 (Relative Normalized expression) was used for
statistical comparisons. One-way ANOVAs followed by a Sidak’s post hoc test were done
to analyze relevant preplanned multiple mean comparisons in the mRNA expression
between tissues (skin vs. tumor) within the same genotype and among mouse genotypes
(BPC-Panx1+/+ vs. BPC-Panx1-/-) within the same tissue type. Outliers were removed using
the ROUT method with a False Discovery Rate of less than 1%, and normality was verified
with the D’Agostino-Pearson test. Immunofluorescence (IF) quantification data were
obtained from individual tumors of four different mice (at least N=3) per genotype and
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analyzed with a two-tailed non-parametric Mann-Whitney test. Statistical significance was
considered when p < 0.05.

4.3 Results
4.3.1

Panx1 global-deletion does not affect primary tumor characteristics
or melanoma progression of Braf(V600E)/Pten(del) mice

To explore the in vivo effects of the Panx1 global deletion on melanoma progression, we
crossed BRafCA/+, PtenLoxP/Loxp, Tyr::CreERT2 (BPC) mice with the global Panx1 knockout
(Panx1-/-, Panx1KO) mouse line, reported on [15, 21]. In the BPC model, a 4hydroxytamoxifen (4-HT)-inducible Cre recombinase is used for the melanocyte-specific
expression of mutant BRafV600E—a constitutively active protein serine kinase—and
inactivation of the Pten phosphatase to produce primary cutaneous malignant melanomas
(11). However, as in (23), we observed that spontaneous melanomas occurred in
approximately 70% of the BPC colony in the absence of tamoxifen exposure. Thus, we
started the 4-HT induction experiments in mice between 3–4 weeks of age that looked
healthy and had no spontaneous melanoma formation.
Our results showed that regardless of the Panx1 genotype, melanocytic pigmented lesions
arose from the skin and quickly grew to form cutaneous melanomas as early as three weeks
after topical application of 4-HT. Furthermore, although we applied 4-HT to a small zone
in the dorsal skin of the lower back, we found that, in both animal groups, multiple tumor
lesions grew not only in the application region but also in distant sites (Fig. 4-1A). As a
result, all the visible melanoma lesions found in the dorsal and ventral/lateral skin of the
animals were considered to determine tumor burden (Fig. 4-1B) and endpoint conditions.
Overall, we observed that BPC-Panx1-/- mice had similar tumor incidence (Fig. 4-1B),
survival (Fig. 4-1C), and mouse weight among sexes (Fig.4-1D) compared to Panx1wildtype counterparts. However, although the total combined tumor growth over time
(Fig.4-1E) was similar between genotypes, two-way ANOVA statistical analysis in
estimated tumor growth parameters (Fig.4-1F and G) showed that the sex of the mouse
might influence melanoma tumor growth in BPC-Panx1+/+ mice. BPC-Panx1-wildtype
male mice had a slightly lower (though not significant) tumor growth rate (Fig.4-1G, two-
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way ANOVA, Sex factor: F1,23 = 4.64, p<.05) and a significant increase (p = 0.188) in
tumor doubling time (Fig.1F, two-way ANOVA, Sex factor: F1,23 = 7.86, p<.05) compared
to female BPC-Panx1-wildtype counterparts. However, this sex-driven difference was not
statistically significant in BPC-Panx1-deficient mice, and overall tumor growth did not
differ between genotypes. These results indicated that Panx1 global deletion in this mouse
model did not impact BRAFV600E/Pten-driven melanoma development.
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Figure 4-1.
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Figure 4-1 Global Panx1 deletion does not improve survival or reduce tumor
progression in the Braf(V600E)/ Pten(del) mouse melanoma model.
(A) Representative picture of Tyr::CreER; BRafCA/+; Pten-/- (BPC) mice knockout (-/-) for
Panx1 with multiples tumors at endpoint. Region of the tamoxifen application is indicated
in the picture. (B) Tumor incidence, recorded as the number of visible cutaneous melanoma
lesions at endpoint, was similar between both mouse sexes and genotypes. (C) KaplanMeier survival curves were similar among BPC-Panx1 wildtype (+/+) or BPC-Panx1-/- mice
(Log-rank test, p = 0.7803). Dotted lines denote 95% confidence intervals. (D) Comparison
of mice body weight after tumor induction showed no differences among genotypes within
the same sex group. Statistical significance was determined by multiple t-tests per
timepoint using the Holm-Sidak method without assuming a consistent SD. (E) Tumor
growth curves showed overlap between genotypes, with a group of mice exhibiting slightly
delayed tumor growth. Individual lines depict measurements per mouse. (F, G) Tumor
growth rate and doubling time were similar among genotypes but significantly different
between males and females within the BPC-Panx1+/+ group. Two-way ANOVA showed
no interaction between genotype and sex, but significant p-values for the sex factor in
tumor doubling time (F1,23 = 7.855, p<.05) and growth rate (F1,23 = 4.642, p<.05),
respectively. Symbols stand for individual data per mouse (BPC-Panx1+/+, n=15, and BPCPanx1-/-, n=13) except for the graph in D, where mean ± SD are shown. Due to unequal
sample sizes per sex, the Tukey-Kramer test was used as posthoc test for pairwise
comparisons shown in F and G. Statistical significance was considered when p<0.05.
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In general, most melanoma lesions were presented with a combination of melanotic (black)
and amelanotic (white) regions (Fig. 4-2A). However, a few exceptions (less than 30% of
animals per genotype) also had completely amelanotic tumors primarily distant from the
tamoxifen application site. A classification of the tumors with the presence or complete
absence of black pigmentation rendered no significant differences in their number among
genotypes (Fig. 4-2A). All mice, regardless of the genotype, developed fast-growing
tumors that, in most cases, were ulcerated by the time of endpoint (Fig. 4-2B). Since our
previous reports indicated that PANX1 is highly expressed in human melanoma tumors
compared to normal skin, we performed real-time-qPCR in matched samples of nontamoxifen treated (adjacent) skin and tumor. Panx1 mRNA expression was found to be
3.2-fold increased (Fig. 4-2C) in tumors of BPC-Panx1+/+ mice compared to non-tamoxifen
induced skin, while undetectable in any tissue sample from BPC-Panx1−/− mice, as
expected. Moreover, mRNA expression of S100a1 melanoma marker [26, 27] had a 5.1fold increase (p<0.05) in tumors of BPC-Panx1−/− compared to non-tamoxifen treated skin
(Fig. 4-2D), indicating that the development of primary tumors occurred independently of
Panx1 expression.
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Figure 4-2
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Figure 4-2 Pigmentation or ulceration of the Braf(V600E)/Pten(del) melanoma lesions
are not influenced by the global Panx1 deletion.
(A, B) Representative pictures of pigmented and ulcerated tumors. Fractions (out of the
total tumors per mice) of pigmented or ulcerated tumors were similar among the genotype
and sex groups. Symbols show individual data per mouse and horizontal lines, and error
bars represent mean ± SD. Data were analyzed with two-way ANOVA. (C, D) mRNA
expression of Panx1 and melanoma marker s100a1 in tumors compared to matched
samples of non-tamoxifen treated skin per mouse. Gapdh and 18s were used as reference
genes, and the normalized expression is shown relative to one of the BPC-Panx1+/+ skin
samples. Box plots represent the 95% confidence interval (CI) and the median (inner line),
with whiskers representing the maximum and minimum values of the gene expression.
Symbols display the individual expression data per mouse. Paired t-test was used to
compare the log2 (normalized expression) of Panx1 and one-way ANOVA followed by a
Tukey test used to compare the expression of S100a1. At least N=5 paired samples were
assayed by triplicate (n=3) for real-time-qPCR analysis. Statistical significance is shown
as p<0.05(*).
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4.3.2

Panx1-deletion does not prevent melanoma metastasis to inguinal
lymph nodes

In all cases, we observed localized and distant clusters of small black pigmented spots
spread in the underside of dorsal skin that was not treated with tamoxifen, suggesting the
presence of melanoma microlesions or that in-transit metastasis may have occurred (Fig.
4-3A). Upon visual inspection after euthanasia, we did not find any evident presence of
black metastatic lesions in major organs (e.g., lungs, liver, or brain). However, melanoma
tumor cells are known for passing through the lymphatic system and entering the
bloodstream to metastasize to other organs [28]. As is characteristic of this mouse model,
we found regional melanoma metastases located in both right and left inguinal lymph nodes
in both BPC-Panx1 genotypes regardless of the sex of the animals (Fig. 4-3B, C, and D).
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Figure 4-3.

Figure 4-3 Panx1 deletion does not prevent the development of Braf/Pten-driven
melanoma micro-lesions or metastasis to inguinal lymph nodes in BPC mice.
(A) Representative pictures of melanoma micro-lesions found underside the dorsal and
ventral/lateral skin and located distant (inset a) and nearby (inset b) to the application sites
of tamoxifen (e.g., lower back dorsal skin). LN: Inguinal draining lymph nodes. (B)
Representative pictures of right and left inguinal lymph nodes showing black pigmentation
indicative of melanoma metastasis. (C) Phase-contrast micrograph of an inguinal draining
lymph node cryosection exhibiting melanin deposits and pigmented cells (white arrows).
(D) Fraction (out of two inguinal LN per mice) of draining lymph nodes classified with
melanoma metastasis based on the presence or absence of visible pigmented lesions.
Symbols correspond to the individual data per mouse where mean ± SD are shown. Data
were analyzed with a two-way ANOVA. Statistical significance was considered when
p<0.05.
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4.3.3

Spleens are significantly enlarged in females of tumor-induced
BPC-Panx1-/- mice compared to males

Initial visual inspection of the spleens in BPC-Panx1-/- mice showed an apparent increase
in spleen size compared with the BPC-Panx1+/+ cohort (Fig. 4-4A). Therefore, we
measured spleen length and weight (normalized to body mass and referred to here as weight
index) (Fig. 4-4B, C) and observed statistically significant sex-dependent differences in
BPC-Panx1-/- mice (two-way ANOVA, F1, 20 = 10.91, p<0.01). In that case, a statistically
significant increased spleen weight index was found in females compared to males of the
BPC-Panx1-/- cohort but not in the BPC-Panx1+/+ mice or among genotypes. Moreover,
spleen weight and length measurements showed a positive correlation (Fig. 4-4D) with
statistically significant (p=0.0247 and p=0.0087) Pearson’s coefficients (r ≥ 0.7) in both
BPC-Panx1+/+ and BPC-Panx1-/- mice, respectively, which confirmed the similar trend
observed with both parameters. We also assessed the cellular proliferation in spleen
cryosections from randomly selected animals of both genotypes (Fig. 4-4E). Interestingly,
quantification of the immunofluorescence staining with the proliferation marker ki67 (Fig.
4-4F) showed significantly fewer proliferative splenic cells in tumor-bearing BPC-Panx1/-

mice than the BPC-Panx1+/+ cohort suggesting that this morphological difference in

spleen size is not due to an increased in situ proliferation of cells (resident or in transit) in
the spleens of tumor-bearing BPC mice.
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Figure 4-4.
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Figure 4-4 BPC-Panx1-/- mice exhibit sex-dependent differences in spleen size not
observed in BPC-Panx1+/+ cohort.
(A) Representative pictures of BPC mice spleens. (B) Morphological comparison of the
spleen measured by length and (C) weight index (spleen weight normalized to body mass)
Two-way ANOVA, F1, 20 = 10.91, p<0.01. A Tukey-Kramer test used as posthoc test for
pairwise comparisons showed a significantly (p<0.01) higher spleen weight index in BPCPanx1-/- females than males, but not in the BPC-Panx1+/+ cohort. Symbols correspond to
data from individual mice where mean ± SD are shown. (D) A positive correlation was
found between the spleen weight and length, confirming the trends of increased spleen size
in female BPC-Panx1-/- mice observed by both measurements. (E) Representative
immunofluorescence micrographs (20x magnification) of cross-sectional views of the
spleen sections stained with the proliferation marker ki67. Yellow arrows indicate the
location of proliferating cells (green). Nuclei (magenta) were counterstained with Hoechst
33342. Scale bar = 200 µm (F) Quantification of ki67 staining in the spleens showing
significant reduction in the % of proliferative cells in spleens of BPC-Panx1-/- mice;
symbols represent individual measurements of at least 12 non-overlapping fields of view
from randomly selected animals: BPC-Panx1+/+ (N=3; n=1 female and n=2 males) and
BPC-Panx1-/- (N=4 females) mice. Box plots represent the 95% confidence interval (CI),
and the mean (inner line), whiskers represent the maximum and minimum counts per
image. Data were analyzed with two-tailed unpaired t-tests. Statistical significance is
shown as p<0.05 (*), p<0.01(**) and p<0.0001(****).
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4.3.4

BPC-mice lacking PANX1exhibit increased CD8 expression in the
skin and melanoma tumors

Due to PANX1’s role in the inflammatory response [12-17], we sought to examine changes
in the infiltration of immune cells within the tumor microenvironment. We performed a
real-time qPCR analysis of gene expression for markers of a selected immune cell
population known to modulate the immune response against melanoma. Therefore, we
included protein tyrosine phosphatase, receptor type, C (Ptprc) (also known as cluster of
differentiation (CD) 45) for leukocytes; CD3 antigen, epsilon polypeptide (CD3ε) for Tlymphocytes; CD4 antigen (CD4) for T-helper lymphocytes;

CD8 antigen, beta

polypeptide (CD8b) for cytotoxic T cells; forkhead box P3 (Foxp3) for regulatory T cells
(T-reg); natural cytotoxicity triggering receptor-1 or NCTR1 (Ncr1) for Natural killer
(NK) cells and the cell surface glycoprotein F4/80 (Agre1) for monocytes/macrophages.
Of note, marker expression was evaluated in melanoma tumors as well as matched samples
of dorsal skin not treated with tamoxifen and devoid of any visible melanoma lesions
(referred to as “adjacent skin”). These adjacent skin samples were used to account for basal
immune infiltration levels or skin-resident immune cells [29, 30] at the time of sample
collection.
When analyzing tumors compared with their matched skin samples, we observed a
statistically significant ~4.3 fold-increase in the expression of CD45 (F3, 20 = 6.24, p<0.01)
in the BPC-Panx1+/+ mice group (Fig. 4-5A) but no differences between genotypes. The
mRNA expression of F4/80 (F3, 18 = 19.38, p<0.0001) was 14.0 (p<0.0001) and 7.7-fold
(p<0.01) higher in tumors than the skin of BPC-Panx1+/+ and BPC-Panx1-/-, respectively
(Fig. 4-5B). On the other hand, transcripts of NCTR1 (F3, 11 = 8.24, p<0.01) (Fig. 4-5C)
were 9.3-fold upregulated (p<0.01) in BPC-Panx1-/- tumors versus adjacent skin. Overall,
T-lymphocyte infiltration measured by CD3ε (Fig. 4-5D) showed a similar expression
regardless of the sample type or Panx1 genotype. However, CD4 mRNA expression (F3, 11
= 27.46, p<0.0001) was significantly augmented in the tumors compared to the skin (Fig.
4-5E) with a 10.5 (p<0.01) and 18.9-fold (p<0.001) increase in the BPC-Panx1-/- and BPCPanx1+/+, respectively; and 5-fold upregulated (p<0.05) in the adjacent skin of BPC-Panx1/-

vs. that of BPC-Panx1+/+. Moreover, Foxp3 (F3, 16 = 9.80, p<0.001) was upregulated in
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tumors of BPC-Panx1+/+ and BPC-Panx1-/- mice compared to the skin (5.9-fold, p<0.05,
and 15.2-fold, p<0.01, respectively) (Fig 4-5G). Lastly, cytotoxic T cell marker CD8 (F3,
16

= 15.39, p<0.0001) was the only marker with a significant increase (9-fold, p<0.01) in

the skin and (9.5-fold, p<0.01) in tumors of the BPC-Panx1-/- mice compared to BPCPanx1+/+ animals (Fig. 4-5F). Overall, these results indicated that Panx1 deficiency did not
impair the recruitment of immune cells to the primary tumors. Interestingly, a higher CD8
mRNA expression in the tissues of BPC-Panx1-/- mice suggested that PANX1 may
modulate migration of CD8+ T cells to target tissues.
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Figure 4-5.
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Figure 4-5 CD8 T-lymphocyte mRNA marker is significantly increased in the nontamoxifen treated skin and melanoma tumors of BPC-mice lacking PANX1.
(A-G) Real-time qPCR analysis of immune cell markers expression in tamoxifen-induced
tumors and matched non-tamoxifen treated skin. Gapdh and 18s were used as reference
genes, and the normalized expression was calculated relative to one of the BPC-Panx1+/+
skin samples. Box plots represent the 95% confidence interval (CI) and the median (inner
line), with whiskers showing the maximum and minimum values of the gene expression.
Each sample was assayed by triplicate (n=3). The symbols represent the expression data of
each mouse (at least N=3 per genotype). The log2 of the expression per group was analyzed
by one-way ANOVA followed by a Sidak post hoc test. Only significant p values of
relevant comparisons between groups are shown as p<0.05 (*), <0.01(**), <0.001(***).
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Given the lack of differences in tumor burden among genotypes and the increased CD8
transcript expression indicative of infiltration of cytotoxic T-lymphocytes in the BPCPanx1-/- tumors, we questioned whether tumor-infiltrated T cells lacking Panx1 had
differences in the anti-tumoral response compared to those of the BPC-Panx1+/+ cohort.
Thus, we assessed the expression of early activation T cell antigen CD69, a membranebound, type II C-lectin receptor known as an early classical marker of lymphocyte
activation [31]. CD69 mRNA trended lower (but not significant) in BPC-Panx1-/- tumors
(Fig. 4-6A). On the other hand, we also investigated the mRNA expression of a marker for
T cell exhaustion, the negative regulatory immune checkpoint receptor lymphocyte
activation gene-3 (LAG-3) [32], but no significant differences in LAG-3 expression were
found between genotypes (Fig. 4-6B). These findings suggested that PANX1 may not
influence tumor-infiltrating T cell activation or exhaustion phenotypes in this BPC model.
We also investigated the mRNA expression of another central player in regulating the
immune responses in melanoma, programmed cell death protein-ligand 1(PD-L1) [33].
PD-L1 can be expressed by tumor cells and exert a negative regulation on cytotoxic T cell
activation. However, PD-L1 mRNA expression in tumors was not significantly different
between the Panx1-genotypes (Fig. 4-6C). Therefore, we concluded that the Panx1
deletion does not influence PD-L1-derived immunosuppression of T cells in the tumor
microenvironment. Finally, due to the association of PANX1 channel function and the
proinflammatory and tumor promoter cytokine: interleukin-1β (IL-1β), we asked whether
the IL-1β expression was affected within the tumor microenvironment of BPC Panx1deficient mice. However, IL-1β mRNA levels (Fig. 4-6D) were highly variable in the BPCPanx1-/- tumors but were not significantly different compared to tumors of the BPCPanx1+/+ mice.

166

Figure 4-6.
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Figure 4-6 Global Panx1-deletion does not affect the mRNA expression of phenotypic
markers of activation of tumor-infiltrated T-lymphocytes.
Real-time qPCR analysis of (A) the early T cell immune activation marker CD69, (B)
checkpoint receptor lymphocyte activation gene-3 (LAG-3), (C) immune checkpoint
molecule programmed cell death 1-ligand (PD-L1), and (D) IL-1β in tumor samples.
Gapdh was used as a reference gene, and the normalized expression is relative to one of
the BPC-Panx1+/+ skin samples. Box plots represent the 95% confidence interval (CI) and
the median (inner line), with whiskers showing the maximum and minimum values of the
gene expression. Each sample was assayed by triplicate (n=3), and the symbols represent
the expression data of each mouse (at least N=4 per genotype). A t-test compared the mean
of the log2 of the relative expression per group; statistical significance was considered when
p<0.05 (*).
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4.3.5

Germline Panx1-deletion increases the tumor infiltration of CD4+,
CD8+ T lymphocytes, and Granzyme B producing cells

We wanted to confirm the differences in tumor T cell infiltration between Panx1 genotypes
using an orthogonal approach. Therefore, we performed immunofluorescence staining on
PLP-fixed tumor cryosections for CD4, CD8, and Foxp3 lymphocytic markers (Fig. 4-7A).
Overall, CD4+ and CD8+ T cells were seen in small but sparsely distributed clusters closer
to the skin epidermis of the primary melanoma tumors, and Foxp3+ T cells showed a more
homogeneous distribution within the tumor core irrespective of genotype (Fig. 4-7A).
Overall, the trends in immune cell infiltration of these markers agreed with our real-time
qPCR results, and in tumors, BPC-Panx1-/- mice had 4 and 2.4 times increased staining for
positive CD4+ and CD8+ T cells, respectively (Fig. 4-7B). On the other hand, the percent
of Foxp3+ T cells in tumors was similar between genotypes. Collectively, these results
confirmed that the deletion of Panx1 favored the infiltration of CD4+ and CD8+ T cells in
the tumors.
We then used staining of the cytotoxic cell protease Granzyme B (GzmB) to assess whether
differences in T- or NK cells’ immune effector capacity (cytotoxicity) could be identified
within the TME. As shown in Fig.4-7 E-F, we observed a significant increase (8.4-fold,
p<0.0001) in the percentage of GzmB+ cells in tumors of BPC-Panx1-/- compared to BPCPanx1+/+ mice. Notably, GzmB protein was localized in intracellular granules, and very
rarely, any extracellular GzmB staining was discernible. These results agree with the higher
infiltration of CD8+ T cells and, likely, NK cells since GzmB can be abundant as cytosolic
granules in both cytolytic immune cell types. Furthermore, these findings suggest that
global Panx1-deletion did not affect the activation and migration of such cell types and
may favor the increased presence of anti-tumoral effector cells within BPC-melanoma
tumors.
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Figure 4-7.
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Figure 4-7 Tumor-infiltrating CD4+, CD8+ T-lymphocytes, and Granzyme B
producing cells are significantly increased in BPC-Panx1-/- tumors.
(A) Representative micrographs (20x, insets at 60x magnification) showing
immunofluorescence staining of primary melanoma tumor cryosections with immune cell
infiltration markers for CD4+, CD8+, and FoxP3+ T-lymphocytes (shown in cyan). Nuclei
(in magenta) was counterstained with Hoechst 33324. (B-D) Immunofluorescence
quantification of CD4, CD8, and FoxP3 positive cells for the whole tumor section. (E)
Representative granzyme B (GzmB) immunofluorescence staining of a BPC-Panx1-/tumor (fluorescence channels on top and brightfield channel at the bottom) with the intratumoral distribution of GzmB+ cells and black pigmented regions in the tumor. Nuclei are
shown in blue, and GzmB is shown in green. Yellow arrowheads indicate stained immune
cells. Scale bars = 40 µm. (F) Quantification of GzmB immunostaining. The percent of
nuclei with positive immune marker staining was normalized per area of the field of view
(FOV). At least three mice (N=3) per genotype were examined with at least 12 nonoverlapping FOV per tumor. Bar graphs stand for the median with 95% CI, and individual
measurements are depicted with symbols. Data were compared using a two-tailed MannWhitney test. Statistical significance is shown as p<0.001(***) and p<0.0001(****).
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Figure S4-1.
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Supplemental Figure 4-1 PANX1 mRNA expression is similar between patients with
and without co-occurrence of BRAF(V600E) /Pten (homozygous deletion).
(A) Analysis of Skin Cutaneous Melanoma TCGA PanCancer data shows a low proportion
(~5.0 %) of patients have co-occurrence of the BRAF(V600E) and homozygous deletion
of PTEN. (B) Both cohorts of patients exhibit similar levels (p=0.4970) of PANX1 mRNA
expression. Overall (C) and progression-free survival (D) are similar between patients with
(red line; n = 144) or without (blue line; n = 19) co-occurrence of BRAF(V600E)
mutation/Pten (deep deletion). Data in graphs were exported from cBioPortal (as of
Jan/12/2021)[34, 35]. RNASeqV2 data (Batch normalized from Illumina HiSeq) is derived
from TCGA PanCancer Atlas datasets, processed, and normalized using RSEM. Bar and
error graphs stand for the geometric mean with 95% CI, and individual patient expression
data is depicted with symbols. A two-tailed unpaired t-test with Welch’s correction was
used to compare the means of log2(mRNA PANX1 expression), and a log-rank test was
used to determine statistical significance (p<0.05) in the Kaplan-Meyer curves.
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4.4 Discussion
PANX1 channels have attracted considerable attention due to their multiple roles in
inflammation, cell death, and cancer [13, 36]. Recently, we have demonstrated that PANX1
influences the regulation of effector molecules that control melanocyte differentiation (e.g.,
MITF and β-catenin) and the metabolism of melanoma cells [9-11]. Furthermore, we have
shown promising results after silencing Panx1 expression and reducing the growth and
tumorigenicity of melanoma cell lines in vitro. In contrast, using the immunocompetent
BPC mouse melanoma model, we did not observe a reduction in Braf(V600E)/Pten(del)driven melanomas or improve mice survival upon global Panx1 deletion. Interestingly,
BPC-Panx1+/+ female mice seemed to display a more aggressive tumor progression than
males. Other researchers have recently noted this outcome in a C57B/6J background, but
the origin of this sex dimorphism has not been clarified yet [37]. It has been speculated that
this may be due to the presence of alternative steroid receptors in melanoma cells or
technical limitations with tamoxifen (an estrogen receptor modulator) differentially
influencing the mouse sexes in this melanoma model [37]. Although there were no
significant differences among genotypes, this sex-dependency was lost in BPC-Panx1-/mice, possibly indicating that Panx1-deletion may influence such a sex-driven phenotype.
It is known that sexual dimorphism exists in the response of Panx1-deficient mice in
ischemia [38] and epilepsy [39], and research on this is lacking in the melanoma and
immune cell recruitment contexts. In contrast to our observation, recent evidence has
shown that tumor progression and anti-tumoral T cell response are sex-dependent in a
syngeneic melanoma mouse model, where females had less tumor growth rate and higher
CD4+ and CD8+ T cell infiltrates compared to males [40]. Thus, sex-driven differences
will require further attention, especially in the melanoma and PANX1 research context.
Of note, our previous in vitro and ex vivo work targeting PANX1 employed murine
melanoma cell lines (B16-F0, -F1, -F10) and BRAF(V600E)-mutant human melanoma cell
lines (A375-P and A375-M2) that do not entirely share the same genomic alterations of the
BPC model [10, 41]. The deletion of Pten is known to have a synergistic effect and
dramatically accelerate BRAFV600E-induced melanoma tumors in BPC mice [21, 22, 42].
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Therefore, these oncogenic mutations may have overridden the anti-tumoral effect of
Panx1-deletion. Also, the deletion of Panx1 may not have the same effect seen with the
use of PANX1 channel blockers (e.g., with carbenoxolone, probenecid, or spironolactone)
due to possible compensation with other channels proteins (e.g., connexins or other
paralogs), and PANX1 blockers are yet to be tested in melanoma using an in vivo model.
Despite the global PANX1 deficiency, micro-metastasis to draining inguinal lymph nodes
did occur in our conditions, as reported elsewhere [21-23, 43]. Thus, we conclude that
PANX1 does not control the early spread of melanoma. Since this is a highly penetrant
mouse model, a syngeneic melanoma model may be more suitable to study the effect of
Panx1-deletion in melanoma metastasis [44]. Furthermore, due to the ubiquitous
expression of Panx1, its global deletion should have affected many cell types, including
melanoma and immune cells. Therefore, we reason that this scenario may resemble the
effect of a continuous, systemic, and irreversible depletion of PANX1 function in which
adaptative or alternative molecular mechanisms are in play to sustain tumor growth.
To date, there are no reports of major abnormalities or immune-related diseases in the
Panx1-deficient mice (reviewed at [13]). Here, we report for the first time that tumorbearing BPC-Panx1-/- female mice have significantly augmented spleen size compared to
male counterparts. Although the tumor may have caused this condition, we found a lower
cell proliferation (ki67 staining) in BPC-Panx1-/- spleens than in the wildtype cohort with
no evident signs of melanoma metastasis in any of the mice. Due to the short timeframe
for tumor growth (up to 2 months) and the sexual dimorphism found only in BPC-Panx1-/spleens, we speculate that developmental differences may account for this phenotypic
characteristic of Panx1-/- mice. Further research is warranted to determine whether global
Panx1-deletion exerts a sex-specific systemic immune dysregulation and whether this is
reflected in the spleen size.
Tumor-infiltrating lymphocytes (TILs) have already been described in this BPC model
[23]. However, others have highlighted that this model does not appear to induce a marked
immune response due to the lack of additional tumoral somatic mutations/neoepitopes [44].
Notably, our results showed that increased TILs were detected in BPC-Panx1-/- tumors.
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Similar to previous reports [23], we found increased T-lymphocytes and macrophage
markers in all the tumors. Interestingly, in those reports, myeloid-derived suppressor cells,
along with high PD-1 expression on the T cells, have been attributed to causing a highly
immunosuppressive environment in this melanoma model. However, we found no
difference in the abundance of tumor-infiltrating T-reg cells between both mice cohorts but
had a limited analysis of generic markers to determine exactly all the sources of possible
immunosuppression. Therefore, it is unclear if other subsets of CD4+ T cells (Th1 or Th17),
macrophages (M1 or M2), or myeloid-derived suppressor cells infiltrated the tumors and
may have contributed to immune evasion and melanoma progression. Despite the
significant increase of CD8+ T cells in Panx1-deficient melanoma tumors, we found no
changes in the activation of TILs as judged by the expression of CD69 as this early T cell
activation marker is expressed by several subsets of tissue-resident immune T cells [45,
46]. Indeed, the higher incidence of GzmB+ cells (could be CD8+ T cells or NK cells) found
in the BPC-Panx1-/- tumors supports an increased immune cell activation phenotype.
However, as these primary tumors were so aggressive, a meaningful tumor reduction may
only be observed if checkpoint inhibitors were applied at early tumor induction stages.
Interestingly, BRAF(V600E), Pten-null melanomas, seem resistant to immune checkpoint
inhibitory antibodies, where PTEN loss inhibits T cell-mediated killing and trafficking to
the tumors [47]. This suggests that targeting PANX1 could be an alternative to overcome
this type of immune resistance in tumors.
Based on the PANX1-mediated release of proinflammatory cytokine IL-1β, PANX1 has
been proposed as a potential target to regulate antitumor immunity in melanoma (reviewed
in [48]). In the current study, we found no significant differences in IL-1β mRNA
expression among cohorts, but we cannot rule out that the secretion of IL-1β, at the protein
level, was not affected in Panx1-deficient tumors. However, earlier studies showed that
marrow-derived macrophages of this Panx1-/- mouse strain have no difference in the
secretion of IL-1β or the inflammasome activation [15]. Recently, Medina et al.
demonstrated that thymocyte-specific Panx1-deletion attenuated metabolite release from
apoptotic lymphocytes and the inflammation in vivo in mouse models of inflammatory
arthritis and lung transplant rejection [8]. This underscores the need for research into the
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crosstalk

between

immune-

and

melanoma

cells

and

cell-specific

PANX1

suppression/inhibition conditions to better understand the implications of PANX1 targeting
in the context of melanoma.

4.5 Conclusions
In conclusion, our study demonstrates that although a Panx1 deletion cannot overcome the
aggressive tumorigenic effect of Braf(V600E)/Pten(del) driver mutations, it increases the
tumor T cell infiltration with a preference in CD8+ cytotoxic T cells. This could be
advantageous since a considerable therapeutic benefit is achieved in patients with a preexisting CD8+ T cell infiltration within the melanoma microenvironment [49]. Although
this transgenic melanoma mouse model was developed to harness two significant
oncogenic alterations (BRAFV600E and PTEN(loss), it is not representative of the larger
patient population since only ~5.0 % of them had co-occurrence of both mutations
(Supplemental Fig. S4-1A). Furthermore, since PANX1 expression seems independent of
genomic alterations of melanoma (Supplemental Fig. S1B) and is present at all stages of
the disease [10], a large patient population may benefit from PANX1 targeted therapy.
Future preclinical studies should include the combination strategies in which PANX1
inhibition could be used initially as neoadjuvant therapy to checkpoint inhibitors (e.g., antiPD-1 or anti-CTLA4) and stimulate cytotoxic T cell tumor infiltration to improve the
efficacy of immunotherapies.
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Chapter 5
5
5.1

Discussion
Summary of main findings

Pannexins are channel-forming glycoproteins supporting ATP, Ca2+, and other
ions/metabolites-dependent signaling [1, 2]. The wide-ranging expression of PANX1 in
several tissues (brain, kidney, liver, and skin) [1], along with the discovery of PANX2's
more widespread expression [3], makes it attractive in the pannexin field, to study them in
the context of their co-expression and interaction, that was previously shown as a factor
regulating their channel function and trafficking [4-6]. In addition, another essential aspect
that has gained notoriety over the years is the regulation by post-translational modifications
(PTMs) that control several pannexin properties, ranging from fine-tuning regulation of
channel activation to determining where the protein will be sorted in the cells [7, 8]. More
importantly, defining how pannexins behave in physiological and pathological conditions
has become a goal in studying this protein family and a promising path for developing
novel and enhanced therapies against a broad range of illnesses, including
neurodegeneration, inflammation, and cancer [9-11]. The overall goal of this thesis was to
fill the gap of knowledge on PANX1 and PANX2 roles in the health and disease states of
the skin. A particular emphasis was given to the regulation of PANX2 by two types of
PTMs (e.g., N-glycosylation and caspase cleavage) that were not addressed by previous
research. As increasing evidence showed that PANX1 (but not PANX2) is heavily involved
in the tumorigenesis of cutaneous melanoma skin cancer, we included an exploratory study
to test PANX1 contribution to melanoma progression in vivo and related events of immune
infiltration.
In Chapter 2, we showed how PANX2 expression in the skin (particularly in keratinocytes)
is represented by an uncharacterized splice variant (Panx2-202) that seems dominant at the
protein level and present throughout skin aging. Moreover, we uncovered the PANX2
cleavable sites in the C-terminus by executioner caspases-3/7 during UV-induced cell death
and the pro-apoptotic role of PANX2 in keratinocytes, which may participate in the
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maintenance of skin homeostasis. In Chapter 3, we delved into the regulation of PANX2
intracellular sorting by N-glycosylation and found that although it is not a prerequisite, it
assists with PANX2 trafficking to the cell membrane, with the latter enhanced by the
concurrent presence of PANX1 in the cell. Importantly, we confirmed that N-glycosylation
was not required for the interaction between PANX2 and the lower glycosylated species of
PANX1. Finally, in Chapter 4, we generated a global Panx1-knockout (KO) melanoma
mouse model to study the outcome of Panx1-deletion on melanoma progression and
immune cell infiltration. We showed that Panx1 global deletion does not reduce the
tumorigenic effect of two prominent oncogenes (Braf and Pten) as mice devoid of PANX1
still exhibited disease progression and had no improvement in survival. However, we
discovered that the lack of PANX1 remarkably increased the spleen size in a sex-specific
manner in this model (a phenotype previously overlooked in all reported Panx1-KO models
to date) and augmented the infiltration of effector anti-tumor T-lymphocytes and Granzyme
B (GzmB) + cells in the TME that could be useful to enhance immunotherapy against
melanoma. To our knowledge, this is the first study to examine the role of PANX1 on
immune infiltration in the cancer context. This chapter will further discuss the relevance
and limitations of our findings and propose new directions to continue advancing our
understanding of pannexins in skin health and disease.

5.1.1

PANX1 and PANX2 expression and implications for regulation of
skin homeostasis

Previous studies have demonstrated that PANX1 and PANX3 expression in the skin have
significance in modulating skin development, renewal, and repair upon injury [12-18].
Furthermore, PANX1 and PANX3 expression levels fluctuate dependent on age, with
PANX1 higher in newborn skin and lower in adult and aged skin, while PANX3 seems to
be unchanged [12, 16]. To the extent of our knowledge, there were only two previous
reports of PANX2 in the skin [3, 19]. In these reports, PANX2 expression at the protein
and mRNA levels were detected in the skin after screening tissues of either wildtype or
Panx1/Panx3 double knockout mice, but its regulation through aging was not addressed.
In Chapter 2, we further characterized PANX2 expression in the mouse skin of different
ages and at cellular levels. Although we found PANX2 expressed as a splice variant
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(PANX2-202) differing from the canonical isoform, further studies will be required to
investigate if this is also the case for other tissues. Indeed, studies of splice variants remain
limited and poorly understood in the pannexin field, in which most of the work has focused
on PANX1 [20, 21]. Early studies identified two PANX2 human splice variants
(PANX2alt1 and PANX2alt2) differing in length and speculated that the expression of one
might play regulatory roles on the other one [22]. My studies and those of Abitbol et al.
[19] were the first to bring attention to this differential expression in murine skin. However,
the functional implications of each splice variant need to be addressed further. Since the
differences in amino acid sequence fall within the first extracellular loop and the Cterminus of PANX2, the alternative splice variants may differ in channel function and
localization.
In terms of its temporal expression, it seems that PANX2 follows a similar pattern to
PANX3 and remains expressed in newborn and adult skin, the opposite to PANX1,
suggesting that PANX2 and PANX3 may be needed in skin maintenance instead of
development or early tissue maturation. This pattern of pannexin expression may be shared
among tissues, although with some differences since, for example, in the murine central
nervous system, PANX1 and PANX2 display opposite trends. Panx1 mRNA levels are
higher in embryonic stages before postnatal day 15 (P15) and decreasing onwards [23, 24].
In contrast, Panx2 transcript and protein levels rise during postnatal development and are
sustained during adulthood [25, 26]. Interestingly, Panx2 expression is downregulated in
immature mouse neurons during neurogenesis but re-expressed after terminal
differentiation. This selective and temporal expression is thought to modulate the timing
of neuronal differentiation [26].
On the other hand, PANX1 and PANX3 overexpression restrain keratinocyte proliferation,
whereas PANX3 promotes keratinocyte differentiation, and excessive PANX1
dysregulates this process affecting epidermal architecture [12, 17]. Moreover, PANX1 and
PANX3 have also been reported to regulate keratinocyte proliferation and migration [12,
17, 18]. Although poorly understood, some of the molecular mechanisms governing these
processes have been elucidated [17]. However, until the writing of this thesis, most of these
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elements warrant further investigation in the PANX2 context. Following our results in
Chapter 2, I propose that PANX2 may be relevant for keratinocyte differentiation and
programmed cell death in the skin, thus supporting skin homeostasis. In agreement with
this, we found PANX2 increased in a differentiating rat keratinocyte cell line and enriched
intracellular immunofluorescence staining in the suprabasal layers of the epidermis, as has
been reported with PANX1 and PANX3 subcellular localization [12, 13, 16, 18]. This
finding highlights the possibility that PANX2 may be required during keratinocyte
differentiation, perhaps as a Ca2+ /ion channel as previously suggested for paralogs PANX1
and PANX3 [17, 27, 28]. The calcium gradient in the epidermis is essential for regulating
keratinocyte differentiation [29], and pannexins could have a redundant function to
connexins, transient receptor potential (TRP), and other intracellular channels closely
related to the regulation of Ca2+ abundance and its uptake by keratinocytes in the epidermis
[30]. It has been speculated that PANX2 could function as a Ca2+ channel at the ER based
on its localization in the ER-mitochondria contact sites [31]. However, there is a lack of
supporting evidence and reliable methods for testing PANX2 Ca2+ channel function.
Additionally, we also detected the PANX2-202 splice variant in primary dermal mouse
fibroblasts, where its mRNA expression is downregulated after TGF-β-induced in vitro
activation into myofibroblasts. As discussed in Chapter 2, this could point out a different
role of PANX2 in these cells, where its expression may restrain fibroblast differentiation
or is no longer required in myofibroblast activation, a subject that could be explored
further.
The germline deletion of Panx1 and Panx3 has consequences for skin architecture as well
as keratinocyte and fibroblast differentiation during wound healing [16-18]. Notably, no
overt skin phenotype was reported in a previous Panx2-KO mouse model, but this mouse
was not thoroughly characterized and is not publicly available [9]. In that case, we could
argue that a closer inspection of the skin in the Panx2-KO model, especially under stress
conditions or after an injury, has the potential to reveal differences compared to the
wildtype counterpart [32]. However, a factor to consider is that any PANX2 deficiency
due to the germline deletion may be ameliorated by compensation with other channels
(such as connexins hemichannels) or other pannexin proteins as it has been suggested for
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the skin and other tissues (e.g., neurons, arterial wall, and vomeronasal organ) using Panx1KO and Panx3-KO models [19, 33]. Furthermore, given the known contribution of
pannexin dysregulation to a myriad of pathophysiological processes [34, 35], the
differential and temporal expression suggest that tight control of pannexin activity is
required for proper cell differentiation and homeostasis in adult tissue. Nevertheless, more
research on the significance of Panx2 expression for skin development and maintenance is
required.

5.1.2

Considerations on the importance of PANX2 N-glycosylation for its
subcellular trafficking and interaction with PANX1

In Chapters 2 and 3, we uncovered the specific sites for caspase cleavage and Nglycosylation modifications previously predicted in [8]. Moreover, we demonstrated the
implications of such PANX2 PTMs for subcellular trafficking, intermixing with PANX1
(Fig. 5-1), and contributions to the cellular homeostasis and programmed cell death
mechanisms. In particular, N-glycosylation appeared crucial for PANX2 proper folding
and intracellular compartmental distribution.
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Figure 5-1.

Figure 5-1 Graphical representation of the proposed model of PANX2 regulation by
N-glycosylation and caspase cleavage.
PANX2 is synthesized in the endoplasmic reticulum (ER) and post-translationally
modified by N-glycosylation, aiding its folding (inset A) and further sorting within the
cells during physiological conditions. PANX1 and PANX2 monomers can interact within
the ER and be transported by an unknown pathway (dotted arrows) to the cell membrane.
Lower glycosylated PANX1 species (Gly0 and Gly1) can interact with PANX2 regardless
of its glycosylation status (inset B). The putative channel function of PANX2 in the ER
may regulate the ER-mitochondrial crosstalk, especially during the activation of
programmed cell death (apoptosis), where PANX2 accelerates the cascade of apoptotic
events leading to caspase 3/7 activation. As the PANX2 C-terminus is targeted by caspase3 cleavage, it is unclear whether this proteolytic cleavage influences its biological function
during cell death (inset C). Figure created with BioRender.com.
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Since all pannexins have consensus sites for N-glycosylation [8], this distinctive PTM may
play a significant role in their regulation, considering that most glycoproteins synthesized
in the ER must undergo glycosylation as the first step for quality control mechanism against
protein misfolding. Furthermore, in the amino acid sequence of PANX2, there is a high
degree of conservation of this site among species (Fig. 5-2), suggesting that from an
evolutionary point of view, glycosylation may be a crucial step to guarantee the proper
folding of PANX2, which at the same time is a larger protein compared to the other
pannexins paralogs. Indeed, the protein quality control system (QC) in the ER is expected
to retain misfolded proteins, where a retrograde export mechanism or ER-associated
degradation (ERAD) pathway secures their degradation by the cytosolic-ubiquitin
proteasome system [36]. Thus, although the intracellular aggregation of the unglycosylated PANX2N86Q mutant was likely protein misfolding due to overexpression, it
confirmed the N-glycosylation importance in PANX2 since the wildtype glycosylated
canonical variant was subjected to similar conditions and never was found aggregated as
the mutant. In that respect, the misfolded PANX2N86Q mutant decreased colocalization with
chaperones (e.g., PDI) and delocalization of Golgi elements (e.g., GM-130) and possibly
triggered cellular stress. However, we did not measure unfolded protein response or
oxidative stress indicators [37], but in our experience, cell death was common upon
transfection of the Panx2 constructs. This suggests that dysregulation of PANX2
expression or defects on its glycosylation may be deleterious for the cell, especially if it
plays pro-apoptotic roles, as shown in Chapter 2 and proposed elsewhere [9, 31, 38].
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Figure 5-2.
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Figure 5-2 N-glycosylation site in mouse PANX2 is highly conserved among species.
Red squares indicate the PANX2 N-glycosylation and the caspase cleavage sites identified
in this thesis. Only N86 exhibited a high degree of conservation. Conservation analysis was
performed in the Consurf web server (https://consurf.tau.ac.il/) [37]. The Homologues
sequences were collected from UNIREF90, and Multiple Sequence Alignment was built
using MAFFT. The homolog search algorithm used was HMMER (E-value: 0.0001).
Maximal sequence identity was 95%, and 150 sequences were sampled conforming to the
list of homologs of a minimum 35% identity. Conservation scores were calculated using
the Bayesian method.
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It is generally accepted that glycoproteins exhibiting high-mannose species are more
localized to the ER, whereas those that transit through Golgi are prone to turn into complex
glycosylated proteins that end in the plasma membrane. Indeed, studies on PANX1
indicated that similar to what we observed with PANX2N86Q, PANX1 glycosylationdefective mutant (N254Q) has a reduced surface expression, but it can still form dye uptake
channels in the cell membrane [8]. Thus, glycosylation in pannexins assists with
intracellular sorting but is not a requirement for cell membrane trafficking. In this respect,
some authors have indicated that based on the characteristic intracellular location and
glycosylation level (up to Gly1 only), PANX2 cell membrane localization may be an
artifact of overexpression and follows an alternative sorting mechanism than the other
pannexins [7, 31, 39]. In this respect, Bhalla-Gehi et al. (2009) showed that PANX1 and
PANX3 follow the same ER-Golgi route through a secretion-associated and RAS related
(Sar1) GTPase-dependent and coat protein II (COPII)-mediated pathway; thus explaining
the resulting Gly2 species [39].
PANX2 does not transit through Golgi in our proposed model, but how it reaches the cell
membrane independently of N-glycosylation remains elusive. Le Vasseur et al. (2019)
showed ectopic EGFP-tagged PANX2 in C6 rat glioma cells and endogenous PANX2 in
mouse brain localized to membranes of the ER-mitochondria contact sites but not in other
organelles [31]. This evidence also suggested that PANX2 does not transit through Golgi
compartments and is retained in the ER. In contrast, although under ectopic overexpression
conditions, in Chapter 3, we detected untagged mouse PANX2 colocalizing with GM-130
(a cis-Golgi marker) and at the cell surface. Thus, we speculate the difference seen in
localization is cell-type and condition-specific, as other authors have reported [8, 26, 31].
Nevertheless, we support the notion that PANX2 follows an alternative anterograde
trafficking pathway that bypasses the Golgi apparatus, which will require further
investigation.
It is important to note that besides glycosylation, there are other determinants of
anterograde trafficking of pannexins. The C-terminus is the most highly heterogeneous
domain varying in sequence homology and length in pannexins. Notably, the PANX1 C-
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terminus has proven to be a potent regulator of its oligomerization and trafficking. There
are examples of mutation or truncation of the PANX1 C-terminal domain enough to cause
its retention in the ER and limit its glycosylation to Gly1 species [40, 41]. Furthermore, a
previous study using a chimeric PANX2 containing the PANX1 C-terminus showed that
the PANX1/2 chimera had a diffuse intracellular distribution different from the canonical
mouse PANX2 and insufficient capacity to relocate to the cell surface [42]. In agreement
with these authors, we can reason that determinants at the C-terminal domain do not control
the mechanism for regulating PANX2 trafficking as in PANX1 [43].
Finally, although co-expression experiments with different pannexins have shown that the
glycosylation state can modulate the level of interaction among paralogs [5], we found that
for PANX2, glycosylation status was not a limiting factor, at least for interacting with
PANX1. We also confirmed that PANX1 and PANX2 intermixing increases the trafficking
of both pannexins to the cell membrane. Such interaction may occur preferentially at the
ER level since we found it consistent that only high-mannose and un-glycosylated PANX1
species are co-immunoprecipitated with PANX2, regardless of PANX2 glycosylation
status [6, 8]. Considering the relevant role of PANX1 in the skin, it would be interesting to
determine if PANX1/PANX2-202 intermixing occurs naturally when both pannexins are
expressed simultaneously in neonatal skin cells and whether it influences their function in
those cells.

5.1.3

Possible pro-apoptotic roles and effects of caspase cleavage of
PANX2 in skin cells

As we discussed before, one of the critical functions of the skin is to act as the first barrier
against external pathogens and other environmental insults, including UV radiation. In
Chapter 2, UVB light was used as a relevant biological model to induce lethal damage to
keratinocytes to test whether PANX2 expression would influence their programmed cell
death response. According to our data, PANX2 promotes keratinocyte death during UVBinduced apoptosis independently of its cleavage at the C-terminus. Thus, we can reason
that the low but continuing PANX2 expression in the upper layers of the epidermis of adult
skin tissue may help ensure opportune apoptosis after deadly insults like UVB, something
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we discuss further in the following paragraphs. However, this hypothesis would need to be
tested in an in vivo context. To evaluate PANX2 relevance for cell death and skin lesions
after UVB skin exposure (sunburn), perhaps a mouse model with inducible and
keratinocyte-specific Panx2-deletion would be better rather than germline-deletion to
reduce any compensatory mechanisms by the expression of other paralogs or channel
proteins.
In addition, due to previous reports on PANX2 participation in different types of cell death
(e.g., cytokine-mediated, thapsigargin-, staurosporine-, ischemia-induced apoptosis and
ferroptosis) [9, 31, 38, 44, 45] and the potential of caspase-3/7 to cleave PANX2 [8], here
we aimed to define the site of this PTM and whether this proteolytic cleavage has any effect
on the UVB-induced programmed cell death. In other contexts, PANX1 at the cell surface
is cleaved by the same executioners caspases cleaving PANX2 [8], activating the channel
constitutively to release ATP and other metabolites in dying cells [46-48]. Since PANX2
is more likely to form intracellular channels in the ER membranes and to be located in the
ER-mitochondria contact sites [31], a plausible theory is that, as we mentioned before,
PANX2 channels may serve as a conduit for ions (e.g., Ca2+) (Fig. 5-1) in the ER as it has
been proven for the intracellular PANX3 channels in keratinocytes [17]. However, further
research will need to address how caspase cleavage would alter PANX2 channel
permeability and the implications for the apoptotic process. In this sense, since we did not
observe a substantial dysregulation of the apoptotic rate between cells expressing wildtype
and caspase cleavage-resistant PANX2D416A, we attempt to speculate that the PANX2
gating mechanism is different and may not be as significantly altered by caspase cleavage
as it happens with PANX1 [46-50].
In physiological conditions during terminal differentiation, caspase-3 is not readily
cleaved/activated [51]. We have observed that PANX2 levels (at least in vitro in REK cells)
are increased during keratinocyte differentiation, implying that PANX2 makes
differentiating keratinocytes more susceptible to cell death if UVB damage occurs. Thus,
by fostering apoptosis of UVB-damaged cells in the skin, PANX2 could be part of a
mechanism to eliminate populations of malignant keratinocytes and act as a tumor
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suppressor as it has been proposed in other cell contexts like glioma [38, 52]. Interestingly,
Cowan and colleagues (2012) showed that PANX1 and PANX3 levels are highly reduced
in human keratinocyte tumors (basal and squamous cell carcinomas) compared to normal
epidermis samples [13]. However, no evidence of dysregulation in PANX2 expression in
these cancers has been shown to date. Therefore, it would be interesting to investigate
whether PANX2 expression may play a protective role against the development of basal
and squamous cell carcinomas that are the most common cutaneous malignancies, mainly
due to sun-damaged skin [53, 54].
Notably, our data showed that the cleavage of PANX2 C-terminus in apoptotic
keratinocytes does not significantly influence the apoptosis rate. However, we cannot rule
out that this caspase-mediated PANX2 cleavage will have the same effect in other cells
and different physiological and pathological circumstances. For example, it has been
shown that caspase-3 activation occurring in the spinous layer of the epidermis (where
differentiating keratinocytes are located) is related to pathologic events in atopic dermatitis
but at the same time could also be occurring in physiological contexts like in basal
(undifferentiated) keratinocytes during epidermal renewal [55]. Since PANX2 is targeted
by caspase-3, we wonder if a link between PANX2 and any of those processes exists in
keratinocytes.

5.1.4

Pannexin 1: a new regulator of tumor immune infiltration in
melanoma

In the context of skin disease, it is known that PANX1 can be dysregulated with a high
expression in malignant melanoma [56]. Since our group has reported that the genetic and
pharmacological inhibition of PANX1 decreases melanoma cells' tumorigenic properties
in vitro and ex vivo [56-58], in Chapter 4, we examined the effect of global deletion of
Panx1 on in vivo melanoma progression by crossing the Genentech Panx1-KO mice [59]
with the inducible melanoma model: BrafCA, PtenloxP, Tyr::CreERT2 (BPC) [60]. Contrary
to our expectations, Panx1 germline deletion did not reduce the effect of BRAF(V600E)
mutant and Pten(deletion) oncogenes in inducing primary tumor formation, invasion to
lymph nodes, nor improved BPC mice survival (Figure 5-3). Although at first, this may
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appear inconsistent, it is essential to note that there are significant differences between in
vitro and ex vivo (melanoma cell cultures, tumors grown in Chick -CAM) [56-58] and in
vivo (mouse model) (herein, Chapter 4) where PANX1 role has been tested. The increased
complexity of the factors (e.g., hallmarks of cancer, driving mutations, TME, and tumorimmune cells interplay) [61, 62] leading to tumor formation and progression to metastatic
disease in melanoma can explain why the simply global deletion of Panx1 does not thwart
melanoma tumorigenesis in vivo.
We also explored if the Panx1 deletion could induce changes in the expression of Panx2
in the non-melanoma skin and the tumors. However, real-time qPCR data indicated that
Panx2 mRNA expression does not significantly change when comparing BPC-Panx1
genotypes (WT vs. KO) and non-melanoma skin versus melanoma tumors, ruling out any
compensatory effect PANX2 may have. Previously, PANX2 was identified as a marker for
prostate cancer cells [45], and it was associated with shorter survival of clear cell renal cell
carcinoma patients [63]. Although not included in Chapter 4, we further analyzed TCGA
patient data that showed no correlation between PANX1 and PANX2 expression or survival
prediction in patients with melanoma (Fig. 5-4). Therefore, we concluded that PANX2
levels are not significantly altered in melanoma skin cancer which would agree with our
data in Chapter 2, where Panx2 expression seems more related to keratinocytes than
melanocytes, the primary cell type dysregulated and causative of melanoma.
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Figure 5-3

Figure 5-3 Graphical representation of main findings in the Panx1-deficient BPC
mouse melanoma model.
Global deletion of Panx1 did not influence tumor onset, invasion to draining lymph nodes,
and melanoma progression in BPC mice. However, splenomegaly was a phenotypic
characteristic of BPC-Panx1KO mice of unknown significance, and there was a significant
increase of effector T-lymphocytes and Granzyme B+ cells (GzmB+) in the TME. Figure
created with Biorender.com.
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Figure 5-4.
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Figure 5-4 PANX2 mRNA expression does not correlate with PANX1 nor predict
survival of patients with malignant melanoma.
(A) Analysis of Panx2 transcript expression in the BPC mouse model (Chapter 4) revealed
similar mRNA expression in tamoxifen-induced tumors compared to matched nontamoxifen treated skin samples regardless of the BPC-Panx1 genotype. Gapdh was used as
the housekeeping gene for normalization. At least N=5 paired samples were assayed by
triplicate (n=3) for real-time-qPCR analysis. Statistical significance is shown as p<0.05(*).
(B) Matched normal skin (data from TCGA and GTEx) and melanoma tumor patient
samples (from TCGA) display no significant differences in mRNA expression. (C) PANX1
and PANX2 mRNA expressions are not correlated and do not predict survival of cutaneous
melanoma patients (D-G). Symbols display the individual expression data per mouse or
patient. Box plots represent the 95% confidence interval (CI) and the median (inner line),
with whiskers representing the maximum and minimum gene expression values. T-test (for
B) or two-way ANOVA and Tukey's post hoc test (for A) were used to compare the means
log2(Expression). Patient samples gene expression and survival analysis were done using
the GEPIA web server [64].
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Remarkably, the spleens of female tumor-induced BPC-Panx1-KO mice were significantly
enlarged compared to male mice, a phenotype not previously reported for Panx1-KO mice.
The spleen is a secondary immunological organ that controls hematopoiesis, red blood cell
clearance, and immune response against blood-borne pathogens and foreign materials [65].
Spleen enlargement (splenomegaly) has been observed in tumor cell transplantable models
[66, 67] where specific immune cells (e.g., T-lymphocytes, monocytes, and
immunosuppressive myeloid cells ) generated or in transit through the spleen can modulate
cancer progression for the host [68]. Furthermore, in age-matched tumor-bearing mice
littermates, the number of splenocytes (spleen cells) can increase progressively in
proportion with the days of tumor growth in mice [69]. Although we did not measure the
cell density or the relative cell size per spleen to rule that out, we do not consider that this
was the cause of such sex-specific difference in spleen size since both cohorts of mice lived
for a comparable length of time after tumor induction. In addition, our measurements of
cell proliferation (assessed by Ki67 immunofluorescence) showed that tumor-bearing mice
lacking PANX1 had a significantly lower number of proliferative spleen cells per field of
view, ruling out any contribution of cell proliferation due to the tumor induction. Is
important to consider that sexual dimorphisms already exists in the response of Panx1deficient mice during pathological states such as ischemia [70] and epilepsy [71], so in this
case the presence of the tumor could be a factor influencing this phenotypic difference in
BPC-Panx1-/- mice.
Furthermore, although malignant melanoma can metastasize to the spleen and cause
splenomegaly, it is an infrequent occurrence in patients and is mainly found after autopsies
[72, 73]. In our case, we did not find a conclusive indication of metastasis to the spleen
(like black lesions seen under the skin and the lymph nodes); thus, further
immunohistochemical analysis was not pursued. To the extent of our knowledge, only one
report of increased spleen size exists for the BPC mouse melanoma model due to the
treatment with an anti-CD40 agonist antibody used to evoke an anti-tumor response and
restrict tumor growth and, as a side note, did not increase in intra-tumoral infiltration CD4+
and CD8+ T-cells [74]. Thus, the increased TILs in skin and tumor tissues of BPC-Panx1KO mice may not be a direct consequence of the splenomegaly but an effect of the Panx1
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germline deletion itself in this mouse strain that will need to be further studied. On the
other hand, it is possible that prolonged pharmacological targeting of PANX1 through
systemic application of PANX1 blockers (CBX, PBN, or spironolactone) could act in the
spleen and cause similar effects on the size of this organ. Thus, future studies looking at
pharmacological inhibition of PANX1 should consider this and evaluate the consequences
for the inflammatory response.
In my opinion, the significant increase of CD4+, CD8+ T-lymphocytes, and GzmB+ cells
in tumors of BPC-Panx1-KO mice needs to be explored further. Although it has been
suggested that this melanoma model is poorly immunogenic [75-78], many authors
continue using it to study factors regulating immune infiltration and to test new approaches
for immunotherapy [74, 79-87]. This "so-called" low immunogenicity strengthens our
results in showing that somehow the Panx1 deletion elicits increased TILs in the context
of this cancer. Indeed, more extensive evidence shows that BRAF-mutated melanomas
exhibit immunologically 'cold' features (reviewed in [88]) where low T cell infiltration
and increased immunosuppressive cells are unfavorable elements for immunotherapy (i.e.,
checkpoint inhibitors). In this respect, as we explained in Chapter 1, checkpoint inhibitors
block the engagement of immune checkpoint molecules in immune (e.g., CTLA-4, PD-1,
PD-L1) and tumor cells (e.g., PD-L1), preventing activation of effector T cells and further
elimination of cancerous cells [89]. Indeed, checkpoint inhibitor therapy is currently the
standard of care for patients with advanced metastatic melanoma [90] but has a limited
patient response rate, in part due to limited tumoral immune cell infiltration. Based on our
results, it is possible that targeting PANX1 before immune checkpoint inhibitor therapy
could increase CD4+ and CD8+ T cell infiltration in TME, boosting the effect of this
immunotherapy. Notably, this treatment could be expanded beyond BRAF-mutant patients
with metastatic melanoma, including a larger cohort that may not qualify for kinase
inhibitor therapy as PANX1 is also overexpressed in most patients regardless of the BRAF
mutation status or the stage of the disease (Chapter 4, Fig S4-1 and [56]).
Of note, β-catenin signaling and PTEN loss have been revealed as a mechanism leading to
a non-T cell-inflamed TME and resistance to therapy in patients [84, 91]. Previously,
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Spranger et al. (2015) showed that the activation of the WNT/β-catenin pathway, intrinsic
of melanoma cells, correlates with the lack of T cells in metastatic melanoma, hindering
the therapeutic effect of checkpoint blockade therapy that depends on the reactivation of
tumor infiltrated CD8+ T cells [87]. Furthermore, the same group showed that activation
of β-catenin in tumor cells causes immune evasion due to defective tumoral recruitment of
CD103+ dendritic cells and defective T cell priming against tumor-associated antigens
[87]. Interestingly, in keeping with our results, the BPC mice used in that study showed
infiltration of CD4+ and CD8+ T-cells but also the expression of markers of T cell
dysfunction (e.g., PD-1 and Lag3), PD-L1, and defective production of IL-2 in the
melanoma tumors, requiring a combination of anti-CTLA-4 and anti-PD-L1 monoclonal
antibodies to delay tumor outgrowth [87]. Interestingly, recent evidence by our group
confirmed that genetic or pharmacological inhibition of PANX1 in melanoma cells
decreases expression and disrupts localization of β-catenin and transcription of
downstream target genes like MITF [58]. Thus, it is conceivable that in our BPC-Panx1KO model, the lack of PANX1 in melanoma cells enhanced T cell infiltration into the TME,
yet checkpoint inhibitor therapy would still be required to ameliorate tumor progression.
However, such models require further verification as we did not test for differences in βcatenin expression in the induced tumors nor used checkpoint inhibitors as a therapeutic
resource.

5.2

Experimental Limitations

In Chapter 2, we proved by real-time qPCR that two Panx2 transcripts could be detected
in the skin at all ages assayed, and using three different affinity-purified polyclonal
antibodies, we verified its expression at the protein level. However, immunoblots indicated
various immunoreactive species that differed from the expected MW of canonical PANX2.
As shown previously for pannexins [1, 8], such variation in the banding profile could
indicate the presence of PTMs or gene-splicing events rendering different transcript and
protein variants. In our case, our assessment of the PANX2-202 splice variant included
verifying predicted isoforms shown in genomic databases. Thus, based on the MW and
transcript sequence differences, we were able to identify which splice variant was most
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likely to be in the skin. However, the use of polyclonal antibodies brings disadvantages to
detecting specifically the protein of interest due to the recognition of multiples epitopes
and increased cross-reaction with similar antigens (false positives) and heterogeneity
within the sample [92]. Thus, the anti-PANX2 polyclonal antibodies may have recognized
not only the PANX2-202 isoform but other unrelated proteins affecting the specificity and
sensitivity of PANX2 detection and localization in the skin. Therefore, further work to
verify PANX2 protein in the skin more accurately should be carried out using a Panx2-KO
mouse model or preincubation with cognate peptides as controls as it has been done in the
past to validate other anti-pannexins antibodies [1, 8, 15]. In addition, despite possibly low
endogenous PANX2 expression in the skin, mass spectrometry would be ideal for peptide
fingerprinting since previous reports indicate that transcription levels are a poor predictor
of PANX2 protein abundance in different tissues [3].
Another aspect that had experimental limitations was the in vitro differentiation studies
done in keratinocytes. As mentioned in Chapter 2, only significant changes in PANX2
expression after Ca2+ induction were detected using the immortalized REK cell line but not
in primary mouse keratinocytes. In addition, some differentiation markers did not
significantly change as were expected (e.g., k5, k14, Ivl) to indicate a proper transition to
terminal differentiation of the primary keratinocytes. Therefore, we cannot rule out that our
in vitro experimental conditions may not have been optimal for complete keratinocyte
differentiation and show significant upregulation of mouse Panx2-202 due to incomplete
or abnormal differentiation, which is typical for in vitro models of keratinocyte
differentiation [93].
On the other hand, to determine the effect of PANX2 cleavage during apoptosis, we used
CRISPR-Cas9-mediated genetic deletion and transient overexpression of canonical mouse
PANX2 and the PANX2D416A mutant rather than using the rat ortholog and stable
expression in the REK cell line. The drastic PANX2 deletion or overexpression could affect
the intrinsic aspects of programmed cell death (e.g., cytosolic Ca2+ flux and mitochondrial
overload [94]), especially considering that PANX2 has been found in the mitochondriaassociated membranes interface that is critical for regulating Ca2+ homeostasis and
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crosstalk between ER-mitochondria during apoptosis (reviewed in [95]). Furthermore, as
we mentioned in Chapter 2, the rat Panx2 has only one spliced form, which is canonical
and has a different conservative substitution (D to E) at the 416 residue that renders this
site uncleavable by caspases 3/7 but maintain the site D400 that is also conserved in human
PANX2 and the mouse splice variant PANX2-202. However, we did not confirm whether
the endogenous rat PANX2 ortholog can still be cleaved by apoptotic caspases or
investigated why wildtype REK cells exhibited the highest rate of apoptosis that the
wildtype mouse PANX2 overexpression could not entirely rescue.
In Chapter 3, we observed that overexpression of the un-glycosylated Panx2N86Q mutant
led to increased intracellular aggregation. Thus, N-glycosylation seems to avoid PANX2
aggregation in the ER and Golgi compartments, possibly due to misfolding of the
Panx2N86Q mutant [96]. However, these misfolding events were likely exacerbated by
overexpression since cells expressing lower levels of the unglycosylated mutant did not
exhibit such a degree of protein aggregation. For that purpose, it would have been
beneficial to use stably expressing cells.
Moreover, as discussed in Chapter 4, the BPC mouse model displayed very aggressive
melanoma tumors, as reported by [60, 97]. The fast tumor growth rate made it impossible
to detect other visceral metastasis (e.g., lungs [60]) that would have been valuable for a
more clinically translatable characterization of immune infiltration. Furthermore, despite
our attempts in limiting the age group for analysis to avoid the known spontaneous
formation of tumors (due to leaky Cre, in >3 months old mice reported by [60]), on some
occasions, multiples spontaneous cutaneous tumors arose, prompting us to euthanize the
mice very early in our protocol. The latter could have limited our ability to determine a
more accurate survival analysis and extend our study to distant metastasis more clinically
relevant to characterize the immune infiltration. In the same chapter, we detected increased
spleen size of tumor-bearing mice; however similar comparison was not performed in nontumor induced or non-BPC mice; thus, it is difficult to define whether this phenotype in
Panx1-deficient mice is distinguished only under melanoma tumor conditions. Moreover,
the tumor immune infiltration characterization was limited to markers for a selected
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immune cell population and using real-time qPCR and immunofluorescence. However, we
omitted other relevant immune cells like MSDCs and markers of other lineage-specific
myeloid cells like M2-polarized tumor-associated macrophages essential in the melanoma
immune evasion and exclusion mechanisms [62, 98]. Besides, using other more highthroughput techniques such as flow-cytometry with multiple and more extensive cell
surface markers would have been beneficial to identify and quantify the immune cell
subtypes in the tumors more accurately.

5.3

Future directions

Although our findings contribute to a better understanding of transcriptional and PTM
regulation of pannexins, they also opened new questions that need to be addressed in
further studies. Throughout the text in previous chapters, we did include some details about
future research that could be done to investigate their role during health and disease in the
skin. In the following paragraphs, we will summarize some of the work that needs to be
addressed to complement the results showed by this thesis.
In Chapter 2, we showed that the PANX2-202 splice variant is the dominant isoform in the
skin. Since most of the research elsewhere has only focused on the canonical variant of
PANX2, further characterization of its expression in other organs, including the brain,
would clarify if this is a tissue-specific variant or has regulatory roles, as was suggested
early on with the other alternative human splice variants [22]. We also noted that PANX2
levels are likely to increase during keratinocyte differentiation in agreement with the high
immunostaining of the suprabasal layer of the mouse epidermis (Chapter 2, Fig 2-2). Thus,
it would be interesting to know whether PANX2 is important or influences the keratinocyte
differentiation process by overexpression and gene silencing experiments, including
organotypic epidermis in vitro models and the analysis of the dorsal skin of PANX2deficient mice under normal and pathological stages (e.g., wound healing), as has been
already done for PANX1 and PANX3 [12, 16-18].
Regarding the pro-apoptotic role of PANX2 in the skin, experiments encompassing the
measurement of the intracellular PANX2 channel function in keratinocytes are desirable.

204

However, we recognize that no PANX2-specific channel blockers, inhibitors, or a
straightforward way of stimulating the opening of PANX2 channels have been reported to
date, making this task extremely difficult, on top of the various intracellular ion channels
that may have a similar activity in the ER. Therefore, a combination of gene silencing and
genetically engineered PANX2 channels, perhaps as done before with PANX1 with the
introduction of Tobacco Etch Virus (TEV) protease sites [47] or photocleavage by
optogenetics [99], would help elucidate the consequences of constitutive PANX2 channel
opening. At the same time, it is puzzling how the caspase cleavage at the PANX2 Cterminus has no apparent effect on the cellular apoptotic rate. Now that we discovered the
specific sites where this cleavage occurs, further work clarifying the role of such
modifications can be undertaken using different cell lines.
Chapter 3 identified N-glycosylation as a regulator for PANX2 subcellular localization,
but the remaining question is whether endogenous PANX2 and its splice variant are
glycosylated and under what circumstances. Interestingly, S-palmitoylation is another
PTM shown in PANX2 un-glycosylated species that likely prevents its localization to the
cell membrane before terminal neuron differentiation [26]. Thus, a further exploratory
study could determine the glycosylation status of PANX2 is influenced by the
differentiation status in keratinocytes. On the other hand, due to the low endogenous
protein levels in this tissue, we did not perform PANX2 de-glycosylation experiments as
these are more amenable in overexpression systems than with lower endogenous protein
amounts. Future experiments should consider cloning the PANX2-202 splice variant and
test if glycosylation and caspase cleavage also regulate this isoform and determine the
influence of co-expression with the canonical on keratinocyte differentiation and apoptosis.
Finally, in Chapter 4, due to the complex interplay of cells expressing PANX1 in the
melanoma TME, using the BPC model, it was not possible to determine in what cell type
(cancer or immune cell) PANX1 exerts a dominant role in aiding the disease progression.
We previously knew that PANX1 contributes to the tumorigenic properties of melanoma
cells and the inflammation in other contexts different from cancer. Our findings suggest
that PANX1 regulates immune phenotypic characteristics like the spleen morphology and
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recruitment of T-lymphocyte effector cells and other GzmB+ cells to the melanoma tumor.
Future experiments should explore this and the molecular mechanisms (e.g., activation of
signaling pathways, nucleotide, cytokine, or metabolite release) or cellular processes (e.g.,
phenotype switching and migration of immune cells) behind this enhanced immune cell
recruitment into the tumor. Experiments involving a more controlled syngeneic melanoma
model or adoptive immune cell transfer from Panx1-KO mice would help elucidate where
and how targeting PANX1 can aid tumor regression. More importantly, exploratory studies
using PANX1 blockers combined with checkpoint inhibitor therapy (anti-PD-1, anti-CTL4
antibodies) could help determine how relevant targeting PANX1 is for immunotherapy and
the clinical setting.
In addition, recent evidence has shown that tumor growth and T cell response is sexdependent in a syngeneic melanoma mouse model where females had less tumor growth
rate and higher populations of CD4+ and CD8+ cells compared to males [100]. Thus, it is
interesting that we found that females had a more aggressive tumor growth compared to
males of the BPC-Panx1+/+ cohort, but this was not the case for Panx1-KO mice. Therefore,
the increased immune cell infiltration in skin and tumors and the sex-specific differences
in spleen size of the Panx1-KO mice may have influenced this, and future work should
include sex as an essential factor for evaluating the anti-tumoral response in Panx1-targeted
experiments.

5.4

Overall conclusions

In summary, the work presented in this thesis complement the growing evidence of the
diverse roles of pannexins contributing to critical cellular processes (e.g., differentiation
and cell death) in health and disease states of the skin. Moreover, we demonstrated how
regulation by PTMs like glycosylation and caspase cleavage define PANX1 and PANX2
localization, their interaction, and potentially their function within the same cellular
context. This thesis further revealed the translational potential of PANX1 that needs to be
studied along with immunotherapy to likely improve the clinical outcome of cutaneous
melanoma.
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